The epigenetic regulation of the EGF-receptor ligands Amphiregulin and Epiregulin and its impact on the outcome of EGFR-targeted therapies by Bormann, Felix
The Epigenetic Regulation of the EGF-receptor
Ligands Amphiregulin and Epiregulin and Its Impact
on the Outcome of EGFR-targeted Therapies.
D i s s e r t a t i o n
zur Erlangung des akademischen Grades





der Humboldt-Universität zu Berlin
von
Dipl. Biochem. Felix Udo Bormann
Präsident der Humboldt-Universität zu Berlin
Prof. Dr. Jan-Hendrik Olbertz
Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I
Prof. Stefan Hecht, Ph.D.
Gutachter/innen: 1. Prof. Dr. C. Sers
2. Prof. Dr. N. Blüthgen
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In 2008, colorectal cancer was the second most common cancer type with 14.3 % new
cases among all male and 13.5 % new cases among all female cancer patients in Germany.1
More frequent was only prostate cancer with 25.7 % in males and breast cancer with
32.1 % in females. With a mortality rate of 11.8 % among all male and 13 % among
all female cancer induced deaths, colorectal cancer was also the second major cause
of cancer induced mortality. The life-time risk to develop colorectal cancer was 7.5 %
for males and 6.1 % for females. Additionally, the life-time risk to die from colorectal
cancer was 3.2 % for male patients and 2.7 % for female patients. Dietary factors like
high consumption of red meat, unsaturated fatty acids and alcohol, as well as inherited
and somatic mutations, are some of the risk factors for the development of colorectal
cancer.2,3,4
To describe the different stages of spontaneous colorectal cancer development, the
adenoma-carcinoma sequence is a commonly used model. During the first stage, the
development of an early adenoma from normal epithelium takes place. In 70 to 80% of
all cases, this stage is caused by a somatic APC mutation in the glandular epithelium
leading to the formation of adenomatous polyps.5 These polyps are dysplastic and
characterized by an altered differentiation of the epithelial cells. A germline mutation
of APC is also responsible for an increased number of polyps (> 100) in the Familial
Adenomatous Polyposis syndrome (FAP).6,7 Due to a loss-of-function mutation, APC is
not able to mediate the degradation of β-catenin in the absence of Wnt-ligands in the
Wnt-signaling pathway.6 Being a Wnt-signal dependent transcription factor, β-catenin
induces, for example, the transcription of T-cell factor-regulated target genes (TCF).
The next stages in the adenoma-carcinoma sequence are the development of late
adenomas and carcinomas caused by mutations in additional genes having key roles in
tumor initiation, progression and maintenance. An increased mutation rate is caused e.g.
by mutations of DNA mismatch repair genes (MMR-genes) like MLH1 8,9 and MSH2.10,11
One consequence of this is the microsatellite instability phenotype (MSI), characterized
by alterations in microsatellites within the genome.
Further examples of key alterations are mutations in spindle formation associated
genes just as Mad2, BubR1, Bub3 and CENPE leading to losses or gains of distinct chro-
mosomal regions or complete chromosomes. The resulting phenotype is called ”chromo-
somal instability phenotype” (CIN).12 By these mechanisms, a huge number of different
somatic mutations may evolve during cancer progression. In one case, Wood et al. iden-
tified more than 80 different somatic mutations within one primary colorectal cancer.13
However, only few of them can be found in large proportions of different primary tu-
mors. One of the most frequently altered genes is TP53 encoding the tumor suppressor
protein p53. Due to CIN leading to alterations at chromosome 17, Loss of Heterogeneity
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(LOH) of TP53 can be observed in 70 % of all CRC cases.7 In the remaining allele,
a somatic mutation can cause a complete loss of p53 function.14 Because p53 is a key
transcriptional regulator of genes associated with cell cycle checkpoints and apoptosis,
loss of p53 leads to continued growth and reduced apoptosis after cellular stress like
hypoxia or DNA strand breaks. Thus, the mutation rate increases and angiogenesis is
favored,15 circumventing hypoxia and leading to metastases.
Deregulation of components of the MAPK-pathway, responsible for cell prolifer-
ation, differentiation and inhibition of apoptosis, and the PI3K-pathway, also responsible
for inhibition of apoptosis, are two other prominent examples of alterations occurring
in cancer tissues.16,17 Due to their importance, both pathways and their influence on
colorectal cancer will be presented in detail in section 1.2. Furthermore, epigenetic
alterations, comprising changes in chromatin structure, DNA methylation and miRNA-
abundances, are crucial factors for the development of colorectal cancer. In section 1.4,
the influence of these factors on gene expression and on the development of cancers,
especially colorectal cancer, will be described.
1.2 The MAP-kinase and PI3-kinase pathway
1.2.1 The EGF-receptor activates MAPK- and PI3K-signaling
The epidermal growth factor receptor (EGFR) is a 170 kDA transmembrane glycopro-
tein.18 It consists of an extracellular domain, a hydrophobic transmembrane domain and
an intracellular domain. The extracellular domain is organized in 4 subdomains respon-
sible for ligand binding. The intracellular domain includes a juxtamembrane domain,
a tyrosin kinase domain and a long carboxyterminal region. This region encompasses
autophosphorylation sites, which are binding sites for SH2-domains and PTB motifs.
EGFR, also known as ErbB1, is one of the four members of the ErbB family of type I
receptor tyrosin kinases. While ErbB2 and ErbB4 have similar structures to ErbB1 and
are highly homologous in their tyrosin kinase domains, ErbB3 lacks this domain. In con-
trast, the extracellular regions responsible for ligand binding are less conserved between
the family members. Therefore, each receptor monomer can bind different ligands called
EGF-like growth factors. At least 12 different EGF-like growth factors were identified
(table 1), of which four are able to bind EGFR, three are able to bind EGFR and ErbB4
and four are able to bind ErbB3 and ErbB4. The receptor bound by Cripto-1 is still
unknown. Interestingly, ErbB2 is not able to bind any ligand, although it is the most
potent dimerization partner for the other ErbB-receptor monomers.
When binding a ligand, EGFR either forms a homodimer with a second EGFR-
monomer or a heterodimer with one of the other monomers. The composition of the
dimer determines the effect of the ligand on the cell. If, for example, ErbB2 is present in
the receptor dimer, ligand dissociation slows down leading to a prolonged signal to the
cell.19 Other factors are for instance the ligands’ or the receptor monomers’ abundances.
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Table 1: EGF-like growth factors and receptors: An X indicates which growth factor is able
to bind which receptor monomer.








Neuregulin 1 (NRG1) x x
NRG 2 alpha and beta x x
NRG 3 x x
NRG 4 x x
Cripto-1 (CR-1) unknown unknown unknown unknown
1.2.2 Signal transduction after receptor activation
After dimerization, tyrosine residues in the carboxyterminal region of the receptor are
autophosphorylated and prepared for binding of SH2-domain containing downstream
proteins such as GRB2. GRB2 has two SH3-domnains being binding sites for the gua-
nine nucleotide exchange factor SOS. By binding, SOS is activated and removes GDP
from Ras (KRAS, NRAS, HRAS), enabling it to get activated by binding GTP. Active
Ras binds and activates downstream targets like Raf-kinase (BRAF, CRAF, ARAF),
which then phosphorylates and activates MEK (MEK1 and MEK2). Active MEK phos-
phorylates and activates MAPK (ERK1, ERK2) which can move into the nucleus and
activate downstream factors like MYC (C-myc). MYC is mainly involved in regulatory
processes of gene transcription responsible for cell proliferation.
Another mechanism of active receptor tyrosine kinases is to trigger the PI3K-pathway
via binding of the adapter protein IRS. Active IRS binds PI3-kinase which phosphoryl-
ates PIP2 to PIP3. PIP3 is able to activate AKT which then, for instance, inhibits pro
apoptotic proteins like BAD.
1.2.3 Alterations of the MAPK- and PI3K-pathway in cancer development
The MAPK- and PI3K-pathway are two of the most important pathways in colorectal
cancer, because they regulate proliferation, differentiation and apoptosis. Mutations of
genes within these pathways lead to permanent activation of proteins causing growth
advantages compared to normal cells. RAS and RAF are components of the MAPK-
pathway whose genes are somatically mutated in a significant subset of all colorectal
cancer cases. KRAS is reported to be mutated in about 50 % whereas BRAF is reported
to be mutated in about 5 % to 15 % of all cases.20,21 Furthermore, somatic mutation of
PI3K can cause permanent activation of the PI3K-pathway. This mutation is present in
3
about 10 % to 15 % of all colorectal cancer cases.20,21
Permanent activation of both pathways is also caused by high abundances of the
EGF-receptor and its ligands. EGFR is highly expressed in about 65 % to 70 % of all
colorectal cancer cases.22 Also, its ligands Amphiregulin and Epiregulin are reported to
be overexpressed in colorectal cancer and other cancer types.23
1.3 Amphiregulin and Epiregulin are ligands of the EGFR
1.3.1 AREG and EREG gene properties
Amphiregulin, first discovered by Shoyab et al.,24 and Epiregulin, first discovered by
Toyoda et al.25 are EGF-like growth factors binding EGFR. Both genes are located on
Chromosome 4q13.3. Betacellulin and Epigen, encoding other EGF-like growth factors,
are located on this chromosomal band, too. Amphiregulin consists of 6 exons, leading
to two major splice variants. Whereas the most abundant AREG precursor protein,
being 252 aminoacids long, is made from exons 1,2,3,4 and 5, the alternative precursor
protein, being 274 aminoacids long, is made from exons 1,2,3,4 and 6. Epiregulin consists
of 5 exons leading to a 169 aminoacid precursor protein. Both, AREG and EREG
are transmembrane proteins, harboring an EGF-like domain containing three disulfite
bonds, necessary for EGFR-binding. In contrast to AREG, EREG is also able to bind
ErbB4 (see table 1). The precursor AREG protein (pro-AREG) contains several cleavage
sites and glycosylation motifs. These motifs lead to different mature AREG proteins
and influence AREG’s biological activity in different cell types.26 Primarily, ADAM-
17, a metalloprotease localized on the cell surface, cleaves pro-AREG and releases a
84 aminoacid soluble biological active form into the extracellular space (shedding).27
After shedding, the remainder of AREG protein can translocate into the nucleus and
regulate global transcription.28 Similar to AREG, the EREG precursor is also shedded
by ADAM-17 to release a 46 aminoacid functional active form into the extracellular
space,29 enabling interaction with EGFR or ErbB4.
1.3.2 AREG and EREG gene function
Being EGFR or ErbB4 activating growth factors, AREG and EREG mediate prolifer-
ation and differentiation. When shedded by ADAM-17, they can function as autocrine or
paracrine, if not shedded, as juxtacrine signal transducers.30 By activating proliferation
after estrogen and progesterone stimulation, AREG plays a central role in the develop-
ment of the mammary glands during puberty and pregnancy.31,32 AREG also mediates
endometrium proliferation and preparation of embryo implantation into the uterus.33,34
During oocyte maturation, AREG and EREG gene expression is increased.35 AREG is
involved in branching and tubulogenesis in several tissues, too, such as prostate,36 kid-
ney37 and lungs.38 Furthermore, AREG is regulated by gonadotropic hormones during
spermatogenesis.39 Finally, AREG is important in bone formation40,41 and crucial in
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neuronal development. It was identified to act as a growth factor in mouse adult neural
stem cells.42,43 In addition to the previously mentioned function in oocyte maturation,
EREG was found to contribute to corneal epithelial wound healing44 and wound healing
in gingival cells.45 EREG expression is also increased during vascular smooth muscle cell
de-differentiation, necessary for vascular remodeling.46
1.3.3 AREG and EREG in malignant tissues
Besides their functions in tissue development, AREG and EREG were also identified to
be expressed in a variety of different cancer types. AREG over-expression was, for ex-
ample, observed in breast,47,48 lung,49,50 liver,51,52 prostate,53 pancreatic,54,55 and colon
cancer.56,57,58 EREG over-expression was identified in breast,59 lung,60 colon61 and other
cancer types, too.62,63 Although EREG was also reported to inhibit tumor derived ep-
ithelial cell lines,25 the main function of both proteins is the stimulation of proliferation
by activating EGFR. Understanding AREG and EREG regulation might help to iden-
tify mechanisms of tumor growth. To do so, addressing the epigenetic features of AREG
and EREG genes might be promising, since epigenetics is a major driver for regulatory
mechanisms of gene expression.
1.4 DNA methylation and histone modifications are epigenetic
regulatory mechanisms
In 1939, Conrad Hal Waddington published his book ”An Introduction to Modern Gen-
etics” in which he first introduced and defined the phrase ”Epigenetics”.64,65 Thus, epi-
genetics is almost 15 years older than Watson’s discovery of the DNA-doublehelix.66
Waddigton created the phrase ”Epigenetics” as a name for a model to describe how
genes might interact with their surroundings to produce a phenotype. Over the decades,
the definition of ”Epigenetics” developed and changed. In one example, epigenetics was
described by Russo et al. as ”The study of mitotically and/or meiotically heritable
changes in gene function that cannot be explained by changes in DNA-sequences.”67 An-
other way of describing epigenetics was made by Adrian Bird. He defined epigenetics as
”The structural adaption of chromosomal regions so as to register, signal or perpetuate
altered activity states”.68 The best understood mechanisms responsible for structural
adaption are DNA methylation and histone modifications, both altering gene expression
during development and cancer progression.69 Of course, other epigenetic mechanisms
are known which also influence gene-expression such as miRNA mediated gene silencing.
However, due to their importance in this work, the explanations in the next sections
focus on DNA methylation and histone modifications.
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1.4.1 DNA methylation and histone modifications
DNA methylation was first discovered by Rollin Hotchkiss in calf thymus DNA in 1948.70
Typically, it occurs at CG dinucleotides (CpGs) in the human genome. The enzymes re-
sponsible for DNA methylation are DNA methyltransferases (DNMTs), first discovered
in 1975.71 DNMT1,72 responsible for maintenance of methylation during cell cycle, and
DNMT3a and 3b73,,74 responsible for de novo methylation, are the most important DN-
MTs in mammals. Genomic regions which can be methylated are e.g. located within the
genes’ promoter regions. There, CpG-rich regions, so called CpG islands, are regulatory
sites capable of inhibiting gene transcription when methylated.75 CpG-islands are char-
acterized by a GC-content greater than 50 % with an observed to expected CpG ratio of
greater than 60 % in a minimum of 200 bp region.76 Other methylation-dependent events
are genomic imprinting77 or X-chromosome inactivation78 causing chromosomal closure.
However, the majority of methylation within the human genome was not discovered in
CpG-islands, but in CpG-positions within CpG-poor regions (1 CpG per 100 bp).79,80 In
a genome wide approach, Brenet et al. recently discovered that first exon methylation
is linked to transcriptional silencing.79 Unfortunately, they were not able to present a
model for the mechanism of intragene methylation-mediated gene expression, yet.
An additional means of DNA modification was discovered recently, called CpG
hydroxymethylation. It is caused by oxidation of methylated CpGs by TET1.81 Although
little is known about CpG hydroxymethylation, it might contribute to gene regulation
and will influence epigenetic research in the future.
Other important epigenetic features are histone modifications. Due to their ca-
pability to determine if DNA is accessible for transcription or not, they have a major
impact on gene expression, too. First described by Albrecht Kossel in 1884,82 histones
are a protein class, containing histone H1 and the core histones H2A, H2B, H3, and
H4. A nucleosome is formed by an octamer of the core histones and 146 basepairs of
DNA.83 Together with H1, the nucleosomes form the chromatin structure where DNA
is condensed up to 10000-fold.84 However, to allow processes like transcription or repli-
cation, this structure needs to change dynamically from a condensed state to locally
open states. These dynamic changes are affected by three covalent histone modifica-
tions on the aminoterminal ends of the core histones: acetylation, phosphorylation and
methylation. Besides some exceptions in yeast and drosophila,85,86 histone acetylation is
mainly linked to transriptional activation.87 One important acetylation site is Lysine 14
at the aminoterminal end of histone 3 (H3K14).88 By introducing or removing acetyl-
groups, histone acetyltransferases (HATs)89 and histone deacetylases (HDACs)90 change
the affinity to DNA and adjacent nucleosomes.
Histone phosphorylation is also associated with transcriptional activation.91 How-
ever, the mechanism is not well understood, yet. Similar to acetylation, phosphorylation
might reduce the affinity to DNA and nucleosomes by introducing a negative charge. It
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was also shown that phosphorylation stimulates HAT activity.92
Histone methylation can be associated either with transcriptional silencing (H3K9
di- or trimethylation)93 or activation (H3K9 monomethylation93 or H3K4 trimethyla-
tion94). One effect of methylated histones is, for instance, the binding of heterochromatin
specific proteins like HP1 in silencing mechanisms.95
1.4.2 Epigenetic regulatory mechanisms
DNA methylation-dependent gene regulation is mainly mediated via two mechanisms.
The first mechanism involves DNA methylation-dependent transcription factors includ-
ing the most prominent ones, AP-296 and Sp1.97 Both do not bind when the binding
sites are methylated, leading to a reduction of gene expression.
The second mechanism comprises the connection between DNA methylation and
chromatin structure, established by proteins binding to methylated DNA. One of the
proteins is MeCP298 which has a methylation binding domain (MBD-domain)99 and
a transcriptional repression domain (TRD-domain). Thus, the protein is able to re-
cruit a corepressor complex, consisting of mSin3A and HDACs, to methylated DNA.
By deacetylation the chromatin changes to the condensed state leading to transcript-
ional silencing.100 Besides of MeCP2, other MBD-containing proteins like MBD2 are
able to recruit HDACs to methylated DNA.101 The functional interaction between DNA
methylation and histone modifications were also verified by studies showing that HDAC
inhibitors like Trichostatin A are able to relief MBD-containing protein mediated trans-
criptional silencing.102,101,103 Opposing this mechanism, chromatin structure can also
influence DNA methylation. By trimethylating H3K27, polycomb group proteins, such
as EZH2, induce transcriptional silent chromatin.104 Furthermore, they are able to re-
cruit DNMTs to the transcriptional silent sites105 leading to methylated DNA.
In contrast to the MBD-containing proteins, the zinc finger containing proteins
ZBTB33 (Kaiso)106 and ZBTB4 are two members of another group of transcription fac-
tors. Their zinc finger motifs show higher affinity to methylated DNA sequences than
to unmethylated DNA in vitro and thereby might repress transcription.107 Addition-
ally, ZBTB33 might be able to suppress gene expression also methylation-independently
through extra zinc finger binding motifs, called BTB/POZ-domains.106 The described
functions of ZBTB33 include, for instance, the recruitment of the N-CoR repressor com-
plex, a protein complex which promotes histone deacetylation leading to silent chro-
matin.108 However, in a recent publication it was shown that the methylation-dependent
binding might only play a minor role in the function of ZBTB33.109 By analyzing
ENCODE-data110 the authors rather identified an association of ZBTB33-binding and
actively expressed genes.
CTCF is also a zinc finger containing DNA-binding factor, which can bind to CpG-
containing sites and to sites without CpGs, too.111 Contrary to ZBTB33 and ZBTB4,
methylation of the CpG-containing binding sites reduces binding affinity.112 CTCF can
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either function as a transcriptional repressor113 or as a transcriptional activator.114 The
most important function of CTCF is to be an insulator protein being necessary to
block promoters from the influence of functionally-independent enhancers.115 CTCFL
(BORIS), a paraloque of CTCF, is able to bind the same DNA motifs as CTCF.116 De-
tected in several cancer cells,117 CTCFL is thought to interfere with CTCF-binding and
to function as an antagonist to CTCF.118
1.4.3 The impact of epigenetic mechanisms in cancer development
Epigenetic mechanisms play a major role in the formation and maintenance of all types
of cancers. In 1983, it was detected that tumor tissues have a globally reduced methylat-
ion content in comparison to corresponding normal tissues.119,120 The results were later
verified by high throughput DNA methylation analysis techniques like microarrays.121
This feature is called hypomethylation and is mainly found in gene poor areas122 but
sometimes, it can also occur at CpG-islands in promoters123 when growth-related genes
are affected. The PAX2 gene promoter e.g. was found to be hypomethylated in en-
dometrial cancers, but not in normal endometrial tissues.124 Besides growth activation,
hypomethylation also plays a role in chromosomal instability125,126 and chromosomal
rearrangement,127 which is for example observable in the reactivation of transposons.128
A further consequence of this, is loss of imprinting which can be seen, for instance, for
the insulin-like growth factor 2 in colorectal cancers (IGF2 ).129,130 During cancer deve-
lopment DNA hypomethylation increases.131 In contrast to hypomethylation, hyperme-
thylation mainly occurs in gene promoters. In different cancer types, the promoters of
the genes BRCA1 ,132 p16,133,134 E-cadherine135 and VHL136 can be methylated, leading
to their down-regulation. The hypermethylation pattern is specific for the cancer type
and increases during cancer development.137,138
For colorectal cancer, a particular hypermethylation pattern is described as CpG-
island methylator phenotype (CIMP). The CIMP-phenotype, first described by Toyota
et al. in 1999, is characterized by hypermethylation of several promoter CpG-islands
associated with inactivation of tumor suppressor genes.139 Toyota et al. suggested a list
of 30 different CpG-islands to distinguish tumors in CIMP positive or CIMP negative
tumors. Since its discovery, the CIMP-phenotype was associated with epidemiological
features, like age, gender or location of the tumor, as well as genetic features, like MSI,
KRAS and BRAF mutations.140,141 For example, when the hMLH1 -promoter is among
the methylated loci, CIMP positive tumors mainly have an MSI phenotype. But, in
contrast to MSI or other well known phenotypic subtypes of cancers, CIMP still is under
controversial discussion and not accepted by the entire scientific society.142,143 The main
reason is that the sites determining CIMP phenotype were not standardized, yet. For
the 30 different CpG-islands of the analyzed CIMP positive tumors a variety of different
methylation patterns is observable.139 As a consequence, each individual tumor might
have a different expression pattern of the 30 genes whose promoters are tested. Also, the
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mechanism for CIMP tumor development is still unknown. Therefore, there is no clear
argument supporting the relevance of the tested CpG-islands for predicting the CIMP
status.
A further example of promoter methylation leading to silenced gene expression is
the retinoblastoma gene (RB).144,145 Silenced RB cannot contribute to a protein complex
containing the chromatin remodeling proteins SWI/SNF,146 HDACs,147 polycomb class
epigenetic silencing proteins148 and DNMT1.149 The complex is necessary to silence RB
targets as e.g. the cell cycle activator gene Cyclin E 150 by changing the chromatin struc-
ture. This is an important example illustrating that DNA methylation is tightly linked to
chromatin structure in cancer cells, too. The findings are further supported by changes
in histone patterns like global loss of H4K16 acetylation or H4K20 trimethylation. These
modifications were identified as common characteristics of cancer cells.151 Additionally,
the expression of histone modifying enzymes differs between healthy tissues and cancer
tissues and also between the cancer types.152 As these examples illustrate, epigenetic fea-
tures play an important role in cancer research. Since these features are also connected
to cancer development or the response of cancer tissues to medication, epigenetics also
raises importance in clinical setting as prognostic, diagnostic and predictive markers.
1.5 Cancer treatment
1.5.1 Standard treatment options for cancer patients
Cancer can be treated by various therapeutic approaches. The most common approach is
a surgery where the tumor and close lymph nodes are removed.153 However, if the tumor
is located in a non-accessible region or if there is a high estimated risk that the tumor
relapses, further treatment options are applied. Radiation therapy is a means of killing
tumor cells by electromagnetic or particle radiation.154 The advantage of this is that ra-
diation can be applied directly to the tumor with optimized intensities for the individual
patient. The disadvantage is that surrounding healthy tissues might be harmed by the
radiation, too, leading to a variety of side effects like hair loss, damaged organs or recur-
ring cancer. A further therapy approach is chemotherapy. Chemotheapy is used to kill
fast proliferating cells, like tumor cells, by compounds influencing cell proliferation.155
One example is the FOLFIRI therapy in colorectal cancers which combines folinic acid,
5-fluorouracil and irinotecan hydrochloride.156 Folinic acid interferes with nucleotide
synthesis processes. 5-fluorouracil is a substitute of Cytosine and Thymine during DNA
polymeration processes. Irinotecan hydrochloride is a topoisomerase inhibitor. Due to
their impact on DNA replication and cell cycle processes, these compounds do not only
kill tumor cells but also other fast proliferating cells like blood cells. This leads to side
effects which are for example fatigue, digest problems or hair loss. To circumvent these
problems, new therapeutics were tested which inhibit cell proliferation by targeting a
tumor specific feature. These targeted therapeutics might be able to only affect the
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tumor and not to influence normal tissue cells.
1.5.2 EGFR-targeted therapies
Over-expression of the EGF-receptor is a feature, widely spread among different tumor
types. EGFR-inhibition will immediately lead to inhibition of cell growth and differen-
tiation. Therefore, several compounds targeting EGFR were developed.
Cetuximab Also called Erbituxr, the most important therapeutic to target EGFR is
Cetuximab. Cetuximab is a chimeric human/mouse monoclonal antibody. The mouse
precursor antibody mAB225 was developed by Gill et al. in 1984.157 They already
discovered that mAB225 is able to inhibit EGF-binding and to block EGFR autophos-
phorylation in A431 cells, an epidermoid carcinoma cell line with EGFR over-expression.
In subsequent experiments, it was investigated that mAB225 also inhibits breast can-
cer,158,159 colon cancer,160,161 renal cancer162 and prostatic cancer cell lines.163,164 Exper-
iments in xenografts165,166 showed similar results and paved the way for the first phase
I clinical trial. Patients with squamous cell carcinomas of the lung were treated with
111In-labeled mAB225 to test for toxicity and to visualize the tumor.167,168 The great
advantages of the antibody therapy was that no toxicity was observed when patients
were treated with high doses and that the antibody targeted the lung tumor cells di-
rectly. This was observed by radiolabel-dependent visualization three to five days after
injection.
In 1993, the mAB225 was chimerized by Naramura et al.169 to avoid human anti-
mouse antibody response (HAMA).170 Similar to mAB225, the mouse-human chimeric
C225, now called Cetuximab, also inhibited cell growth in several cancer cell lines and
xenografts.171,172,173,174 As a consequence, numerous phase II and phase III clinical trials
were performed. In most of the cases Cetuximab was combined with other drugs or
treatment options like radio- or chemotherapy. In a phase III clinical trial from 2005,
it was seen that initial treatment of metastatic colorectal cancer with Cetuximab plus
chemotherapy (FOLFIRI) reduced the risk of disease progression by 15 % in compari-
son to treatment with FOLFIRI alone (CRYSTAL-study).175 In this study, it was also
seen that KRAS -wildtype patients responded significantly better to chemotherapy plus
Cetuximab than KRAS -mutant patients. However, also among the KRAS -mutant pa-
tients a subset of patients responded better to Cetuximab plus FOLFIRI (odds ratio (95
% CI) = 0.80 (0.44 - 1.45), odds ratio > 1: benefit from Cetuximab plus FOLFIRI).
Finally, as a result of this study, Cetuximab was approved in the USA and in Europe
for the treatment of metastatic colorectal cancers e.g. in combination with FOLFIRI
when the tumor highly expresses EGFR. Yet, this treatment option is only valid for
KRAS -wildtype patients.
Besides Cetuximab, other antibodies were developed to interfere with EGFR-
function in colorectal cancer. One example is Panitumumab (Vectibixr) which was
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also approved for monotherapy and in combination with chemotherapeutics. However,
small molecules targeting the intracellular tyrosine kinase domain of the EGFR are also
promising. The most widely used ones are Erlotinib and Gefitinib.
Erlotinib and Gefitinib Erlotinib was shown to induce cell cycle arrest and apoptosis
in cancer cell lines.176 Also, Gefitinib was shown to inhibit the MAPK-pathway in high
EGFR expressing cancer cells.177 Both compounds were subjected to several clinical tri-
als. In contrast to Cetuximab, Erlotinib as well as Gefitinib failed to increase response in
combination therapies with chemotherapeutics.178,179,180,181 However, as a monotherapy,
Erlotinib succeeded to increase the life-span of NSCLC-patients.182 Gefitinib also led to
a better outcome, but only in patients harboring EGFR mutations.183 The SATURN-
trail confirmed an increased effect for patients with EGFR mutations, too.184 As a
consequence of these studies, FDA and EMA approved Erlotinib for the treatment of
non-small cell lung cancer and pancreatic cancer. Gefitinib was also approved for the
treatment of non-small-cell lung cancer, if the tumor comprises an activating EGFR
mutation. However, none of the compounds were approved for treatment of colorectal
cancer until now. But, phase II clinical trials are in progress.185,186,187,188
Targeted therapies gain importance in clinical treatment procedures. Patients are
stratified with biomarkers like KRAS - or EGFR mutations to increase the response rates
of such therapies. However, other biomarkers will be necessary to further optimize the
stratification procedure for example to exclude patients who will not respond, although
they are KRAS -wildtype.
1.5.3 AREG and EREG expression are predictive markers for EGFR-
targeted therapies
Due to their influence on EGFR-activation leading to activated PI3K- and MAPK-
pathways, AREG and EREG might interfere with inhibitory mechanisms of EGFR in-
hibitors. Because of this, they were considered as potential predictive markers to evaluate
the outcome of EGFR-targeted therapies. Several studies were e.g. performed in non-
small cell lung cancers. On the one hand, Ishikawa et al. and Masago et al. showed that
AREG expression correlates with a poor response to Gefitinib in NSCLC-patients.189,190
On the other hand, Yonesaka et al. found out that Gefitinib as well as Cetuximab led to
a higher growth inhibition in high AREG expressing NSCLC-cell lines compared to low
AREG expressing NSCLC-cell lines.191 They verified the cell line data by immunohis-
tochemistry analyses in patient-derived NSCLC-tumors. High AREG-staining indicated
a stable disease after Erlotinib or Gefitinib treatment, whereas low AREG expressing
patients mainly showed progressive disease. Vollebergh et al. also verified these results
by testing the sera of a large patient cohort. High AREG levels were associated with a
significantly decreased risk of death after Erlotinib or Gefitinib treatment.192 Interest-
ingly, in the same study, low TGF-α levels correlated with a better prognosis than high
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TGF-α levels.
In metastatic colorectal cancers, AREG and additionally EREG were also identi-
fied as predictive markers for the outcome of EGFR-targeted therapies. In a 110-patient-
study, Khambata-Ford et al. observed that high AREG mRNA and high EREG mRNA
expression levels were mainly detected in patient biopsies which responded to Cetuximab
therapy. They also showed that high AREG and EREG mRNA expression correlates
with a longer progression-free survival time. Finally, they verified previous data illustrat-
ing that KRAS -wildtype patients responded better to Cetuximab than KRAS -mutant
patients.193 However, in their study, the mutation status of the patients did not influence
the potential of AREG and EREG as predictive markers. In contrast to these results, Ja-
cobs et al. observed that the KRAS mutation status is indeed a criterion for the potential
role of AREG and EREG as predictive markers. In their study, including 220 patients,
high AREG as well as high EREG mRNA expression correlated with the response to-
wards a therapy including Cetuximab and Irinotecan in KRAS -wildtype patients.194 In
a study, containing 226 patients, Pentheroudakis et al. verified the findings of Jacobs et
al. for AREG.195 However, in contrast to the study performed by Jacobs et al., they ad-
ditionally observed that EREG mRNA expression correlates with the response towards
Cetuximab irrespective of the KRAS mutation status.195 That EREG can also be a
prognostic marker for overall survival of colorectal cancer patients who never received
EGFR-targeted therapy, was shown in another trial by Kuramochi et al.52 Similar to
Pentheroudakis et al., high EREG mRNA expression correlated with a higher overall sur-
vival rate in mutant KRAS -patients. Interestingly, in KRAS -wildtype patients EREG
mRNA expression correlated with a lower overall survival rate. A study performed by
Yoshida et al. verified the potential of AREG and EREG, but also the potential of other
EGFR-ligands to predict the response towards EGFR-targeted therapies.196 The results
were obtained by immunohistochemistry experiments. Therefore, it would be easy to
include AREG and EREG evaluation in routine diagnostic procedures without the need
to purify RNA. However, although the studies mentioned above mainly point towards a
positive therapy response of colorectal cancers with high AREG and EREG levels when
treated with EGFR-targeted therapeutics, it is still under investigation how other tumor
characteristics, like mutations, might influence these findings. Therefore, the identifi-
cation of the biological background of the tumor in combination with the AREG and
EREG expression and their regulation mechanisms is very important.
1.5.4 Epigenetic markers for diagnosis and cancer treatment
As already mentioned, the CpG island promoter methylation patterns varies between
healthy and cancer tissues and also among different cancer types.137 Therefore, the
identification of specific methylation patterns could serve as a good diagnostic tool for
cancer characterization. One example is the determination of the CIMP-status in co-
lorectal cancer patients described in section 1.4.3.
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Nevertheless, the methylation status of single loci might also contribute to can-
cer diagnosis. The methylation status of the Glutathione S- transferase P1 promoter
(GST1P), for example, can be used to distinguish malignant from benign tissues. In
prostate cancer patients, the GST1P -promoter is mainly hypermethylated197 but in be-
nign hyperplastic prostate tissues it is often unmethylated.198 As a second example,
promoter methylation of the BRCA1 gene occurs in an early stage of hereditary breast
cancer development.199 Therefore, it might contribute to the diagnosis of breast can-
cer onset in high-risk patients. As a further advantage, several studies showed that
methylation analyses might be easily applied on biopsies or biological fluids.200,201,202
In prognostic procedures, epigenetic features can also be used to predict the po-
tential course of disease. In head and neck cancer, methylation of the p16 promoter
correlates either with a decreased survival in TP53 -wildtype patients or with a better
survival in TP53 -mutant patients.203 Also, in colorectal cancers, p16 promoter methyl-
ation correlates with a poor prognosis.204 Another example is the DNA repair gene
O6-methylguanine-DNA methyltransferase (MGMT ). A correlation was found between
promoter hypermethylation of this gene and a poor prognosis of patients with brain can-
cers.205 Interestingly, in B-cell lymphomas, hypermethylation of the same gene correlates
with an increased overall survival.206
MGMT promoter methylation might also play a role in predicting the outcome
of cancer treatment procedures. In gliomas, it corresponds with the clinical response
to alkylating agents like carmustine207 or temozolomide.208 Other examples are hy-
permethylation of the hMLH1 promoter, which correlates with resistance to cisplatin-
based chemotherapy in ovarian cancer209 and hypermethylation of the reduced folate
carrier gene (RFC ), which is associated with a diminished response to methotrexate-
based chemotherapy in lymphomas of the central nervous system.210
The impact of epigenetic features as biomarkers during clinical evaluation processes
raised in the last years and might become as important as mutation patterns. However,
the difference between mutations and epigenetic features is that the latter can be al-
tered by epigenetic compounds such as DNA methyltransferase inhibitors or HDACis.
Thus, epigentically silenced genes could be reactivated, which is not possible for mu-
tated genes. Therefore, it is not surprising that epigenetic compounds are also discussed
as potential drugs in cancer treatment. DNA methyltransferase inhibitors, such as 5-
Azacytidine (Vidaza) or 5-Aza 2’deoxycytidine (DAC), have already been approved for
the treatment of myelodysplastic syndrome and leukemia.211 Zebularine has entered clin-
ical trials, too.212 Also HDACis were already approved for cancer treatment. Vorinostat
and Depsipeptide are for example used for treating cutaneous T-cell lymphoma.213,214
Other HDACis are subjected to phase I215,216,217,218 and phase II clinical trials.219,220,221
But in monotherapy, these compounds mainly show little or no clinical activity.222,223,224
However, preclinical data suggests that combination therapies using HDACis together
with other inhibitors might increase response.225,226,227,228,229
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1.6 Future prospects
Cancer is a heterogeneous disease having many molecular characteristics. To cope with
this heterogeneity, cancer is normally treated with chemotherapeutics or by radiothe-
rapy in order to destroy unspecifically most of the tumor cells. The introduction of
targeted therapies, such as Cetuximab in colorectal cancers, led to a more specific way
of cancer treatment. However, patients which might benefit from such a treatment
option must fulfill several molecular requirements, such as the KRAS -wildtype status
or EGFR-expression. Nevertheless, also a subset of patients, which do not fulfill the
requirements might benefit from that treatment. On the contrary, a subset of patients
treated, does not respond, but might respond to other yet unknown treatment options.
To circumvent this dilemma, several research projects were launched aiming for deeper
insights into the molecular mechanisms of cancer cells. The international Cancer Genome
Consortium e.g. was founded to analyze 50 different cancer genomes for their genomic,
transcriptomic and epigenomic changes in comparison to normal tissues. Another project
is the ColoNET consortium, founded to create an in silico model of the most important
signaling pathways involved in processes within colorectal cancer cells. These pathways
might contribute to identify new potential biomarkers in tumor therapy. Data was first
collected by analyzing well characterized colorectal cancer cells in vitro and in vivo. In
subsequent experiments, these findings should be approved in tumor tissues. Two of the
potential biomarkers identified were AREG and EREG whose expression correlates with
the outcome of EGFR-targeted therapies.193,194
1.7 Aim of the work
Within this work, the epigenetic regulation of the EGFR-ligands Amphiregulin and
Epiregulin was analyzed. Different colorectal cancer cell lines were tested for their AREG
and EREG mRNA and protein expression and the alteration of expression after treat-
ment with DNMT inhibitors and HDAC inhibitors. These results led to the following
questions:
1) Where are the epigenetic regulatory regions within the AREG and EREG genes?
2) Do these regulatory regions have promoter function?
3) What is the mechanism of epigenetic regulation?
4) Are the epigenetically regulated regions useful biomarkers for EGFR-targeted ther-
apies?
5) Is it possible to increase therapy sensitivity by increasing AREG or EREG expression,
either by epigenetic alteration or by over-expression experiments?
6) Can the in vitro findings be adopted to in vivo systems?
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0.2 µm syringe filters Whatman
0.5 µl PCR tubes Applied Biosystems
10 µl, 100 µl, 300 µl, 1250 µl filter tips Sarstedt
10 µl, 200 µl, 1000 µl pipet tips Eppendorf
1250 µl Bulk Tips Matrix
2 ml, 5 ml, 10 ml 25 ml pipet tips BD Falcon
6-well plates BD Falcon
24-well plates BD Falcon
96-well-plates BD Falcon
96-well PCR Platte, farblos ”Fast” Typ Biozym
96-well-plate Nunc MaxiSorpr flat-bottom Thermo Scientific
Adhesive Clear qPCR Seals Biozym
Cell culture flasks 75 cm2 BD Falcon
Cell scraper 25 cm Sarstedt
Cryovials 2ml Cellstar
polypropylene tubes 5 ml, 75 x 12 mm Sarstedt
Illustra MicroSpin G-50 Columns GE Healthcare
Lab glasware Duran
MicroAmpr 8-Cap Strip Applied Biosystems
MicroAmpr Clear Adhesive Film Applied Biosystems
MicroAmpr Fast 8-Tube Strip 0.1 ml Applied Biosystems
MicroAmpr Fast Optical 96-well Reaction Plate 0.1 ml Applied Biosystems
Nylon transfer membranes Hybond N+ Amersham pharmacia
Petri dishes 10 cm BD Falcon
Reaction tubes 1.5 ml, 2 ml Eppendorf
Reaction tubes 15 ml, 50 ml BD Falcon





8-Channel Electronic Pipette, 15 - 1250 µl Matrix
8-Channel Multipipet 200 µl Eppendorf
Agarose gel chamber Bio-Rad
Agarose gel documentary system Biostep
Balance BP 2100 S Sartorius
Balance RC 210 P Sartorius
BD FACSCaliburTM BD biosciences
Benchmark Plus Microplate Spectrophotometer Bio-Rad
Bio-Plex 200 Biorad
Cell Counter TC10 Bio-Rad
Centrifuge AllegraTM 6R Beckman Coulter




Centrifuge AvantiTM J25 Beckman Coulter
Clean bench LaminAirr HBB2448 Heraeus instruments
Clean bench Class II NUIARE
Clean bench HS12 Hera
Cryo 1 ℃ freezing container Nalgene
Hybridisation oven 6V/12V Unitherm
Hypercassette Amersham
Incubator GFL 3031 GFL
Incubator Hera cell 240 Hera
Luminoscan RS Labsystems
Lumat LB 9507 Berthold Technologies
MicroAmpr Adhesive Film Applicator Applied Biosystems
Microscope Leica DMIL Leica
Nanophotometer IMPLEN
Neubauer Improved cell counting chamber Carl Roth
PCR cycler T1 Thermal Cycler Biometra
Ph-meter CG 840 Schott
Pipet Boy Eppendorf
Pipets: 0.5 - 10 µl, 10 - 100 µl, 100 - 1000 µl Eppendorf
Plate shaker IKAr MTS 2/4 IKA
Power Supply EPS 200 Pharmacia Biotech
Qualitronr DW-41 Microcentrifuge Krackeler Scientific
Real-Time PCR system StepOneTM Plus Applied Biosystems
Sonicator Transsonic T310-H Elma
Stirrer IKAMAG RET IKA
Thermomixer 5436 Eppendorf
UV-crosslinker Hoefer
Vortexer Reax 2000 Heidolph
Water bath GFL 1003 GFL
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2.1.3 Chemicals and solutions
Table 4: Chemicals
Chemicals Company
2’ Propyl valeric acid (Valproat, VPA) Sigma
3,3’ ,5,5’ Tetramethylbenzidine (TMB) Sigma
3-(N-morpholino)propanesulfonic acid (MOPS) Fisher Scientific




Albumin bovine (BSA) Serva
BactoTM Agar BD
BactoTM Tryptone BD
BactoTM Yeast Extract BD
BD FACSCleanTM BD
BD FACSFlowTM BD
Calcium chloride (CaCl2) Merck
Calcium phosphate (CaPO4) Merck
Cambinol Sigma-Aldrich
Cetuximab Charité pharmacy
Dimethyl sulfoxide (DMSO) Sigma
Disodium hydrogen phosphate (Na2HPO2) Merck
dNTPs Roche
Ethylene diamine tetraacetic acid (EDTA) Sigma




Fetal Calf Serum (FCS) Biochrom AG
Formaldehyde (37 %) J.T.Baker
G418 PAA
Gefitinib LC Laboratories
Glacial acetic acid Merck
Glycerin Merck
Hydrogen peroxide (H2O2) J.T.Baker
Isopropyl alcohol (IPA) J.T.Baker
Magnesium chloride (MgCl2) Merck
Magnesium sulfate (MgSO4) Merck
Manganese(II)chloride (MnCl2) Sigma
Methanol J.T.Baker
Piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES) Merck
Polyoxyethylene (20) sorbitan monolaurate (Tweenr-20) Serva
Potassium dihydrogen phosphate (KH2PO4) Merck
Potassium acetate (CH3COOK) Merck
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Chemicals Company
Potassium chloride (KCl) Merck
Propidium iodide (PI) Fluka
Protamine sulfate Sigma
Rubidium chloride (RbCl) Sigma
Sodium acetate (CH3COONa) Merck
Sodium chloride (NaCl) Merck
Sodium nitrate (C6H5Na3O7) Merck
Suberoylanilide hydroxamic acid (SAHA) Cayman
Sulfuric acid (H2SO4) Roth






Table 5: Commercial solutions
Commercial solutions Company
1 kb DNA ladder NEB
2x TaqManr Gene Expression Mastermix Applied Biosystems
2x Power SyBrGreenr Mastermix Applied Biosystems
2x GoTaqr qPCR Mastermix Promega
100 bp DNA ladder NEB
100 bp DNA ladder PeqLabs
6 x DNA loading dye Thermo Scientific
Ampicilin (50 mg/ml) Sigma
Antibody Diluent Zytomed
Bio-Plexr cell lysis buffer Biorad
Bio-Plexr detection buffer Biorad
Bio-Plexr resuspension buffer Biorad
Bio-Plexr wash buffer Biorad
cOmplete, Mini, +EDTA Roche
DMEM Lonza
IPTG (100 mM) Sigma
Kanamycin (50 mg/ml) Sigma
LipofectamineTM 2000 Invitrogen
Liquid DAB + Substrate Chromogen System Dako
NaCl-solution PeqLabs
Optimem Gibco
Penicillin/Streptomycin (10 mg/ml) Biochrom
Peroxidase-Blocking Solution, Dako RealTM Dako
Sodiumpyrovate solution NaPyr (100 mM) Gibco
Trypsin/EDTA (0.05%/0.02%) Biochrom




VLE RPMI 1620 Biochrom AG
X-gal (40 mg/ml) Roth




1x LB medium BactoTM Tryptone (10 g), BactoTM Yeast
Extract (5 g), NaCl (10 g), pH = 7.5, ad
1 l ddH2O
1x lowsalt LB medium BactoTM Tryptone (10 g), BactoTM Yeast
Extract (5 g), NaCl (5 g), pH = 7.5, ad 1
l ddH2O
1x LB agar or 1x lowsalt LB agar ad 15 g BactoTM Agar per 1 l 1x LB or
1x lowsalt LB
10x MOPS MOPS (0.2 M), CH3COONa (80 mM),
EDTA (10 mM)
10x Tris EDTA buffer (TE) Tris-Base (0.1 M), EDTA (0.01 M), pH =
8.0
20x SSC per 1 l: 175.3 g NaCl, 88.2 g C6H5Na3O7
(Sodium citrate), dissolve in RNase-free
water
50x Tris-acetate EDTA buffer (TAE) Tris-Base (242 g), Glacial acetic acid (57.1
ml), EDTA (18.6 g), pH = 7.5 - 7.8, ad 1
l ddH2O
Citrate buffer (IHC) 10mM Citric Acid, 0.05 % Tween 20, pH
6.0
D10-medium DMEM (500 ml), FCS (10 %), Ultraglu-
tamine (1 %), Pen/Strep (0.1 mg/ml)
ELISA: Reagent Diluent 1% BSA in 1x PBS, pH = 7.4, 0.2 µm
filtered
ELISA: Stop Solution 2N H2SO4
ELISA: Wash Solution 0.05% Tweenr-20 in 1x PBS, pH = 7.4
FACS-dilution buffer 0.1 % Triton X-100, 0.5 % BSA in 1x PBS
pH = 7.4
Glycerin stock solution Glycerin (65 %), MgSO4 (0.1 M), Tris-HCl
(0.05 M), pH = 8
Homogenization buffer PIPES (10 mM), NaCl (400 mM), EGTA
(1 mM), MgCl2 (3 mM), pH = 7.4
N1 buffer (Northern blot) 2x SSC, 0.1 % SDS ad H2O
N2 buffer (Northern blot) 0.1x SSC, 0.1 % SDS ad H2O
Phosphate buffered saline (PBS) NaCl (137 mM), KCl (2.7 mM), Na2HPO4
(10 mM), KH2PO4 (1.8 mM) pH = 7.4
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Solutions Receipt
RNA-loading buffer per 2 ml: 1310 µl RNAse-free water, 210
µl 10x MOPS, 350 µl formaldehyde, 130
µl 80 % glycerin, 2 µl Ethidium bromide
(10 mg/ml), 0.03 % Bromphenol Blue
RPMI-medium VLE RPMI 1640 (500 ml), FCS (10 %),
Ultraglutamine (2 mM), Pen/Strep (0.1
mg/ml), NaPyr (1 mM)
SOC-medium Bacto Tryptone (2 %), Bacto Yeast Ex-
tract (0.5 %), NaCl (8.6 mM), KCl (2.5
mM), Mg2SO4 (20 mM), α-D-Glucose (20
mM)
Tris-buffered saline (TBS) Tris-base (50 mM), NaCl (150 mM), pH
= 7.6
TFBI CH3COOK (30 mM, pH = 5.8), RbCl (100
mM), CaCl2 (10 mM), MnCl2 (50 mM),
Glycerol (15 %)
TFBII Mops (10 mM, pH = 7), RbCl (10 mM),
CaCl2 (75 mM), Glycerol (15 %)
2.1.4 Commercial kits
Table 7: ELISA kits and antibodies
Target Antibody Company
Human AREG polyclonal AB, AB-262-NA RnD systems
goat IgG
Rabbit anti goat 61-1620 Invitrogen
HRP-conjugated antibody
Target ELISA kits Company
AREG Duosetr dy262 RnD systems
BTC Duosetr dy261 RnD systems
EGF Duosetr dy236 RnD systems
EREG E91945Hu USCN
TGF-α Duosetr dy239 RnD systems
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Table 8: Bio-Plexr assays
Protein Phosphorylation site Beadnumber Company
AKT Ser473 75 Biorad
ERK1/2 Thr202/Tyr204, 38 Biorad
Thr185,Tyr187
MEK1 Ser217/Ser221 40 Biorad
EGFR Tyr 20 Biorad
Table 9: TaqMan Gene Expression Assays: All assays are human specific unless otherwise
indicated.
Gene Dye Assay ID Company
AREG VIC Hs00155832 m1 Applied Biosystems
AREG(mouse) FAM Mm00437583 m1 Applied Biosystems
BTC FAM Hs01101204 m1 Applied Biosystems
CTCF FAM Hs00902008 m1 Applied Biosystems
CTCFL FAM Hs00966548 g1 Applied Biosystems
EREG VIC Hs00914313 m1 Applied Biosystems
EREG(mouse) FAM Mm00514794 m1 Applied Biosystems
UBE2D2 FAM Hs00366152 m1 Applied Biosystems
ZBTB33 FAM Hs00272725 s1 Applied Biosystems
ZBTB4 FAM Hs00394164 m1 Applied Biosystems
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Table 10: Other commercial kits
Other commercial kits Company
T7 High Yield RNA Synthesis Kit NEB
BCA protein assay kit Thermo Scientific
CalPhosTM kit Clontech
Cell Proliferation Kit II (XTT) Roche
Developer and Replenisher X-OMAT EXII Kodak
Dual-Luciferaser Reporter (DLRTM ) Assay Promega
Fixer and Replenisher RP X-OMAT LO Kodak
Gatewayr Technology with ClonaseTM II Invitrogen
High Pure RNA isolation kit Roche
Phusion site-directed Mutagenesis kit Thermo Scientific
PolyATtractr mRNA Isolation System IV Promega
Qiagenr Multiplex PCR Kit Qiagen
Qiagenr EpiTect Bisulfite Kit Qiagen
Qiagenr Plasmid Maxi kit Qiagen
Qiagenr Plasmid Midi kit Qiagen
Qiaprep Spin Miniprep Kit Qiagen
QIAquickr Gel extraction kit Qiagen
QIAquickr PCR purification kit Qiagen
QIAshredder kit Qiagen
RNase-free DNase Set Qiagen
RNeasyr Mini Kit Qiagen
Transcriptor High fidelity cDNA synthesis kit Roche
Venorr GeM Mycoplasm Detection kit Minerva Biolabs
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2.1.5 Enzymes
Table 11: Commercial enzymes: Enzymes were purchased together with suitable buffers and
substrates
Enzymes Buffer and Substrates Company
AmpliTaqr Gold 10x Buffer, dNTPs Applied Biosystems
AvaI NEB-buffer 4 NEB
BamHI NEB-buffer 2,3,4 NEB
CIP NEB-buffer 2,3,4 NEB
EcoRI NEB-buffer 2 NEB
EcoRV NEB-buffer 3 NEB
HindIII Buffer R Fermentas
DNA Pol. I lg Fragment
(Klenow)
NEB-buffer 2 NEB
M.SssI NEB-buffer 2, 32 mM SAM NEB
NcoI NEB-buffer 1,2,3,4 NEB
Pfu UltraTM DNA Pol. 10x buffer, 10 mM dNTPs, Agilent Technologies
Phusionr HF DNA Pol. 5x HF buffer, 10 mM dNTPs Thermo Scientific
T3-RNA-polymerase RNAPol Reaction buffer NEB
T4-ligase T4 Ligase buffer NEB
T4-PNK T4 PNK buffer, ATP NEB
T7-RNA-polymerase RNAPol Reaction buffer NEB
2.1.6 Cell lines
Table 12: Cell lines: Cell lines, used in this work, are listed together with their corresponding
growth medium and known mutations in the MAPK- and PI3K- pathway (COSMIC cell line
project (http://cancer.sanger.ac.uk/cancergenome/projects/cell lines), Roche Cancer Genome
Database (http://rcgdb.bioinf.uni-sb.de/MutomeWeb) and group internal results). For the
receipt of the media see table 6.
Cell line Mutations Medium
293T WT D10
CaCO2 WT D10
Colo678 KRAS (G12D) RPMI
HCT116 KRAS (G13D), PIK3CA (H1047R) D10
HT29 BRAF (V600E), KRAS (Q61L), PIK3CA (P449T) D10
LIM1215 KRAS (A146T) D10
RKO BRAF (V600E), PIK3CA (H1047R) D10
SW480 KRAS (G12V) D10
All cells are stored in a cell culture stock in the group of molecular tumor patho-
logy. Cells were checked regularly for their identity using a PCR-based approach and for





DH5α TM F– Φ80lacZ∆M15 ∆(lacZYA-argF) Invitrogen
U169 recA1 endA1 hsdR17 (rK–,
mK+) phoA supE44 λ– thi -1 gyrA96
relA1
PIR1 F– ∆lac169 rpoS(am) robA1 creC510 Invitrogen
hsdR514 endA recA1
uidA(∆Mlu I)::pir-116
Stbl3TM F– mcrB mrr hsdS20 (rB-, mB-) Invitrogen
recA13 supE44 ara-14 galK2 lacY1
proA2 rpsL20 (StrR) xyl-5 λ- leu mtl-1
2.1.8 Primers and oligonucleotides
The sequences of the primers and oligonucleotides which were used in this work are
shown in the supplementary material 8.1. Primers and oligonucleotides were designed
using the webtool Primer3 (V 0.4.0).230 A melting temperature of 60 ℃ was attempted
for all primers except the primers used for mutagenesis. In that case a temperature of
about 65 ℃ was suggested by the Phusion site-directed Mutagenesis kit.
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2.1.9 Plasmids
Table 14: Plasmids: plasmids are shown, which are used for cloning procedures or transfection.
Plasmids Function antibiotics Source
conc. in LB
EX-A0114-M02 Vector for transient unknown GeneCopoeia
transfection (AREG)
pBluescript II KS+ RNA expression vector Ampicilin kindly provided
50 ng/µl by M. Morkel,
Berlin
pCpGl-basic CpG-free firefly- Zeocin 25 ng/µl kindly provided
Luciferase by M. Rehli,
containing plasmid Regensburg
for promoter analysis
pCpGl-CMV Positive control Zeocin 25 ng/µl kindly provided
for promoter analysis by M. Rehli,
Regensburg




pCDH-IRES-GFP- Destination vector Ampicilin kindly provided
Puro 50 ng/µl by P. Medina
Berlin
pDONRTM 221 Donor vector Kanamycin Invitrogen
50 ng/µl
pmD2G Lentivirus packaging Ampicilin kindly provided
vector 50 ng/µl by A Kramer,
Berlin
psPAX Lentivirus packaging Ampicilin kindly provided
vector 50 ng/µl by A Kramer,
Berlin




2.1.10 Software, webtools and databases






CTCF-binding sites unknown http://bsproteomics.essex.ac.uk:8080
Ensembl Genome Browser release 68-69 http://www.ensembl.org/index.html
In silico PCR unknown http://genome.ucsc.edu/
Ascent Software (Luminoscan) 2.1 Labsystems




R statistics234 2.12.2 http://www.R-project.org/
Sequence Manipulation Suite235 2 http://www.bioinformatics.org/sms2/
StepOneTM Software 2.2.2 Applied Biosystems
UCSC Genome browser236,237 unknown http://genome.ucsc.edu/
WinMDI 2.8 Joe Trotter, The Scripps Institute
2.2 Standard procedures
2.2.1 Standard PCR
Standard PCRs were mainly performed with the AmpliTaqr Gold Taq Polymerase.
Table 16: PCR components and cycling conditions for standard PCR
Standard PCR
Reaction volume 10 - 50 µl
AmpliTaqr Gold 0.25 - 0.5 U / 20 µl rxn.
Reaction Buffer 1x
dNTPs 25 -200 µM each
Primer forw 0.05 µM - 0.2 µM
Primer rev 0.05 µM - 0.2 µM
Template genomic DNA 10 - 100 ng
Template Plasmids 100 pg
Cycling conditions 95 ℃ 15 minutes
40x
{
95 ℃ 30 seconds




Alternatively, standard PCRs were performed using 2x Mastermixes of various
suppliers e.g. Multiplex PCR Kit from Qiagen or DreamTaq Green DNA Polymerases
from Thermo Scientific. Primer concentrations and template amount as well as cycling
conditions remain equal as shown in table 16.
2.2.2 High fidelity PCR
High fidelity PCR was performed either with Phusionr DNA-polymerase or with Pfu
UltraTM High fidelity DNA-polymerase.
Table 17: PCR components and cycling conditions for High fidelity PCR
PfuUltraTM Phusionr HF
Reaction volume 50 µl 50 µl
DNA-polymerase 2.5 U 1 U
Reaction buffer 1x 1x
dNTPs 1 mM each 0.2 mM each
Primer forw 0.2 µM - 0.5 µM 0.5 µM
Primer rev 0.2 µM - 0.5 µM 0.5 µM
Template genomic DNA 50 -250 ng 50 - 250 ng
Template plasmids 100 pg 100 pg
Cycling conditions 95 ℃ 2 minutes 98 ℃ 30 seconds
40x 40x
{ {
95 ℃ 30 seconds 98 ℃ 10 seconds
Tmprimer 30 - 60 seconds Tmprimer +3 ℃ 30 sec
72 ℃ 1 minute per kb 72 ℃ 30 sec per kb
} }
72 ℃ 10 minutes 72 ℃ 10 minutes
4 ℃ HOLD 4 ℃ HOLD
The PCR components and cycling conditions are described in the corresponding
section when differing from the description above.
2.2.3 Colony PCR
Besides digestion, a further method to identify a plasmid after transformation is colony
PCR. Bacteria colonies were picked and transferred into 2 ml reaction tubes containing
100 µl LB medium. After incubating the tubes at 37 ℃ for two hours standard PCR
reactions were performed using primers which identify the plasmid and flank the insert,
primers which identify the insert and one plasmid primer plus one insert primer to




Qiagen Multiplex PCR kit was used for strand-specific PCR of bisulfite-converted c-
DNAs. Bisulfite conversion was performed using the Epitect-kit (Qiagen) as described
by the manufacturer. The PCR-volumes for the strand-specific PCR were set to 10
- 20 µl. Primer concentrations were set to 0.2 µM. The temperature program was as
following: 15 minutes at 95 ℃, 40 x (30 seconds at 94 ℃, 60 seconds at 58 ℃, 60 seconds
at 65 ℃) and a final elongation step at 72 ℃ for 10 minutes.
2.2.5 Primer phosphorylation
Primers were either purchased phosphorylated at their 5’OH group or they were phos-
phorylated using T4 Polynucleotide Kinase (T4 PNK). The 10µl reaction contained: 1x
T4 PNK buffer (NEB), 2.5 U of T4 PNK, 1 mM ATP and 77.5 µM primer. After 30 mi-
nutes at 37 ℃ the enzyme was heat inactivated for 20 minutes at 65 ℃. Phosphorylated
primers were stored at -20 ℃ without purification.
2.2.6 Agarose gel electrophoresis
DNA gel electrophoresis To analyze DNA fragment lengths 1.5 - 2 % (w/v) agarose
gels were produced as follows: Per 100 ml, 1.5 - 2 g agarose were combined with 100 ml
1x Tris-acetate EDTA buffer. After dissolving by heating in a microwave and cooling
to hand warm temperature, 2 µl Ethidium bromide (10 mg/ml) were added and the gel
was casted into an appropriate gel chamber. After coagulation 5/6 volume sample plus
1/6 volume 6x loading dye were loaded onto the gel and run for 45 to 90 minutes at 30
V to 70 V in 1x Tris-acetate EDTA buffer. The percentage of the gels as well as the run
time and the voltage depended on the expected fragment length. After electrophoresis,
gels were applied to the gel documentary system, and fragments were detected by UV
excitation of Ethidium bromide, a DNA-double-strand intercalating dye.
RNA gel electrophoresis To analyze RNA-integrity after isolation or to prepare
RNA containing membranes for Northern blot experiments, agarose gels were prepared
as follows: Per 100 ml, 1.2 g agarose were combined with 72.2 ml RNase-free water.
After dissolving by heating in a microwave and cooling to hand warm temperature 10
ml 10x MOPS- buffer and 17,8 ml formaldehyde (37 %) were added. After casting and
coagulation of the gel, 1/3 of the sample plus 2/3 of the RNA-loading dye were combined,
denatured at 95 ℃ for 2 min and loaded onto the gel. The gel was run at 40 - 50 V for
1 to 4 h. After electrophoresis, gels were applied to the gel documentary system, and
fragments were detected by UV excitation of Ethidium bromide, or gels were used for
Northern blot experiments.
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2.2.7 Plasmid restriction digest
Plasmids and PCR-products to be digested were incubated with the appropriate restric-
tion enzyme and the corresponding buffer (see table 11) and incubated at 37 ℃ for one
hour up to over night digestion. Afterwards, the enzymes were heat inactivated when
possible and the digest products were isolated when necessary. Digested plasmids were
isolated after agarose gel electrophoresis using the kit ”QIAquickr Gel extraction kit”,
whereas PCR products were isolated using the kit ”QIAquickr PCR purification kit”.
2.2.8 Plasmid in vitro methylation
In a 40 µl reaction, 6 µg of plasmids to be methylated were combined with 6 U CpG-
Methyltransferase (M.SssI), 160 µM S-Adenosyl-Methionine and 1x NEB buffer 2. In
vitro methylation was performed at 37 ℃ for 1.5 to 2 h. After heat inactivation of the
enzyme at 65 ℃ for 20 minutes, the plasmids were isolated using the kit ”QIAquickr
PCR purification kit”.
2.2.9 Generation of DNA blunt ends
Plasmids or inserts were incubated for half an hour at 37 ℃ with a 10-fold excess of DNA
Polymerase I large Klenow fragment to convert sticky ends into blunt ends after digest.
Blunt-ended fragments were then either isolated using the ”QIAquickr PCR purification
kit” or dephosphorylated (2.2.10).
2.2.10 Plasmid dephosphorylation
To reduce plasmid re-ligation, linearized plasmids were incubated for one hour at 37 ℃
with a 10-fold excess of Calf intestinal alkaline phosphatase (CIP). Dephosphorylated
plasmids were then isolated using the ”QIAquickr PCR purification kit”.
2.2.11 Plasmid ligation
T4-ligase was used to ligate linearized dephosphorylated plasmids with inserts prior to
transformation. In a 20 µl reaction 50 to 200 ng of a plasmid were combined with an
insert at a molar ratio of 1 to 3, 1x ligation buffer and 400 U of T4-ligase. The ratio was
calculated using equation 1.





) = minsert (in ng) (1)
Ligation was mainly performed over night at 16 ℃. As controls, a ligase free ligation and
an insert free ligation was added to the experiment.
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2.3 Cell culture
2.3.1 Thawing of cells
Cells are stored in liquid nitrogen. First the cryovial was removed from the storage unit
and set into a 37 ℃ water bath. After fast thawing, the cells were transferred into 15
ml reaction tubes. The appropriate cell culture medium was added dropwise to the cell
suspension to limit the probability of an osmotic shock. Afterwards, the reaction tube
was centrifuged at 800 rpm for 5 min. Then the supernatant was replaced by fresh
medium, the pellet was resuspended and transferred to a clean cell culture flask and
stored ON in a cell incubator at 37 ℃ and 5 % CO2. On the next day, the medium was
again replaced by fresh medium to remove dead detached cells from the culture flask.
2.3.2 Maintenance
The cell lines grew in 75 cm2 cell culture flasks at 37 ℃ supplemented with 5 % CO2
and approximately 96 % H2O. Cells were splitted when the cell monolayer covered ap-
proximately 70 to 90 % which occurred every second or third day.
The standard splitting procedure was as follows: After the medium was fully re-
moved from the cells, the monolayer was rinsed one time with 1x PBS (see table 6).
Afterwards, 1.5 ml Trypsin/EDTA-solution (see table 5) were added to the monolayer to
detach the cells from the flask. Detaching reaction was performed in the cell incubator
at 37 ℃ for 5 to 10 minutes. The completely detached cells were dissolved in 8.5 ml
medium and transferred into a new 15 ml reaction tube followed by 5 min centrifugation
at 800 rpm. After complete removal of the supernatant the cell pellet was redissolved
in 10 ml fresh medium. 1 to 5 ml of the cell suspension, depending on the time, when
a full flask was needed the next time, was then refilled into the cell culture flask and
supplemented with fresh medium to get 10 ml total volume. Alternatively, the cells were
frozen or seeded appropriately for an experiment.
2.3.3 Freezing
To store cells for future experiments, cells were frozen in liquid nitrogen. After splitting,
the cell pellet was resuspended in 1.5 ml medium supplemented with 10 % DMSO and
transferred into a cryovial. To avoid destruction of the cells by the formation of ice
crystals a slow decrease in temperature was necessary. The vial was put into a cryobox
filled with IPA and stored first in a -80 ℃ freezer. After the vial was completely frozen,
it was transferred into the liquid nitrogen hold.
2.3.4 Cell treatment procedures
During this work several colorectal cancer cell lines were treated with several different
compounds. These experiments were done either in 96-well plates with a cell growth
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area of 0.31 cm2 per well, in 24-well plates with 1.9 cm2, 6-well plates with 9 cm2 or
10 cm petri dishes with 60 cm2. The 96-well plates were used for growth determination
experiments (XTT), the 24-well plates were used for protein phosphorylation analysis
and the other two devices enabled the collection of supernatant for protein analysis or
RNA for RNA-expression analysis.
In general, four timepoints were analyzed per experiment. Three wells of a 96-
well plate were used per treatment for growth determination, one well of a 6-well plate
or one petri-dish was used per treatment for RNA and supernatant sample collection
per timepoint. The timepoints analyzed for cells treated with EGF-receptor inhibitors
were 24, 48, 72 and 96 h. For cells treated with epigenetic interfering compounds, the
timepoints tested included 72, 96, 120 and 144 h, because these compounds can only
interfere during cell cycle and therefore are supposed to be effective after a longer period.
The number of cells seeded per well or plate depended on the overall duration of
the experiment and the cell growth rate to avoid overgrowth. The number of seeded cells
was approximately 2500 to 5000 cells per cm2 growth area for the shorter experiments
up to 96 h, whereas the number of seeded cells was approximately 1000 to 4200 cells
per cm2 growth area for the longer experiments up to 144 h. After seeding, the cells
incubated at 37 ℃ for 24 h. Then treatment was performed daily by replacing the
complete medium with fresh medium or fresh medium containing the compound or the
solvent. The concentrations of the compounds used and the appropriate solvents are
shown in table 18.
Table 18: Compounds in treatment experiments
Name Type Solvent Concentration
Cetuximab EGFR inhibitor NaCl 9 g/l 10 µg/ml
Erlotinib EGFR inhibitor DMSO 10 µM
Gefitinib EGFR inhibitor DMSO 10 µM
DAC DNMT inhibitor NaCl 9 g/l 2.5 µM
Cambinol HDACi DMSO 20 µM
SAHA HDACi MetOH 1 µM
TSA HDACi DMSO 25 ng/ml
Valproat HDACi MetOH 1 mM, 2mM
Zebularine DNMT inhibitor NaCl 9 g/l 100 µM
2.3.5 Cell post-treatment experiments
After treating the cells for 144 h with DNA methyltransferase inhibitors (DNMT in-
hibitors) or HDACis the cells were replated into 96-well plates as follows. The super-
natant was removed and stored for ELISA. Afterwards, the plates or wells were rinsed
with 1x PBS (see table 6) and treated with 1 ml of Trypsin/EDTA solution (see ta-
ble 5). After 5 minutes of incubation at 37 ℃ the cells were redissolved in 5 ml fresh
medium and centrifuged for 5 minutes at 800 rpm. Then the pellet was redissolved in
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fresh medium and cells were counted using a Neubauer improved cell counting chamber
or the TC10 cell counter. 1500 cells per well of untreated, solvent treated and compound
treated cells were replated into four 96-well plate, reflecting four different timepoints in
a cell proliferation assay (Cell Proliferation Kit II (XTT) ).
After 24 h of incubation the supernatant of each well was replaced by medium or
medium plus EGFR inhibitors (see table 18) or the appropriate solvent. For the next four
days cellular viability was measured as described by the manufacturer. XTT absorbance
was measured 4 h and 24 h after dispension of the XTT solution. Also for the next four
days the medium of the remaining plates was replaced daily by fresh medium or medium
plus inhibitor/solvent.
2.3.6 Cell transfection experiments
To transfect cells with DNA using LipofectamineTM 2000, cells were seeded into a suitable
well that they were 70% - 90% confluent at the time of transfection. In table 19 the
composition of each transfection reaction is shown for the appropriate well size, as used
during this work.
Table 19: Compounds in transfection experiments
6 well 12 well 96 well
Solution 1
Optimem 250 µl 100 µl 8.3 µl
DNA 1 µg - 2µg 250 ng 21 ng - 55 ng
Solution 2
Optimem 250 µl 100 µl 8.3 µl
LipofectamineTM 2000 9 µl 4 µl 0.33 µl
Solution 1 and 2 were incubated at RT for 5 minutes before they were mixed. After
a second incubation step for 20 minutes at RT, the transfection solution was applied to
the cells dropwise. The cells were then incubated at 37 ℃ in the cell incubator for four
hours. Afterwards, the medium was completely replaced by fresh medium. The cells
were then put into the cell incubator until progression of the experiment.
2.3.7 Sample collection
To detect proteins in the supernatant of cells, the medium was transferred into a new
reaction vessel. Detached cells were pelleted by centrifugation at 10000 rpm and 4 ℃.
The supernatant was then transferred into a new reaction tube and stored for ELISA-
experiments at -20 ℃ (see table 7). To analyze the mRNA, the cells were processed as
described in section 2.6.
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2.4 Standard bacteria procedures
2.4.1 Generation of chemically competent bacteria PIR1
One commercial chemically competent bacteria stock PIR1 was used to generate up to
200 chemically competent bacteria stocks for transformation of pCpGl-basic and pCpGl-
basic derived plasmids. Bacteria from the commercial stock were transferred into 6 ml
LB-medium and agitated at 37 ℃ over night. On the next morning the complete volume
was transferred into 1.4 l LB-medium and agitated for four hours at 30 ℃. Then the
bacterial suspension was centrifuged for 25 minutes at 4000 rpm and 4 ℃. The pellet was
then dissolved in 150 ml TFBI -buffer (see table 6) and incubated on ice for one hour.
As a next step the suspension was again centrifuged for 25 minutes at 4000 rpm and 4
℃. Finally, the pellet was dissolved in 20 ml TFBII -buffer (see table 6) and aliquoted
in 1.5 ml reaction tubes which were chilled with dry ice. The 100 µl aliquots were then
used directly for transformation or stored at -80 ℃.
2.4.2 Agar plates and transformation
Agar plates: LB-Agar was melted slowly in a microwave. 15 ml per agar plate were
then transferred into 50 ml reaction tubes, cooled down to hand warm temperature and
combined with antibiotics (see table 14). The LB-Agar was then casted into 10 cm
petri-dishes and cooled down to room temperature. For PIR1 transformed bacteria low-
salt agar plates were casted. For bacteria, transformed with pBluescript II KS+, the
agar plates were supplemented with X-Gal (80 µg/ml) and IPTG (200 µM) to enable
blue-white screening.
Transformation: 25 µl of commercial chemically competent bacteria stocks (see table
13) or 100 µl of self made bacteria stocks (see 2.4.1) were combined with 2 to 10 µl
ligated plasmids and incubated on ice for 30 minutes. Then the bacteria were incubated
at 42 ℃ for 30 seconds (heatshock) and combined with 200 µl SOC-medium. After a one
hour agitation step at 37 ℃, 100 µl were streaked out on an agar plate and incubated
at 37 ℃ over night. Besides the plasmids of interest, every time an undigested isolated
plasmid was transformed as a positive control, an empty bacteria stock was used as a
negative control, a ligase free ligation was used as a molecular cloning procedure control.
2.4.3 Plasmid identification and isolation
After transformation, plasmid containing bacteria could be identified through their re-
sistance towards the antibiotics on the agar plate. Colonies formed on the plate. Us-
ing a pipet tip, a number of these colonies was picked and transferred into 2 ml LB-
medium, supplemented with the appropriate antibiotic. For pCpGl-basic derived plas-
mids, colonies were picked into 2 ml low-salt LB medium. Only insert-containing pBlue-
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script II KS+ -plasmid containing white colonies were picked and transferred into 2 ml
LB-medium. Each 2 ml sample was then agitated at 37 ℃ over night.
On the next day 1.5 ml of each sample was used for plasmid isolation using the
”Qiaprep Spin Miniprep Kit”. Isolated plasmids were then tested for the insert and the
orientation of the insert by restriction digest (see 2.2.7), or they were characterized by
colony PCR (see section 2.2.3) using insert and plasmid specific primers. The remaining
0.5 ml were shock frozen as described in section 2.4.4. Alternatively, after identification
of positive clones, the remaining bacteria were transferred into 100 ml or 500 ml LB-
medium or low-salt LB medium supplemented with the corresponding antibiotic (see
table 14) and agitated over night at 37 ℃. On the next day an aliquot of the bacteria
was shock frozen as described in section 2.4.4. The remaining bacteria were used for
plasmid isolation. Plasmids were isolated using either the kit ”Qiagenr Plasmid Midi
kit” or the kit ”Qiagenr Plasmid Maxi kit”. Isolated plasmids were then checked again
by restriction digest and by Sanger sequencing.
2.4.4 Storage of bacteria
0.5 to 1 ml of bacteria suspension was transferred into 2 ml cryovials and combined with
an equal amount of glycerin stock solution. After mixing, the vial was shock frozen
using liquid nitrogen. The bacteria were stored at -80 ℃. If necessary, bacteria could
be re-amplified by transferring a small amount of the frozen stock using a pipet tip into
fresh LB-medium supplemented with the corresponding antibiotic.
2.5 Protein expression analysis
Proteins were detected by ELISA experiments using the kits described in table 7.
2.5.1 Protein isolation
Proteins were isolated using 300 µl lysis buffer per 10 cm petri dish. Lysis buffer contained
78 % Homogenization buffer, 20 % cOmplete, Mini, +EDTA (1 tablet per 2 ml ddH2O)
and 2 % Triton X-100. After removal of cell medium and two wash steps with PBS,
lysis buffer was added, cells were scraped using a rubber policeman and transferred into
a 2 ml reaction tube. The tube was sonicated for one minute and stored on ice for ten
minutes. This step was repeated two times. Afterwards, the tube was centrifuged for
ten minutes at 13000 rpm and 4 ℃. The supernatants were stored at -20 ℃. Protein
concentrations were determined prior to ELISA using the BCA protein assay kit.
2.5.2 Enzyme-linked Immunosorbent Assay (ELISA)
The protocol was performed mainly as described by the manufacturer. In brief, a 96-well
Nunc Maxisorpr plate was coated with capture antibodies, covered with an adhesive strip
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and stored over night at RT. On the next day, each well was washed 3 times with ELISA
Wash solution and blocked with 300 µl Reagent diluent for at least 1 hour. After each
well was washed again 3 times, 100 µl sample or standard was dispensed in duplicates
into the wells. As sample, either 100 µl cell supernatant or 10 µg cell lysate was applied
to each well. Cell lysates and standards had been diluted prior dispense using ELISA
Reagent diluent. The plate was covered with an adhesive strip and incubated over night
at 4 ℃. On the next day, the plate was washed again 3 times and detection antibodies
were dispensed into the wells. After incubation at RT for at least 2 hours, the wells were
washed again 3 times, incubated for 20 minutes with Streptavidin-HRP, washed 3 times
and incubated with 100 µl TMB per well. After 15 to 20 minutes a blue color occurred
indicated the abundance of the protein of interest. A color change to yellow occurred
after dispensing 100 µl 1N H2SO4 per well. Optical density of each well was measured at
450 nm with a correction wavelength of 540 nm. Standard curves were generated in Excel
using a four parameter logistic curve fit. Please refer to the manual of the appropriate
ELISA-kit for exact concentrations of the antibodies and the standards used, as well
as the dispensed volumes (see table 7). The results were evaluated by comparing the
optical densities of each well with the optical density of the standard curve. For cell lysate
measurement, the protein amounts in pg refer to an input amount of 10 µg total protein.
For supernatant measurement, the results were normalized to the RNA concentrations
of the corresponding samples (see section 2.6.1). One pg RNA equals one pg produced
per day per 1 ng isolated RNA.
2.6 Gene expression analysis
2.6.1 RNA isolation
RNA was isolated either using the kit ”High Pure RNA isolation kit” (Roche Diagnostics)
or using the kit ”RNeasyr Mini Kit” (Qiagen). After the supernatant was removed from
the cells, the plate or the well was rinsed with 1x PBS and the cells were collected with
the corresponding kits’ lysis buffer. When using the Qiagen kit, the lysed cells were
then homogenized using the kit ”Qiashredder” (Qiagen). The remaining procedure of
RNA isolation was performed as described in the manual of the kit. Isolated RNA was
measured using a Nanophotometer (IMPLEN) and stored at -80 ℃.
2.6.2 CDNA synthesis
The kit ”Transcriptor High fidelity cDNA synthesis kit” (Roche Diagnostics) was used
for cDNA synthesis. Either 1 µg or the maximum possible volume of isolated RNA
was converted. CDNA synthesis was performed using random hexamers and cDNA was
stored afterwards at -20 ℃. For real-time-PCR, cDNA was used without any further
purification.
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2.6.3 Real-time PCR using the TaqMan approach
Real-time-PCR was mainly performed using the TaqManr approach from ABI. Here,
probes labeled with a fluorescent dye were used to observe the PCR amplification. Each
10 µl reaction was composed of 1x TaqManr Gene Expression Mastermix, one or two
1x primer probe sets and the cDNA template. The 1x TaqManr Gene Expression Mas-
termix contained the Taq-polymerase, dNTPs and cofactors in unknown concentrations.
Each 1x primer probe set contained the locus-specific primers and the TaqManr probes,
labeled either with the dye FAMTM or VICr. The template was applied directly from
the cDNA-synthesis or diluted up to 1:10. For gene expression analysis the signal of the
gene of interest was compared with the signal of an unregulated control gene. In this
work UBE2D2 was used as a control. The temperature program for real-time PCR was
as follows:
10 minutes - 95 ℃
40x
{ 10 seconds - 95 ℃, 1 minute - 60 ℃, data collection }
Due to their capability of analyzing two probe sets per reaction, duplex reactions were
possible, when the appropriate singleplex reactions gave similar results. After verifi-
cation experiments (data not shown) the pairs AREG/UBE2D2 and EREG/UBE2D2
were confirmed to be used in duplex reactions. In singleplex reactions, the ∆Ct values
(Ct (control) - Ct (gene of interest) ) were calculated from the means of the Ct values of
three technical replicates. In multiplex reactions, each ∆Ct value could be calculated per
well. Statistical analysis, calculation of ∆∆Ct and relative quantification was performed
as described by ABI.238
2.6.4 Real-time PCR using the SybrGreen approach
SybrGreenr is a further means of analyzing mRNA-expression. In contrast to TaqManr
an intercalating dye is used to observe the amplification of the PCR-product. Each 20
µl reaction was composed of 1x Power SybrGreenr Mastermix (Applied Biosystems) or
1x GoTaqr qPCR Mastermix (Promega), 0.2 µM of forward and reverse primers and
the cDNA-template. The 1x commercial mastermixes contained the Taq-polymerase,
dNTPs and cofactors in unknown concentrations. The template was applied directly
from the cDNA-synthesis or diluted up to 1:10. As for TaqMan, UBE2D2 was used as
control gene. The temperature program for real-time PCR was as follows:
10 - 15 minutes - 95 ℃
40x
{ 15 seconds - 95 ℃, 1 minute - 60 ℃, data collection }
As a final step, a melting curve was performed (0.5 ℃ per minute) to analyze for unspe-
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cific PCR-products.
The ∆Ct values (Ct (control) - Ct (gene of interest) ) were calculated from the means
of the Ct values of three technical replicates. Statistical analysis, calculation of ∆∆Ct
and relative quantification was performed as described by ABI.238
2.7 Protein phosphorylation analysis
Protein phosphorylation was analyzed using the Bio-Plexr Suspension Array System
(Bio-Rad). This method is a protein multiplex detection method, involving two specific
antibodies per target protein in a sandwich ELISA-based approach. One antibody is
coupled to a polystyrene-bead filled with two fluorescent dyes in distinct target specific
ratios. Up to 100 different ratios are distinguishable, meaning that theoretically 100
different proteins might be detected. The other antibody is labeled with biotin which is
necessary to couple a streptavidin-coupled fluorescent dye (phycoerythrin) to the anti-
body. The beads bound to the target proteins are then subjected to a flow cell, where
two lasers excite the beads individually. One laser excites the polystyrene-bead, which
identifies the target, the other laser excites the dye at the second antibody. The measured
fluorescence can be used to quantify the target molecules per bead.
2.7.1 Protein isolation
Cells were grown and treated in 24-well plates. The medium was removed and the cells
were washed 1x with cold 1x PBS. 25 µl Bio-Plexr cell lysis buffer supplemented with
Bio-Plexr factor 1 (1:250), factor 2 (1:500) and PMSF (500 µM) were dispensed into each
well. After sealing, the cells were shook on ice on a shaker for 20 minutes and afterwards
the plates were frozen at -80 ℃. After thawing, the lysis buffer was transferred into
reaction tubes and protein concentration was determined by the BCA protein assay kit.
2.7.2 Data aquisition
1. The first bead-coupled antibodies of either the pEGFR assay (Singleplex) or the
pMEK1, pERK1/2 and pAKT assays together (Multiplex, see also table 8) were diluted
1:100 in Bio-Plexr wash buffer. 50 µl of these dilutions were transferred per well into a
96-well filterplate.
2. The liquid was removed using a plate vacuum manifold and the plate was washed
three times with 80 µl Bio-Plexr wash buffer per well.
3. 10 to 15 µg of isolated protein were transferred into the wells, the plate was sealed,
followed by an incubation step at RT over night on a plate shaker (400 rpm).
4. The second step was repeated once.
5. The second detection antibodies of either the pEGFR assay (Singleplex) or the
pMEK1, pERK1/2 and pAKT assays together (Multiplex) were diluted 1:50 in Bio-
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Plexr detection buffer. 25 µl of these dilutions were transferred per well into the plate.
6. After a further incubation step on the plate shaker for 45 minutes (400 rpm), the
plate was washed again as indicated in step 2.
7. 50 µl 1x Streptavidin-PE was transferred into each well and the plate was incubated
in the dark for 10 minutes on the plate shaker (400 rpm).
8. The plate was washed again as indicated in step 2, but using Bio-Plexr resuspension
buffer instead of wash buffer.
9. After the last wash step, 85 µl Bio-Plexr resuspension buffer was inserted in each
well and the plate was subjected to the Bio-Plexr 200 machine.
10. 100 beads per target protein were set in the mode ”Run at high RP1-target”. The
upper gate value was set to 14,000.
2.8 Functional analysis of genomic regions
2.8.1 Plasmid generation for functional analysis
Figure 1:
Figure 1: pCpGl-basic: Klug and Rheli239 designed a CpG-free vector for promoter analysis
experiments. This vector contained a multiple cloning site in front of a firefly Luciferase gene.
Various constructs were cloned into the multiple cloning site. The figure was adopted from:
Klug and Rehli. Functional analysis of promoter CpG methylation using a CpGfree luciferase
reporter vector. Epigenetics. 2006; 1(3): 127-130
PCpGl-basic, a CpG-free Luciferase containing vector (Klug and Rheli,239 see figure
1), was used to analyze CpG-methylation dependent functional aspects of the AREG
promoter and the exon 2.
Human genomic DNA was used as input for a standard PCR containing primers
which harbor locusspecific parts and 5’- overhang sequences. In the overhang sequence
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the forward primers contained a BamHI restriction site whereas the reverse primers con-
tained a HindIII restriction site. The primer sequences are shown in the supplementary
material 8.1. They were used to amplify the AREG promoter sequence, the AREG exon
2 and the exon 2 sequence divided into two parts. The temperature program of the PCR
was as follows:
15 minutes - 95 ℃
10x
{30 seconds - 95 ℃, 30 seconds - 60 ℃, 30 seconds - 72 ℃}
30x
{30 seconds - 95 ℃, 30 seconds - 70 ℃, 30 seconds - 72 ℃}
HOLD 4 ℃
After PCR the PCR products as well as pCpGl-basic were digested with BamHI and
HindIII as described in 2.2.7. Isolated linearized pCpGl-basic was then dephosphory-
lated (see 2.2.10), ligated with the isolated PCR product (2.2.11), transformed into PIR1,
identified and isolated (2.4.2 and 2.4.3). Due to the BamHI and HindIII restriction sites,
plasmids were generated with forward oriented inserts.
For the generation of the promoter-containing plasmids, pCpGl-basic was digested
with HindIII and NcoI. The CpG-free EF1-promoter was amplified by PCR from the
control plasmid pCpGl-CMV-EF1 using the same program as shown above. Primers
were used having 5’ overhangs which contain either a HindIII restriction site (forward
primer) or an NcoI restriction site (reverse primer). To create a CpG-free Tata-binding
motif, two oligonucleotides were used, which anneal to a DNA double strand Tata motif
containing sequence with 3’-overhangs on both strands. The 3’ overhangs could be ligated
into digested HindIII and NcoI restriction sites. The EF1 -PCR product as well as the
Tata-binding motif forming oligonucleotides were ligated with the linearized plasmid to
form pCpGl-Tata and pCpGl-EF1. Plasmids were transformed and isolated (see 2.4.2
and 2.4.3).
PCpGl-basic, pCpGl-Tata, pCpGl-EF1 and pCpGl-AREG-promoter were used to
create plasmids harboring the exon 2 insert sequence in both orientations. First, the
plasmids were linearized with BamHI. The exon 2 insert as well as the exon 2 parts were
created as described above and digested with HindIII and BamHI. For the exon 2 reverse
plasmid (pCpGl-AREG-exon2-R), the insert was created directly using primers without
5’ overhang. The single-stranded overhangs of both the linearized plasmids as well as the
digested PCR products were filled to doublestranded DNA using the Klenow fragment
(see 2.2.9). The plasmids were then dephosphorylated and ligated with the PCR products
(see 2.2.10 and 2.2.11). Plasmids were transformed and isolated as described in section
2.4.2 and 2.4.3.
Finally, plasmids, harboring specific mutations were necessary to analyze the influ-
ence of the CTCF-binding site on the function of the exon 2 region. pCpGl-AREG-exon2-
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AREG-promoter, pCpGl-AREG-exon2-R-AREG-promoter and pCpGl-AREG-exon2-R-
Tata were mutated using the kit ”Phusion site-directed mutagenesis kit” and the 5’
phosphorylated primers CTCFtoHINDIII 1/2 (see: 2.2.5). These primers bind down-
stream the CTCF-binding site on both strands of the plasmid and have a 5’- overhang
that form a HindIII restriction site (see figure 2). The formation of PCR products was
performed as described by the manufacturer. The PCR-temperature program was as
follows.
30 seconds - 98 ℃
40x
{10 seconds - 98 ℃, 30 seconds - 71 ℃, 2 minutes - 72 ℃}
10 minutes - 72 ℃
HOLD 4 ℃
Circular plasmids were created by ligation. Afterwards, the plasmids were transformed
into PIR1 bacteria, isolated and characterized as described in 2.4.2 and 2.4.3.
All generated plasmids are listed in supplementary section 8.2. The sequences of
all plasmids are shown in supplementary section 8.3.
For methylation dependent promoter function analysis, several plasmids needed
to be in vitro methylated. Methylation was performed as described in section 2.2.8.
Methylated plasmids were analyzed for their methylation by restriction digest using
the methylation sensitive restriction enzyme AvaI. One example, on how methylated
plasmids were identified, is shown in supplementary section 8.5.
Figure 2:
Figure 2: Principle of plasmid mutagenesis: Phosphorylated primers which bind downstream
a CTCF-binding site on both strands of a plasmid and which harbor sequence unspecific parts,
forming together a HindIII restriction site (HindIIIa, HindIIIb) were used in the ”Phusion
site-directed mutagenesis kit” to create linear products to form new plasmids after ligation.
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2.8.2 Cell transfection and sample preparation
Plasmids were transfected either in two replicates in 12 well plates or in three replicates
in a 96 well Costar Cluster-Plate as shown in section 2.3.6. All pCpGl-basic derived
plasmids, which contain a Firefly Luciferase gene were transfected simultaneously with
a Renilla Luciferase gene containing control plasmid. After replacing the transfection
medium with fresh medium, cells were incubated in the cell incubator over night. On the
next day the medium was completely removed from the plate and each well was washed
once with 1x PBS.
12 well plate assay 200 µl 1x Passive Lysis Buffer (PLB: Dual-Luciferaser Reporter
(DLRTM Assay) were pipetted into each well. Cells were scraped from the plate and
transferred into a new reaction tube. The tubes were stored at -80 ℃.
96 well plate assay 20 µl 1x PLB (Dual-Luciferaser Reporter Assay) were pipetted
into each well. The plate was shaken for 30 minutes at 600 rpm on the plate shaker IKA
MTS 2/4, sealed and afterwards stored at -80 ℃.
2.8.3 Detection of Firefly and Renilla Luciferase activity
Luminescence measurement using Lumat LB 9507 20 µl of PLB -lysed cells
were transferred into a 5 ml polypropylene tube (Sarstedt) and mixed with 90 µl of Lu-
ciferase Assay Reagent II (LARII: Dual-Luciferaser Reporter (DLRTM) Assay). Firefly
luminescence was measured for 10 seconds. Afterwards, 90 µl of 1x Stop & Glow reagent
was tranferred into the glas vial and mixed carefully. Renilla luminescence was then
measured for 10 seconds.
Luminescence measurement on Luminoscan RS The Costar Cluster-Plate, used
for transfection, was thawed to room temperature and shaken for 10 minutes at 600 rpm.
Alternatively, 20 µl of PLB -lysed cells were transferred into the wells of a 96-well Costar
Cluster-Plate. Firefly and Renilla luminescence were measured as follows:
1. Start a clock. Pipet 70 µl of Luciferase Assay Reagent II into the first well of the
plate
2. Wait 10 seconds.
3. Pipet 70 µl of Luciferase Assay Reagent II into the second well of the plate
4. Wait 10 seconds.
5. Repeat that procedure until a maximum of 8 wells were pipetted.
6. Load the plate into the plate reader.
7. When 2 minutes are passed from the first pipet step, start measuring luminescence.
8. Measure each well for 10 seconds in high gain and collect the data.
9. When 4 minutes are passed from the first pipet step, start measuring again.
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10. Measure each well for 10 seconds in high gain and collect the data.
11. When 6 minutes are passed from the first pipet step, start measuring again.
12. Measure each well for 10 seconds in high gain and collect the data.
13. Remove plate from the reader, stop the clock and repeat the whole procedure for
the same wells but pipetting Stop & Glow reagent instead of LARII.
14. Repeat all steps, to measure all wells on the plate.
The described procedure ensured that every well was measured at the same time after
pipetting the substrate solution and that each well was measured 3 times independently.
2.9 AREG protein over-expression experiments
2.9.1 Transient transfection
LIM1215 and HCT116 cells were transfected with plasmids encoding AREG (EX-A0114-
M02, GeneCopoeia) and with a plasmid encoding EGFP as a control. Transfection was
performed in 6 well plates as described in section 2.3.6. AREG protein expression was
tested by ELISA 24, 48, 72 and 96 hours after transfection.
2.9.2 Lentiviral transduction
Lentivirus generation Several steps are required to generate lentiviruses for the over-
expression of AREG:
1. 5’ ATTB-site containing primers were used to amplify the AREG transcript sequence
by high fidelity PCR (2.2.2). The plasmid EX-A0114-M02 (see table 14) was used as a
template. In addition to the complete AREG transcript, a shorter transcript lacking the
C-terminal end of the AREG protein was created. The C-terminus has been previously
described as a potential regulatory protein in the nucleus.28
2. The kit: ”Gatewayr Technology with ClonaseTM II” was used to produce the Entry
clones by BP-reaction. As a donor vector 150 ng of pDONRTM were recombined with
50 fmol of the PCR product. The recombined plasmid was transformed into DH5α TM
as described in section 2.4.2. Isolated plasmids were sequenced with M13 primers prior
to the next step.
3. The expression plasmids were produced by LR recombination reaction using 150 ng of
the entry clones and 150 ng pCDH-IRES-GFP-Puro as described in the kit ”Gatewayr
Technology with ClonaseTM II”. Recombined plasmids were transformed into Stbl3,
selected and isolated as described in section 2.4.2 and 2.4.3. The correct inserts were
identified by digest with NheI and HindIII and comparison with in silico data (see sup-
plementary material section 8.6).
4. Viruses were produced using 293T cells at S2 conditions. Transfection of the vi-
ral components and the expression clone was performed using the CalPhosTM -kit from
Clontech in 293T cells at about 40% confluency. 8.4 µg of the expression clones or as
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control pCDH-IRES-GFP-Puro were combined in 526 µl H2O with 6 µg psPAX and
3.6 µg pmD2G plasmids. The overall volume was adjusted to 600 µl with 2M Calcium
solution (supplied with the kit). The plasmid mixture was added dropwise to 600 µl
2x HBSS (supplied with the kit) while vortexing carefully. After an incubation of 20
minutes at RT, the mixture was spread dropwise onto the 293T cells. The cells were
incubated over night in the cell incubator. On the next day the medium was replaced
by fresh medium. The following day the virus containing supernatants were collected
and centrifuged at 800 rpm for 5 minutes to remove cellular debris. The procedure was
repeated again on the next day. All supernatant was then passed through a 0.2 µl filter
and stored at -80 ℃.
Transduction LIM1215 cells were used for transduction at 70 % confluency. First the
medium was replaced by medium containing protamine sulfate (c = 8 µg/ml ) followed
by a 30 minute incubation step at 37 ℃. Afterwards, the cells were transduced by adding
the filtered virus containing supernatants to the wells. Medium was changed each day
for the next two days. On the second day the fresh medium was supplemented with
puromycin (c = 0.02 µg/ml) to select for the transduced cells. Selection was performed
for two weeks. The cells were then stored as described in section 2.3.3 or used for
experiments.
2.10 Northern blot analysis
To detect a potential AREG reverse non-coding RNA, Northern blot analyses were
performed with RNA-probes from different regions within the AREG gene.
2.10.1 Probe generation
RNA probes were derived from the plasmid pBluescript II KS+ , which harbors a T3-
and T7-RNA promoter flanking a multiple cloning site. Inserts were cloned into the
plasmid in the following way:
1. The inserts were produced by high fidelity PCR (2.2.2) containig the Pfu Ultra Poly-
merase and phosphorylated primers (2.2.5). The Tm of the reaction was set to 58 ℃.
2. pBluescript II KS+ was linearized with EcoRV to create blunt ends (2.2.7). After-
wards, the blunt ends were dephosphorylated (2.2.10).
3. After agarose gelelectrophoresis (2.2.6) the linear plasmid was isolated (QIAquickr
Gel extraction kit, Qiagen).
4. Insert and plasmid were ligated (2.2.11) and transformed into DH5α TM (2.4.2).
5. pBluescript II KS+ enables blue-white screening for colonies containing plasmid plus
insert. Only white colonies were isolated and characterized (2.4.3). The sequences are
shown in supplementary material 8.8.
6. Isolated plasmids were digested either with EcoRI or HindIII to obtain linear plas-
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mids for RNA-polymerization (see supplementary material 8.7).
7. 1 µg of the digested plasmids were introduced to the kit ”T7 High Yield RNA Syn-
thesis kit”. Probes were generated as described in the manual using either T7 or T3
RNA-polymerase, and [α-32P]-UTP. Incubation was performed at RT for 2 h.
8. The template DNA was digested using DNaseI by incubating the reaction for 15
minutes at 37 ℃.
9. Finally the probes were purified using the Illustra MicroSpin G50-columns (GE-
Healthcare) and radioactivity was determined using a radioactivity counter.
Steps 7 to 9 were performed by the technician Cornelia Gieseler.
2.10.2 Blot-membrane generation
The technician Cornelia Gieseler generated the blot-membranes. Equal amounts of poly-
A-RNA, which were isolated using the kit ”PolyATtractr mRNA Isolation System IV”
(Promega) were loaded per lane onto an RNA-agarose gel (see 2.2.6) Gels were run at
50 V for 4 h. The RNA-transfer from the gels to the blots was performed in subsequent
steps:
1. A basin was filled with 20x SSC -buffer and covered with a glas-plate.
2. A Whatman 1MM paper was wet with 20x SSC and placed on the glas plate in a way
that two sites of the paper reach into the 20x SSC in the basin.
3. Two gel-sized Whatman 1MM papers were placed onto the wet Whatman paper.
4. After wetting in 5x SCC for 5 min, the gel was placed upside-down onto the Whatman
papers.
5. A nylon transfer membranes (Hybond N+) was placed onto the gel.
6. Then, 4 dry 1 MM Whatman papers were placed on top of the nylon membrane.
7. Paper towels were put on top of the Whatman paper to a height of approx. 10 cm
and a final glas plate was placed on top of the towels.
8. The blotting device was adjusted with a heavy weight and left over night.
9. On the next day, all towels and papers were removed, the samples were marked on
the membrane and the membrane was put in 2x SCC.
10. The membrane was dried for 1 minute by placing it on a dry Whatman paper.
11. The membrane was transferred with the RNA side-down on a UV transilluminator
(254 nm wavelength), and the RNA on the membrane was crosslinked for an appropriate
length of time.
12. Finally, the membrane was shrink-wrapped and stored at -20 ℃.
2.10.3 Hybridization and readout
Hybridization and readout was also performed by the technician Cornelia Gieseler using
the following steps:
1. The membranes were unwrapped and transferred into hybridizing tubes.
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2. 10 ml Ultrahyb -Buffer (Amerhsham) was added to each membrane for pre-hy-
bridization at 68 ℃ for 2 hours
3. Then, each RNA-probe was added completely to the appropriate membrane and the
membranes were incubated at 68 ℃ ON.
4. On the next day, the hybridization buffer plus probes were removed and the mem-
branes were washed using buffer N1 for 15 minutes at 30 ℃.
5. Afterwards, the membranes were washed again using buffer N2 for 15 minutes at 68
℃.
6. Then the membranes were shrink-wrapped and put into a film-chamber together with
2 radiographic films.
7. After ON-incubation at -80 ℃, the films were developed by using the developer and
fixer system from Kodak.
2.11 Immunohistochemistry
The IHC-experiments were performed by the technician Kerstin Möhr using 0.3 µm
paraffin slices on standard microscopic glass slides.
2.11.1 Dewaxing
1. The slides were incubated at 70 ℃ for 20 minutes.
2. The slides were incubated 3 times for 5 minutes in 100 % Xylene.
3. The slides were incubated 2 times for 5 minutes in 100 % Ethanol.
4. The slides were incubated each 3 minutes in 96 %, 90 %, 80 % and 70 % Ethanol.
5. Finally, the slides were incubated 3 minutes in H2O.
2.11.2 Demasking
1. The slides were put into citrate buffer and incubated in a steam cooker for 20 minutes.
2. The slides were cooled down slowly to room temperature and incubated for 15 minutes
in H2O.
3. Finally, the slides were incubated for 10 minutes in a 3 % H2O2-solution.
2.11.3 Blocking and 1st antibody incubation
1. 100 to 150 µl Peroxidase-Blocking Solution, Dako RealTM was pipetted onto the cells
on the slides.
2. The slides were incubated for 30 minutes in a wet chamber.
3. After rinsing with 1x TBS, the AREG-Antibody was diluted 1:400 in antibody Diluent
(Zytomed) and transferred to the cells.
4. The slides were incubated over night at 4 ℃ in a wet chamber.
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2.11.4 2nd antibody incubation and staining
1. After rinsing with 1x TBS, the 2nd antibody (rabbit anti goat, HRP-conjugated) was
pipetted onto the slides in a 1:350 dilution.
2. The slides were incubated 1 hour at room temperature.
3. After rinsing with 1x TBS, Liquid DAB + Substrate Chromogen System (Dako) was
added to the slides.
4. The antibody-staining was stopped after 60 seconds by rinsing with H2O.
5. The slides were incubated for 10 seconds in hematoxylin-solution to stain the nuclei.
6. The slides were washed in H2O.
7. Finally, the slides were incubated for each 10 seconds in 70 %, 80 %, 90 %, 96 % and
100 % Ethanol.
2.11.5 Embedding
1. 20 to 75 µl of 1:1 solution containing Xylene and Vitro-Clud was pipetted onto the
slides.
2. A cover-glass was put onto the slide and the slide was dried.
2.12 External methods
Methylation analysis as well as Xenograft experiments were performed by external co-
laborators within the Colonet consortium. Methylation analysis was performed by Dr.
Sascha Tierling in the Institute of Genetics and Epigenetics in Saarbrücken, Xenograft
experiments were performed by Maria Rivera in the group of experimental pharmacology
in the Max-Delbrück Center Berlin-Buch.
2.12.1 Methylation analysis
The following protocols were written and operated by Dr. Sascha Tierling:
DNA preparation and bisulfite treatment DNA was prepared using standard
protocols. Bisulfite treatment was performed on 500 ng genomic DNA. Briefly, DNA
was treated with 2 M sodium bisulfite and 0.6 M NaOH, then denatured for 15 min at
99 ℃ and incubated for 30 min at 50 ℃. We introduced two thermo spikes of 99 ℃ for
5 min followed by two incubation steps of 1.5 h at 50 ℃. Purification was achieved by
loading, desulfonation with 0.3 M NaOH and washing with 1 x TE on a microcon YM-30
column (Millipore, Schwalbach, Germany). Bisulfite DNA was eluted in 50 µl 1 x TE.
Promoter methylation analysis by 454 GS-FLX sequencing Amplicons were
generated using region- specific primers with the recommended A and B adaptors (Roche,
Mannheim, Germany) at their 5’ -end. PCR of bisulfite-treated DNA was performed in
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a total volume of 30 µl containing 3 µl Hot Star-Taq reaction buffer (Qiagen, Hilde,
Germany), 2.4 µl dNTPs, 2.5 mM each, 100 nmol of each primer, 1.25 U Hot Star-Taq
(Qiagen, Hilden, Germany) and 2 µl of bisulfite DNA. After initial denaturation at 95
℃ for 15 min, 40 cycles were carried out (denaturation 95 ℃ for 1 min, annealing 54 ℃
for 1 min, extension 72 ℃ for 1 min and final extension 72 ℃ for 5 min). PCR prod-
ucts were visualized on 1.2 % agarose gels, purified using the Gel/PCR DNA Fragments
extraction kit (AVEGENE, Taipei, Taiwan) and measured by intercalating fluorescence
dye (Qubit HS-Kit, Invitrogen, Darmstadt, Germany) using Qubit Fluorometer (Invit-
rogen, Darmstadt, Germany). After amplicon pooling, emulsion PCR was performed
using Lib-A emPCR protocols. DNA-containing beads were recovered, enriched and
sequenced from the A-adaptor on a XLR70 TitaniumPicoTiterPlate according to the
manufacturers protocols (Roche, Mannheim, Germany).
MsSNuPE-experiments and HPLC separation Fifty ng of genomic DNA were
used as a template in a 30 µl reaction volume in the presence of 3 mM Tris-HCl, pH 8.8,
0.7 mM (NH4)2SO4, 50 mM KCl, 2.5 mM MgCl2, 0.06 mM of each dNTP, 3 U HotFire
DNA polymerase (Solis BioDyne, Tartu, Estonia) and 1 µM primers. 5 µl of the PCR
products were treated with 1 µl of ExoSAP (1:10 mixture of Exonuclease I and Shrimp
Alkaline Phosphatase, USB) for 30 min at 37 ℃. To inactivate the ExoSAP enzymes
the reaction was incubated for 15 min at 80 ℃. Afterwards, 14 µl primer extension
mastermix (50 mM Tris-HCl, pH 9.5, 2.5 mM MgCl2, 0.05 mM of all four ddNTPs, 3.6
µM of each SNuPE primer, 2.5 U Termipol DNA polymerase (Solis BioDyne, Tartu,
Estonia)) was added. Primer extension reactions were performed at 96 ℃ for 2 min
followed by 50 cycles 96 ℃ / 30 sec, 50 ℃ / 30 sec, 60 ℃ / 2 min. Separation of
products was conducted at 50 ℃ by continuously mixing buffer B (0.1 M TEAA, 25 %
acetonitril) to buffer A (0.1 M TEAA), either over 15 min: 23-31 % (AREG A2), or 15
min: 22-35 % (EREG A2).
2.12.2 Xenograft experiments
The in vivo experiments (generation and treatment of xenografts, as well as tissue collec-
tion) were carried out by Maria Rivera in the group of experimental pharmacology in the
Max-Delbrück Center Berlin-Buch. 5x106 LIM1215 cells were injected subcutaneously
into immunodeficient NMRI nu/nu mice. Per treatment five mice were used. Three inde-
pendent experiments were performed. In the first experiment (MV10107) the influence
of Valproat alone and in combination with Erlotinib on tumor growth was examined.
In the second experiment (MV10532) the treatment mode was changed to evaluate the
effect of Valproat treatment prior to Erlotinib treatment on tumor growth. And in the
third experiment, the influence on tumor growth of 5-Azacytidine alone and in combi-
nation with Erlotinib was tested. After cell injection, tumor growth was measured two
times a week. When the tumors reached a volume of approximately 0.1 to 0.2 cm3 the
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treatment started, which was for MV10107 on day 19, for MV10532 on day 12 and for
MV10533 on day 13 post injection. The treatment modes and the concentrations of the
used inhibitors are shown in table 20. The concentrations correspond to the highly tol-
erable doses in human treatment. After finishing the experiments, the mice were killed
and the tumors were shock frozen in liquid nitrogen. Afterwards, the tumors were stored
at -80 ℃. Parts of the tumors were used for RNA isolation and AREG/EREG mRNA
expression analysis (see section 2.2.7) as well as immunohistochemistry experiments.
49
Table 20: Design of xenograft experiments to compare in vitro results in an in vivo system:
i.p.: intraperitoneal injection, p.o.: oral treatment
MV10107 Application Days Dose (mg/kg/inj.)
Solvent (PBS)
Valproat i.p. Mon-Fri, 2x/day 200
Erlotinib p.o. Mon -Fri 50
Cetuximab i.p. every 7th day 2x (q7dx2) 50
Valproat + i.p. Mon-Fri, 2x/day 200
Erlotinib p.o. Mon -Fri 50
MV10532 Application Days Dose (mg/kg/inj.)
Solvent (NaCl)
Solvent (NaCl) i.p. day 1 to 6
Erlotinib p.o. day 7 to 11 50
Erlotinib + p.o. day 1 to 6 50
Valproat i.p. day 7 to 11 200
Valproat + i.p. day 1 to 6 200
Erlotinib p.o. day 7 to 11 50
MV10533 Application Days Dose (mg/kg/inj.)
Solvent (NaCl)
Erlotinib p.o. days 1-5, 7, 13-17, 22, 23 50
5-Azacytidine i.p. days 1-5, 7, 13-17, 22, 23 5
5-Azacytidine + i.p. days 1-5, 7, 13-17, 22, 23 5
Erlotinib p.o. days 1-5, 7, 13-17, 22, 23 50
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3 Results
3.1 Amphiregulin and Epiregulin are differentially expressed
in colorectal cancer cell lines
Figure 3:
Figure 3: AREG and EREG expression in different colorectal cancer cells: Seven colorectal
cancer cell lines were tested for their AREG and EREG mRNA expression and protein levels at
4 different timepoints. 1st row: The ∆Ct values were calculated by subtraction of the AREG
or EREG Ct-value from the control Ct-value. 2nd row: The AREG or EREG protein amounts
in the supernatant were normalized to the corresponding RNA concentration. 3rd row: The
AREG and EREG protein amounts are shown per 10 µg total cell lysates (see section 2.5.2).
The mRNA expression of Amphiregulin and Epiregulin was tested in several co-
lorectal cancer cells at four timepoints by real-time PCR. The amounts of the cor-
responding proteins in the supernatant or the cell lysates were also tested by ELISA
experiments (see figure 3). EREG protein was neither detected in the cell lysates nor
in the supernatants by the ELISA assay used. Negative values in the ELISA-barplots
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indicate that the ELISA raw data of these samples was equal or lower than the raw
data of the negative controls. Therefore, although comparison with the standard curve
led to negative values, these values should be considered as zero. In contrast to EREG,
there was a good correlation between AREG mRNA expression and protein amounts.
Low AREG mRNA expression correlated with a lack of detectable AREG protein in the
supernatant or in the cell lysate, whereas high AREG mRNA expression correlated with
high AREG protein amounts. Although there was a discrepancy between the AREG pro-
tein amount in HCT116 cells between the supernatant and the cell lysate, the data could
still be used to divide the cells in three groups of AREG mRNA and protein expressing
cells and two groups of EREG mRNA expressing cells. The AREG groups consisted
of cells with low AREG mRNA expression and no or only very low detectable amounts
of AREG protein (SW480, RKO and Colo678), cells with medium AREG mRNA ex-
pression and low detectable amounts of AREG protein (LIM1215 and HT29) and cells
with high AREG mRNA expression and high amounts of AREG protein (HCT116 and
CaCO2). The EREG groups consisted of cells with no or very low EREG mRNA ex-
pression (SW480, RKO, Colo678 and LIM1215) and cells with medium to high EREG
mRNA expression (HCT116, CaCO2).
The EREG mRNA expression correlated with the AREG mRNA expression, too. The
cells comprising the low AREG expressing group appeared in the group of no or very
low EREG mRNA expressing cells (SW480, RKO, Colo678). In a similar way, the cells
comprising the high AREG expressing group appeared in the group of medium to high
EREG mRNA expressing cells (HCT116, CaCO2). However, this only holds true for the
EREG mRNA expression, since EREG proteins were not detected.
3.2 AREG and EREG are regulated epigenetically
When testing HCT116 cells for their mRNA expression patterns with and without ex-
pressed DNA methyltransferases, Sers et al. found out that the AREG mRNA expression
was reduced in the cells, lacking DNMTs.240 These data indicated that at least AREG
is regulated by epigenetic regulatory mechanisms. To address this, two cell lines of
the low AREG expressing group (SW480, RKO), one cell line of the medium AREG
expressing group (LIM1215) and two cell lines of the high AREG expressing group
(HCT116, CaCO2, see section 3.1) were tested for their AREG and EREG expres-
sion after treatment with the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine
(Decitabine, DAC) and Zebularine or after treatment with histone deacetylase Inhibitors
(HDACi).
DAC is a derivative of Deoxycytidine whereas Zebularine is a derivative of Cytidine.
Both are precursors of Deoxycytidine triphosphate, a building block for DNA. After in-
corporation into DNA, DAC as well as Zebularine inhibit DNA methyltransferases and
as a consequence lead to a demethylation of the whole genome after several rounds of
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DNA replication.
Histone deacetylases are responsible for the formation of heterochromatine by re-
moving acetyl groups from lysines at the N-termini of histones. As a consequence the
affinity of histones to DNA increases, which leads to a blocking of the DNA for transcrip-
tion factors and to a down-regulation of the transcriptional machinery. By inhibiting
histone deacetylases, transcriptional rates are increased all over the genome.
3.2.1 AREG and EREG expression increases after treatment with the
DNMT inhibitor DAC
Figure 4:
120 h: 144 h:
Figure 4: AREG and EREG mRNA expression after DAC treatment: Five cell lines were
tested for their AREG and EREG mRNA expression after treatment with 2.5 µM DAC for 120
and 144 h. The data were sorted according to the AREG mRNA expression of the untreated
cells (see figure 3). In each plot the relative quantification of the expression is shown compared
to the untreated control (RQ = 1).
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Figure 5:
120 h: 144 h:
Figure 5: AREG protein expression after DAC treatment: Five cell lines were tested for their
AREG protein amount in the supernatant after treatment with 2.5 µM DAC for 120 and 144
h. The data were sorted according to the AREG mRNA expression of the untreated cells (see
figure 3). In both plots the relative AREG level is shown compared to the untreated control
(rel. AREG = 1).
As shown in figures 4 and 5, DAC led to an up-regulation of AREG mRNA and
AREG protein as well as EREG mRNA. EREG protein was not tested. By comparing
the initial AREG and EREG levels (see figure 3) and the effect of DAC onto mRNA
and protein expression (see figures 4 and 5), it was observed that the increase of AREG
and EREG mRNA and protein levels by DAC was higher in cells which expressed lower
initial levels of AREG and EREG and vice versa. One exception was SW480 at 144 h
showing a reduced AREG mRNA expression but an increased protein level.
The cell lines were also treated with 100 µM of the DNA methyltransferase inhibitor
Zebularine. But compared to DAC, Zebularine did not change the AREG expression after
120 or 144 h of treatment (see supplementary material 8.9, figures 73 and 74). Neither
AREG mRNA expression nor AREG protein levels in the supernatant were increased.
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3.2.2 AREG and EREG expression increases after treatment with histone
deacetylase inhibitors
Figure 6:
120 h: 144 h:
Figure 6: AREG and EREG mRNA expression after Valproat treatment: Five cell lines were
treated with 1 mM or 2 mM Valproat (Valproat 1 or 2) for 120 and 144 h. The data were
sorted according to the AREG mRNA expression of the untreated cells (see figure 3). In each
plot the relative quantification of the expression is shown compared to the untreated control.
Figure 7:
120 h: 144 h:
Figure 7: AREG protein expression after Valproat treatment: Five cell lines were treated
with 1 mM or 2 mM Valproat (Valproat 1 or 2) for 120 and 144 h. The data were sorted
according to the AREG mRNA expression of the untreated cells (see figure 3). In both plots
the relative AREG level is shown compared to the untreated control.
To test if AREG and EREG expression can also be changed by HDACis, the cells
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were treated for 120 and 144 h with 1 and 2 mM Valproat as described in section 2.3.4. As
shown in figure 6 and 7, there is no correlation between the AREG and EREG expression
in untreated cells and the change of AREG and EREG expression by Valproat, as seen
for DAC treated cells (see figure 4). Treatment with 2 mM Valproat increased the AREG
mRNA expression only in LIM1215 by a factor of three to four at both timepoints. For
the other cells, Valproat seemed to affect the expression in a different way. For SW480
cells, an increased AREG mRNA expression was also seen. Compared to the untreated
control, an increase by a factor of 2.5 was seen after 120 h treatment. However, at 144 h
AREG mRNA expression declined again to 1.5 fold. Valproat affected the EREG mRNA
expression to a larger extent. For the very low expressing cells LIM1215 and SW480
treatment with 1 and 2 mM Valproat increased the EREG mRNA level between 5 and
60 fold at both timepoints. In contrast, RKO only showed an increased EREG mRNA
level after 120 h, when treated with 1 mM Valproat. The EREG protein expression
after Valproat treatment was tested by Stephan Bartels (Charité Berlin, Institute for
Pathology) in his Master thesis.241 But similar to the results obtained for untreated cell
lines in this work (see figure 3) EREG protein was not detected in any of the tested
samples, irrespective of Valproat treatment.
Valproat treatment influenced the AREG protein levels (figure 7) similar to the
AREG mRNA expression. LIM1215 increased levels up to 5 times. However, unlike
AREG mRNA expression, 2 mM of Valproat led to an increase of AREG protein in
RKO and SW480 after 144 h of treatment. Thus, mRNA expression and protein levels
are not consistent following inhibition of histone deacetylation.
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Figure 8:
120 h: 144 h:
Figure 8: AREG and EREG mRNA expression after TSA treatment: Five cell lines were
treated with 25 ng/ml TSA for 120 and 144 h. The data were sorted according to the AREG
mRNA expression of the untreated cells (see figure 3). In each plot the relative quantification
of the expression is shown compared to the untreated control.
Figure 9:
120 h: 144 h:
Figure 9: AREG protein expression after TSA treatment: Five cell lines were treated with 25
ng/ml TSA for 120 and 144 h. The data were sorted according to the AREG mRNA expression
of the untreated cells (see figure 3). In both plots the relative AREG level is shown compared
to the untreated control.
To confirm the influence of histone deacetylation on AREG or EREG expression,
the effect of other HDACis was tested. Trichostatin A (TSA) led to an up-regulation
of the AREG mRNA level in all tested cells after treatment for 120 h and in all cells
except SW480 cells after 144 h (see figure 8). However, in that cell line EREG mRNA
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expression increased by about 90 fold compared to the untreated control. For the other
cell lines except HCT116 cells the EREG mRNA level was also increased upon treatment
with TSA. AREG protein levels increased also for all cells but in contrast to the mRNA




Figure 10: AREG mRNA expression after treatment with different HDACis: LIM1215 and
SW480 were treated with different HDACis for 144 h (TSA: 25 ng/ml, Cambinol 20 µM, SAHA
1 µM, Valproat 1 mM, DMSO: solvent control for TSA and Cambinol, Methanol: solvent control
for SAHA and Valproat). In both plots the relative quantification of the expression is shown
compared to the untreated control.
To investigate, if inhibition of histone deacetylases generally leads to an up-
regulation of AREG, and to address, if the abrupt changes in the AREG expression are
common in the cells, LIM1215 and SW480 cells were tested for their AREG mRNA
expression after treatment with the previously tested TSA and Valproat, but also with
two additional HDACis, SAHA and Cambinol. AREG mRNA was analyzed for 6 time-
points between 24 h and 144 h. In figure 10 is shown that all four HDACis in LIM1215
and all HDACis except Cambinol in SW480 led to an up-regulation of AREG mRNA.
In contrast to LIM1215, the HDACis led to a higher up-regulation of AREG mRNA
expression in SW480 at early timepoints, but the effect diminished towards the late
timepoints, although the cells were treated daily with the HDACis. In LIM1215 the
AREG mRNA expression remained almost stable at all timepoints.
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To conclude, AREG and EREG expression were mainly increased by the DNA
methyltransferase inhibitor DAC in different cells. The effect depended on the initial
AREG or EREG expression. Expression was also increased by HDACi treatment but in
this case it did not depend on initial AREG or EREG expression. In contrast to expres-
sion changes by DAC treatment, expression changes by treatment with HDACis strongly
varied between the timepoints of the experiments and between different experiments, too.
Also discrepancies between AREG and EREG mRNA and protein expression were seen
after treatment. Nevertheless, the experiments show that AREG and EREG might be
regulated by epigenetic mechanisms. In the next step, the potential epigenetic regulatory
control regions of both genes were identified.
3.3 AREG and EREG promoters are mainly unmethylated in
colorectal cancer cell lines
The AREG gene as well as the EREG gene are located at chromosome 4q13.3. The
promoter regions of both genes were tested first for their methylation by second gene-
ration 454 GS-FLX sequencing. The locations of the promoters in relation to the genes
are shown in figure 11.
Figure 11:
Figure 11: Chromosomal positions of AREG and EREG genes and gene promoters: Both
genes AREG and EREG are located on chromosomal band 4q13.3. The positions of the
corresponding promoters are indicated by black bars.
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The experiments leading to figure 12 and the figure itself were made by Dr. Sascha
Tierling (Institute of Genetics and Epigenetics, University of Saarland, Saarbrücken).
Figure 12:
Figure 12: Methylation of AREG and EREG promoters after 454 GS-FLX deep bisulfite
amplicon sequencing: Five different cell lines and DNA from normal colon mucosa were tested
for their AREG and EREG promoter methylation. Per sequenced sample, 40 to 50 reads are
shown, represented by the lines. CpG-positions are represented by the columns. Genomic
positions are defined by the first proximal and last distal CpG of the analysed amplicon.
Averaged DNA methylation and total number of reads are given at the right of the respective
map. Blue: the CpG is unmethylated, Red: the CpG is methylated, White: the methylation
status was not detected.
AREG and EREG promoters were mainly unmethylated in the cell lines CaCO2,
HCT116, LIM1215 and SW480 and the colon mucosa. In RKO cells, the AREG pro-
moter was also mainly unmethylated, however, the EREG promoter region was highly
methylated.
Since AREG and EREG mRNA and protein levels were shown to be up-regulated
in the cells by DAC, but the promoters were mainly unmethylated in the tested cells, the
epigenetic regulatory regions might be at different regions within the genes. To identify
these regions Dr. Sascha Tierling screened for CpG-positions within the AREG and
EREG genes, which were methylated and lost their methylation among DAC treatment.
He identified two CpGs in both genes by msSNuPE experiments fulfilling these criteria
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(data not shown, patent filed). The positions within the genes are shown in figure 13.
The CpGs within the AREG gene were named CpG p150 and CpG p220, the CpGs
within the EREG gene were named CpG p143 and p297.
Figure 13:
Figure 13: Chromosomal positions of AREG and EREG genes and intragenic CpGs: The
intragenic AREG CpGs p150 and p220 are located within the AREG exon 2, whereas the
intragenic EREG CpGs p143 and p297 are located within the EREG intron 1.
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3.4 The methylation of intragenic CpG-sites within the AREG
and EREG genes varies among different colorectal cancer
cell lines
Figure 14:
Figure 14: Methylation of AREG and EREG intragenic CpG-sites in different colorectal can-
cer cells: Seven colorectal cancer cells were tested for their intragenic methylation at AREG
CpG p150 and p220 and at EREG CpG p143 and p297 (see figure 13) at four different time-
points. The methylation index shows the content of methylation indicating products within the
primer extension products in msSNuPE-experiments and is an indicator for DNA methylation
at the given CpG. A methylation index of 1 means fully methylated whereas a methylation
index of 0 means fully unmethylated. Cells were sorted according to their AREG mRNA
expression (see figure 3).
In section 3.1 was shown that the tested cell lines could be divided into low, medium
and high AREG expressing cells. The comparison of figure 3 and figure 14 shows that the
cells of the AREG high expressing group (HT29, HCT116 and CaCO2) were completely
unmethylated at the AREG CpG p150 (MI = 0) and showed little methylation at AREG
CpG p220 (Methylation index < 0.2). In contrast, methylation of these CpGs was
observed among the AREG low and medium expressing cells. RKO and LIM1215 showed
high methylation (MI > 0.5). Also SW480 showed a higher methylation than the cells
of the AREG high expressing group (CpG p150: MI > 0.1 with an average of 0.23,
CpG220: MI > 0.2 with an average of 0.32). With the exception of Colo678 (CpG p150:
MI average of 0.1, CpG p220: MI average of 0.18), methylation of the two AREG CpGs
seemed to correlate with the AREG mRNA expression.
However, EREG mRNA expression did not correlate with the methylation at the
62
identified CpGs within the EREG gene (see figure 3). Within the EREG medium and
high mRNA expressing cells, HT29 was not methylated at the CpG p143 and CpG
p297, whereas CaCO2 was fully methylated. Also in the EREG low expressing cells, the
methylation index within RKO and Colo678 ranged from 1 to 0. Thus, methylation of
CpGs p143 and p297 did not correlate with the EREG mRNA expression.
As a next step it was tested if DAC-treatment leads to a decrease of methylation
in the observed CpGs to clarify if the increase of gene expression observed earlier could
be explained by differential methylation within these regions.
3.5 Epigenetic compounds change the methylation of the in-
tragenic CpG-sites in AREG and EREG genes
SW480, RKO and LIM1215, the cells exhibiting the highest methylation indices at AREG
CpG p150 and CpG p220, were tested for methylation of these CpGs after treatment
with the DNA methyltransferase inhibitor DAC (see figure 15). SW480 cells became
fully unmethylated in both CpGs after 72 h of treatment. Demethylation remained
up to 144 h of treatment. In LIM1215 and RKO cells, treatment with DAC also led
to a decrease of methylation in both CpGs, however, methylation did not disappear
completely in all timepoints as seen for SW480. Nevertheless, the methylation indices of
both CpGs dropped in RKO cells from high (0.8 < MI < 1) to low (0 < MI < 0.3) and in
a similar way in LIM1215 from high (0.5 < MI < 0.8) to low (0.1 < MI < 0.3). Since it
was shown earlier that AREG mRNA expression correlated with methylation in AREG
CpG p150 and CpG p220, an explanation of the AREG mRNA expression change after






Figure 15: AREG intragenic methylation after DAC treatment: Three cancer cell lines were
tested for their intragenic methylation at AREG CpGs p150 and p220 after treatment with 2.5
µM DAC at four different timepoints. The methylation index (MI) shows the content of methy-
lation indicating products within the primer extension products in msSNuPE-experiments and
is an indicator for DNA methylation at the given CpG. A methylation index of 1 means fully







Figure 16: EREG intragenic methylation after DAC treatment: Four cancer cell lines were
tested for their intragenic methylation at EREG CpGs p143 and p297 after treatment with 2.5
µM DAC at four different timepoints. The methylation index (MI) shows the content of methy-
lation indicating products within the primer extension products in msSNuPE-experiments and
is an indicator for DNA methylation at the given CpG. A methylation index of 1 means fully
methylated whereas a methylation index of 0 means fully unmethylated.
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The intragenic EREG CpGs p143 and p297 were methylated in the four cell lines
SW480, RKO, LIM1215 and CaCO2. Therefore, it was also tested if methylation changed
after DAC treatment (see figure 16). In contrast to what was observed for AREG,
methylation of the EREG CpGs did not decrease in SW480 and LIM1215, although
SW480, for example, had a methylation index similar to the AREG CpGs. In RKO and
CaCO2 methylation of the CpGs decreased. The strongest effect was observed in CaCO2.
However, EREG mRNA expression did not change in CaCO2 after DAC treatment (see
figure 4). Unfortunately, the samples RKO 72 h and 144 h as well as LIM1215 96 h -




Figure 17: AREG intragenic methylation after TSA treatment: SW480 and LIM1215 were
tested for their intragenic methylation at AREG CpG p150 and p220 after treatment with 25
ng/ml TSA at six different timepoints. The methylation index (MI) shows the content of methy-
lation indicating products within the primer extension products in msSNuPE-experiments and
is an indicator for DNA methylation at the given CpG. A methylation index of 1 means fully
methylated whereas a methylation index of 0 means fully unmethylated.
In addition to investigating the effect of DAC treatment it was also tested, whether
HDACis have an effect on the intragenic methylation of the AREG gene, since treatment
with HDACis mainly led to an increase of AREG expression, too (see section 3.2.2). The
effect of TSA onto the methylation of AREG CpGs p150 and p220 is shown for the cells
SW480 and LIM1215 in figure 17. Both cells differ in their initial methylation index,
but in contrast to DAC treatment, methylation of the tested CpGs was changed upon
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TSA treatment in none of the cells. However, in LIM1215 a reduction of CpG p150
methylation was observed from MI = 0.8 to MI = 0.6. A tendency was also seen for
CpG p220 but to a lower extend.
Besides the effect of TSA, the effect of Valproat on the methylation of the intragenic
AREG CpGs (see figure 18) and EREG CpGs (see figure 19) was tested, too. Neither





Figure 18: AREG intragenic methylation after Valproat treatment: SW480, RKO and
LIM1215 were tested for their intragenic methylation at AREG CpG p150 and p220 after
treatment with 1 mM or 2 mM Valproat (Valproat 1 and 2) in four different timepoints. The
methylation index shows the content of methylation indicating products within the primer ex-
tension products in msSNuPE-experiments and is an indicator for DNA methylation at the
given CpG. A methylation index of 1 means fully methylated whereas a methylation index of







Figure 19: EREG intragenic methylation after Valproat treatment: Four different cell lines
were tested for their intragenic methylation at EREG CpG p143 and p297 after treatment with
1 mM or 2 mM Valproat (Valproat 1 and 2) in four different timepoints. The Methylation index
was calculated after msSNuPE experiment. A methylation index of 1 means fully methylated
whereas a methylation index of 0 means fully unmethylated.
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To summarize, DAC treatment led to a decrease of methylation at the intragenic
AREG CpGs. Contrary, DAC had a lower effect on the methylation of the intragenic
CpGs of the EREG gene. The HDACis TSA and Valproat did not influence methylation.
3.6 The AREG intragenic CpG-site has methylation-depend-
ent promoter function
As shown in section 3.4, AREG expression correlated with the intragenic methylation at
CpG p150 and p220 within AREG exon 2. To address the biological function of these
CpGs, a promoter function of exon 2 was tested. For that, plasmids were generated with
the CpG-free plasmid pCpGl-basic as backbone239 (see figure 1). Because pCpGl-basic is
a CpG-free plasmid, in vitro methylation of all plasmids would only lead to methylation
within the insert, but not in the plasmid. Thus, a potential methylation-dependent
promoter function can be analyzed.
Plasmid generation is described in section 2.8.1. Four groups of plasmids were
made, which are described in figures 20 to 23. PCpGl-basic derived plasmids were used
to analyze functions of AREG promoter and exon 2 directly (see figure 20). Besides
the AREG-promoter, also the EF1 -promoter and a Tata-binding motif were cloned into
the pCpGl-basic plasmid to be combined in subsequent steps with the AREG exon 2
sequence. The obtained pCpGl-AREG-promoter derived plasmids (see figure 21) as
well as pCpGl-EF1 and pCpGl-Tata derived plasmids (see figures 22 and 23) were used
to analyze AREG exon 2 function, when coupled to a promoter or promoter element.
PCpGl-AREG-exon2-R, pCpGl-AREG-exon2-Tata and pCpGl-AREG-exon2-R-Tata
were methylated in vitro to analyze methylation dependency (see figure 24).
A CTCF-binding site located within AREG exon 2, was mutated in the plasmids
pCpGl-AREG-exon2-R, pCpGl-AREG-exon2-AREG-promoter, pCpGl-AREG-exon2-
R-AREG-promoter and pCpGl-AREG-exon2-R-Tata, to analyze the influence of this
transcription factor binding site on promoter function (see figure 24). All pCpGl-basic
derived plasmids contain a Firefly-Luciferase reporter-gene (Luc). Luminescence was
used to evaluate promoter function, after supplying firefly luciferin to the extracts of the
transfected cells. As a transfection control a Renilla-Luciferase reporter-gene containing
plasmid (Ren) was used in each experiment (see section 2.8.3).
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Figure 20:
Figure 20: pCpGl-basic derived plasmids for promoter function analysis: The complete se-
quence and two parts of the sequence of AREG exon 2 were cloned into the plasmid pCpGl-basic
(see figure 1). The intragenic CpGs p150 and p220 are located within exon 2 of the AREG
gene (represented by white circles). A CTCF-binding site is located within exon 2 of the
AREG gene, too (represented by ”CTCF”). Also the sequence of the AREG-promoter, the
EF1 -promoter and the Tata-binding motif were cloned into the plasmid (see section 2.8.1).
The insert-orientations are indicated (arrows) in front of the Firefly-Luciferase gene (Luc).
The name of each plasmid is shown how they are used in the text.
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Figure 21:
Figure 21: pCpGl-AREG-promoter derived plasmids for promoter function analysis: The
complete sequence and two parts of the sequence of AREG exon 2 were cloned into the plasmid
pCpGl-AREG-promoter (see figure 20) The intragenic CpGs p150 and p220 are represented
by white circles, a CTCF-binding site is indicated by ”CTCF”. The insert-orientations are
indicated (arrows). The name of each plasmid is shown how they are used in the text.
Figure 22:
Figure 22: pCpGl-EF1 derived plasmids for promoter function analysis: The complete se-
quence and two parts of the sequence of AREG exon 2 were cloned into the plasmid pCpGl-EF1
(see figure 20) The intragenic CpGs p150 and p220 are represented by white circles, a CTCF-
binding site is indicated by ”CTCF”. The insert-orientations are indicated (arrows). The name
of each plasmid is shown how they are used in the text.
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Figure 23:
Figure 23: pCpGl-Tata derived plasmids for promoter function analysis: The complete se-
quence and two parts of the sequence of AREG exon 2 were cloned into the plasmid pCpGl-Tata
(see figure 20) The intragenic CpGs p150 and p220 are represented by white circles, a CTCF-
binding site is indicated by ”CTCF”. The insert-orientations are indicated (arrows). The name
of each plasmid is shown how they are used in the text.
Figure 24:
Figure 24: pCpGl-basic w/o MCS and in vitro modifications of the plasmids for promoter
function analysis: To address the effect of the MCS on the promoter function, a MCS-free
pCpGl-basic was created. To address methylation-specific effects on the promoter function
and the effect of the CTCF-binding site located within AREG exon 2, plasmids were modified
by methylation (represented by black circles) or by mutation (represented by red star).
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In LIM1215 cells, an increased promoter function was observed for the AREG
promoter-containing plasmid (see figure 25 A). AREG exon 2 and also the tested AREG
exon 2 parts did not have promoter function within the tested plasmids. Also, no increase
in promoter function was seen for the CpG-free EF1-promoter and the Tata-binding
motif. Next, the sequences of AREG exon 2 or the AREG exon 2 parts e2150 and e2220
were coupled to the AREG promoter-sequence containing pCpGl-basic derived plasmid
(see figure 25 B). The sequences of e2150 as well as e2220 did not change promoter function
of the AREG promoter neither in forward nor in reverse orientation. A minimal increase
of promoter function was observed when coupling the AREG exon 2 sequence completely
to the promoter. But this increase was not significant. The promoter function analysis
of the AREG exon 2 coupled to the EF1 is shown in figure 25 C. Compared to EF1,
none of the exon 2 derived sequences increased promoter function. Actually, all observed
values are near to zero.
When coupling AREG exon 2 in reverse orientation to the Tata protein binding
motif (see figure 25 D), promoter function was significantly increased compared to the
Tata-binding motif alone. But when coupling any other sequence to the Tata-binding
motif, no significant increase was observed. However, as seen in figure 25 D, the ex-
periment was accompanied with very high standard deviations of the measurements,
which are caused, for example, by bad transfection efficiency. As a consequence, the
results are not trustworthy for the very low measured data. Therefore, LIM1215 cells






Figure 25: Promoter function analysis in LIM1215 cells: Promoter analysis was performed by
luminescence measurement using the DLR Assay (Promega) after transfection into LIM1215.
Firefly-luciferase derived luminescence (Luc) was normalized by Renilla-luciferase derived lu-
minescence (Ren). A: pCpGl-basic derived plasmids, B: pCpGl-AREG-promoter derived plas-
mids, C: pCpGl-EF1 derived plasmids, D: pCpGl-Tata derived plasmids. A two-tailed het-







Figure 26: Promoter function analysis in HCT116 cells: Promoter analysis was performed by
luminescence measurement using the DLR Assay (Promega) after transfection into HCT116.
Firefly-luciferase derived luminescence (Luc) was normalized by Renilla-luciferase derived lu-
minescence (Ren). A: pCpGl-basic derived plasmids, B: pCpGl-AREG-promoter derived plas-
mids, C: pCpGl-EF1 derived plasmids, D: pCpGl-Tata derived plasmids. A two-tailed het-
eroscedastic student’s t-test was performed for some of the samples: *: p-value < 0.05 , **:
p-value < 0.01
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Similar to LIM1215, promoter function was also detected in HCT116 for the AREG
promoter (figure 26 A). As before, no promoter function was seen for the EF1 promoter,
the Tata-binding motif as well as the AREG exon 2 derived sequences. Besides the
AREG exon 2 part e2150 containing plasmid, the promoter functions of the measured
plasmids were even lower than the function of the insert free pCpGl-basic.
When introducing the AREG exon 2 sequence into the AREG promoter sequence
containing pCpGl-plasmid (figure 26 B), the promoter function increased significantly
compared to the AREG promoter alone. Surprisingly, the promoter function increased
stronger, when coupling the AREG exon 2 sequence in reverse orientation to the AREG
promoter sequence. The increase was highly significant. Due to this result it is probable
that the AREG exon 2 sequence rendered enhancer effects to the AREG promoter in
HCT116 cells. The AREG exon 2 part e2220 showed also a significant increase of promoter
function, when coupled to the promoter in reverse orientation. However, the effect was
lower than the effect of the complete AREG exon 2 sequence indicating that both CpGs,
or the whole AREG exon 2 is necessary for the enhancer effect.
Similar to the results in LIM1215, EF1 as well as the EF1 derived plasmids did not
have promoter function in HCT116 (see figure 26 C). Therefore, EF1 and EF1-derived
plasmids were omitted from future experiments.
The Tata-binding motif did not show significant promoter function in HCT116 cells
(figure 26 D). When introducing the AREG exon 2 sequence to the Tata-binding motif
in forward orientation, promoter function increased. Interestingly, when introducing the
AREG exon 2 sequence in reverse orientation, promoter function increased highly sig-
nificant about 10-fold. Also the AREG exon 2 sequence parts, e2150 and e2220, increased
promoter function 3-fold and 4-fold respectively when coupled to the Tata-binding motif
in reverse orientation.
In the last two experiments it is obvious that the values obtained by the promoter
assays were very low. To test whether the values were above background, an experiment
was performed using HCT116 cells and the plasmids pCpGl-AREG-exon2-R-Tata and
pCpGl-AREG-promoter, which differ in the values created by promoter function experi-
ments by approximately one magnitude. After transfection, the cell extracts were diluted
7 times in 2-fold steps to determine the measurement background of the Luminoscan RS






Figure 27: Validation of promoter function experiments: HCT116 cells were transfected
with pCpGl-AREG-exon2-R-Tata or pCpGl-AREG-promoter together with the Renilla control
plasmid. The cell lysates were diluted in 2-fold steps and luminescence was measured using
the DLR Assay (Promega). A: Firefly-luciferase derived luminescence, B: Renilla-luciferase
derived luminescence, A-B: ”experimental results”: values obtained in all promoter function
experiments within this study: blue: HCT116, green: LIM1215, red: CaCO2. C: Firefly-
luciferase derived luminescence (Luc) was normalized by Renilla-luciferase derived luminescence
(Ren).
Firefly-luciferase derived luminescence as well as Renilla-luciferase derived lumi-
nescence was observed in all diluted samples (see figures 27 A and B). Besides the
Firefly-luciferase derived luminescence of the 1/128 dilution, which had a very high er-
ror bar, the values showed a linear correlation to the dilution. The graphs describing
this linear correlation did not flatten to a constant luminescence value, which means
that the background of the Luminoscan RS luminometer was not reached, yet. Also,
when normalizing the Firefly-luciferase derived luminescence by Renilla-luciferase de-
rived luminescence, all dilutions gave similar results (see figure 27 C). The normalization
procedure is applicable for values down to approximately 0.4 for Renilla- and 0.06 for
Firefly-derived luminescence. As seen at the right sides of the Firefly and Renilla-plots
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(see figures 27 A and B), all values within these study obtained for HCT116 and CaCO2
transfected cells lie above these thresholds. Only some values of the LIM1215 transfected
cells lie below the value of the Firefly-luciferase derived luminescence, which might be
due to the low transfection efficiency in LIM1215 cells mentioned earlier. To summarize,
this experiment demonstrated that the values obtained in this study are valid and could
be analyzed.
The results of the t-tests are a second issue when interpreting the results of the
promoter function experiments. Although the p-values calculated, showed that the re-
sults of two plasmids differ significantly, the significance is sometimes hardly observable
in the figures, especially when other plasmids led to much stronger results (see e.g. fig-
ure 26 D or figure 29 C). Nevertheless, to verify the t-tests, figure 26 D was enlarged
as an example to show that the significance calculated is also visible in the plots (see
supplementary material section 8.4).
In the following two experiments, it was analyzed, how methylation of AREG CpG
p150 and p220 affects promoter function.
Figure 28:
Experiment 1: Experiment 2:
A B
C D
Figure 28: Methylation-dependent promoter function analysis in HCT116 cells: Promoter
analysis was performed by luminescence measurement using the DLR Assay (Promega) after
transfection into HCT116 cells. Firefly-luciferase derived luminescence (Luc) was normalized
by Renilla-luciferase derived luminescence (Ren). Two independent experiments were made.
(left and right). upper A and B: pCpGl-AREG-promoter derived plasmids, C and D: pCpGl-
Tata derived plasmids. Black filled circles indicate an in vitro methylated insert. A two-tailed
heteroscedastic student’s t-test was performed for some of the samples: *: p-value < 0.05 , **:
p-value < 0.01
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In both additional experiments, the sequence of AREG exon 2 increased promoter
function significantly when coupled in reverse orientation to the AREG promoter (see
figure 28 A and B). Similar to the experiment before (see figure 26 B), the AREG
exon 2 sequence also increased promoter function when coupled to the AREG promoter
sequence in forward orientation (see figure 28 A).
When coupling the sequence of AREG exon 2 in reverse orientation to the Tata-
binding motif (see figure 28 C and D), a highly significant increase of AREG promoter
function was observed in both experiments and confirmed the earlier results. Interes-
tingly, when methylating the sequence of AREG exon 2, the promoter function increased
stronger when comparing with the unmethylated sequence. The effect was even signi-
ficant in experiment 1. In the same experiment there was also observed a significant
increase, when coupling AREG exon 2 in forward orientation to the Tata-binding mo-
tif. Similar to the reverse-oriented exon 2 sequence, a further significant increase was







Figure 29: methylation-dependent promoter function analysis in CaCO2 cells: Promoter
analysis was performed by luminescence measurement using the DLR Assay (Promega) after
transfection into CaCO2 cells. Firefly-luciferase derived luminescence (Luc) was normalized
by Renilla-luciferase derived luminescence (Ren). A: pCpGl-basic derived plasmids, B: pCpGl-
AREG-promoter derived plasmids, C: pCpGl-Tata derived plasmids. Black filled circles indi-
cate an in vitro methylated insert. A two-tailed heteroscedastic student’s t-test was performed
for some of the samples: *: p-value < 0.05 , **: p-value < 0.01
Promoter function of the plasmids was also analyzed in CaCO2 cells. (see figure
29). Similar to the other cell lines, AREG promoter showed promoter function whereas
EF1 and the Tata-binding motif alone did not. (figure 29 A). In contrast to the other
cell lines, coupling AREG exon 2 to the AREG promoter led to a decreased promoter
function compared to the promoter alone (see figure 29 B and data not shown). This
effect was orientation-independent. When coupling AREG exon 2 in forward orientation
to the Tata-binding motif (figure 29 C), the promoter function of the Tata-binding motif
decreased. The decrease was even significant for the methylated sequence. But similar
to HCT116, coupling AREG exon 2 to the Tata-binding motif in reverse orientation led
to a 6-fold increase of promoter function. However, in contrast to HCT116, additional







Figure 30: Methylation and CTCF dependent promoter function analysis in HCT116
cells: Promoter analysis was performed by luminescence measurement using the DLR Assay
(Promega) after transfection into HCT116 cells. Firefly-luciferase derived luminescence (Luc)
was normalized by Renilla-luciferase derived luminescence (Ren). A: pCpGl-basic derived plas-
mids, B: pCpGl-AREG-promoter derived plasmids, C: pCpGl-Tata derived plasmids. Black
filled circles indicate an in vitro methylated insert, A red star indicates that the CTCF-binding
site was mutated to a HindIII binding site. A two-tailed heteroscedastic student’s t-test was
performed for some of the samples: *: p-value < 0.05 , **: p-value < 0.01
To address the potential influence of the CTCF-binding site within the AREG exon
2 sequence on the promoter function, mutated plasmids were generated using the Phusion
site-directed mutagenesis kit (Thermo Scientific). Afterwards, the promoter function was
compared to the non-mutated counterparts. HCT116 was used for analysis, because it
showed the best results in the experiments before (see figure 30).
The sequence of AREG exon 2 in reverse orientation had a highly significant
stronger promoter function than the same sequence in forward orientation (see figure
30 A). But when mutating the CTCF-binding site within these sequences, the promoter
function dropped significantly. When methylating the AREG exon 2 reverse-oriented
sequence, promoter function increased compared to the unmethylated sequence, but
81
not significantly. But, similar to the unmethylated state, mutation of the methylated
reverse-oriented AREG exon 2 sequence led to a significant drop in promoter function,
too. Surprisingly, pCpGl-basic alone showed promoter function as high as the plasmid
containing the AREG exon 2 reverse-oriented sequence.
When coupling the reverse-oriented AREG exon 2 sequence to the AREG promoter se-
quence, promoter function increased significantly similar to the experiments before (see
figure 30 B). However, mutation of this plasmid led to a complete loss of promoter func-
tion. Also, similar to the experiments before an increase of promoter function of the
AREG promoter was observed when coupling the AREG exon 2 sequence in forward
orientation to the AREG promoter. However, the effect was not significant. But when
mutating the CTCF region, promoter function decreased significantly.
Last, the promoter function of the AREG exon 2 sequence coupled to the Tata-binding
motif was evaluated (see figure 30 C). As in the experiments before, the reverse-oriented,
but not the forward oriented AREG exon 2 sequence increased promoter function of the
Tata-binding motif highly significant. Also as seen before, methylation of the reverse-
oriented AREG exon 2 increased promoter function significantly. And similar to the
AREG promoter coupled plasmids, mutation of the CTCF-binding region in unmethy-
lated as well as methylated reverse-oriented AREG exon 2 sequences led to a highly
significant drop of promoter function in Tata-motif coupled plasmids.
In the final experiment of this study, the conflict was addressed that pCpGl-basic
and pCpGl-AREG-exon2 showed similar promoter function. A new plasmid was gener-
ated which lacks the multiple cloning site. Also, the influence of the CTCF-binding site
on promoter function was analyzed again. The results are shown in figure 31. The pro-
moter function dropped significantly for the pCpGl-basic plasmid without MCS which
indicates that the MCS has promoter function (see figure 31 A). Similar to the exper-
iments before, mutating the CTCF-binding site of AREG exon 2 leads to a significant
drop of promoter function compared to the unmutated plasmids when coupled to the






Figure 31: Repetition of CTCF-dependent promoter analysis and evaluation of the influence
of the MCS: Promoter analysis was performed by luminescence measurement using the DLR
Assay (Promega) after transfection into HCT116 cells. Firefly-luciferase derived luminescence
(Luc) was normalized by Renilla-luciferase derived luminescence (Ren). A: pCpGl-basic derived
plasmids, B: pCpGl-AREG-promoter derived plasmids, C: pCpGl-Tata derived plasmids. Black
filled circles indicate an in vitro methylated insert, A red star indicates that the CTCF-binding
site was mutated to a HindIII binding site. A two-tailed heteroscedastic student’s t-test was
performed for some of the samples a: *: p-value < 0.05 , **: p-value < 0.01
To summarize, the AREG exon 2 region, comprising CpG p150 and CpG p220
showed different promoter activity in different cells. In HCT116, it showed enhancer func-
tion in both orientations, when coupled to the AREG promoter. By mutating the CTCF
site, the promoter function decreased strongly. When coupled to the Tata-binding motif
in reverse orientation, the AREG exon 2 sequence highly increased promoter function.
Interestingly methylation enhances this effect. Nevertheless, mutation of the CTCF-
binding site had also a strong negative effect on promoter function in the methylated
plasmids.
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3.7 Zinc finger binding transcription factors are differentially
expressed in colorectal cancer cell lines
Mutation of a CTCF-binding site within the AREG exon 2 sequence led to a drop of pro-
moter function (see section 3.6). Therefore, the zinc finger binding transcription factors
CTCF or CTCFL might contribute to AREG gene expression. To test this hypothesis,
first CTCF as well as CTCFL mRNA levels were analyzed in different colorectal cancer
cells. In addition, the mRNA expression of the zinc finger binding transcription factors
ZBTB4 and ZBTB33 were also tested, because similar to CTCF and CTCFL, the pro-
teins are able to bind CpG-containing DNA sequence motifs as well as CpG-free DNA
sequence motifs.242
Figure 32:
Figure 32: Transcription factor mRNA expression in in different colorectal cancer cells: Five
colorectal cancer cell lines were tested for their CTCF, CTCFL, ZBTB4 and ZBTB33 mRNA
expression from 72 h to 144 h after first medium change. Left: The ∆Ct-values were calculated
by subtraction of the AREG or EREG Ct-value from the control Ct-value. The cells were
sorted according to their AREG mRNA expression (compare with figure 3).
In figure 32 the mRNA expression of CTCF, CTCFL, ZBTB4 and ZBTB33 is
shown in five different colorectal cancer cell lines at four timepoints. The cancer cells
were sorted according to their initial AREG gene expression (compare figure 3). CTCF -
mRNA expression was present in all cell lines independent of their AREG expression,
which is represented by high ∆Ct-values. The AREG low expressing cell line SW480
as well as the AREG high expressing cell line CaCO2 showed a reduced mRNA expres-
sion compared to the remaining cell lines. CTCFL mRNA was not expressed in the
cells. ∆Ct-values of -10 and less indicate that the Ct-values for CTCFL rose at very
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late cycle numbers, reflecting a very low mRNA level. RKO as well as LIM1215 showed
no CTCFL-mRNA expression at all. Contrary to CTCF, ZBTB4 as well as ZBTB33
showed a differential mRNA-expression pattern in different cells. An inverse correlation
between AREG mRNA expression and transcription factor expression was observed for
ZBTB33. Low AREG mRNA expressing cells (SW480, RKO) expressed higher ZBTB33
mRNA levels than high AREG mRNA expressing cells (HCT116, CaCO2). Also ZBTB4
mRNA expression differed between the cells and similar to ZBTB33, CaCO2 showed the
lowest mRNA expression. Furthermore, a time-dependent variation in all cells occurred
except in CaCO2 showing that ZBTB4 and ZBTB33 might be regulated during prolifer-
ation. Although LIM1215 and HCT116 cells showed an increased ZBTB4 and ZBTB33
mRNA expression over time, the AREG mRNA expression remained stable (see fig-
ure 3). In HCT116 cells, the AREG protein level increased in the supernatant also
time-dependently. However, this did not fit the inverse correlation seen for all cells.
Nevertheless, other arguments strengthen the influence of ZBTB33 on the AREG ex-
pression.
Natalia Kuhn, a phd-student in the group of molecular tumorpathology at the
Institute for Pathology (Charité Berlin), performed an experiment reducing the ZBTB33
expression in LIM1215 cells by transfecting siRNAs targeting ZBTB33 (see figure 33).
She observed in 3 independent experiments that AREG and EREG mRNA expression
is stronger in cells expressing less ZBTB33. In these experiments the inverse correlation
between AREG and ZBTB33 found in cell lines could be verified.
Figure 33:
Figure 33: AREG and EREG expression in LIM1215 cells transfected with siRNAs targeting
ZBTB33 : LIM1215 cells were transfected transiently with siRNAs targeting ZBTB33 in 3
independent experiments. As controls LIM1215 cells were either left untransfected (solvent)
or were transfected with an unspecific siRNA (scrambled). Afterwards, RNA of these samples
was converted into cDNA which was tested by real-time PCR for their ZBTB33, AREG and
EREG expression.
85
3.8 An antisense transcript was addressed by Northern blot
experiments and strand-specific PCR
In HCT116 cells, the AREG exon 2 sequence increased promoter function, when coupled
in reverse orientation to the AREG promoter sequence or the Tata protein binding motif
(see section 3.6). One possible explanation could be that AREG exon 2 stimulates the
expression of a product, which is coded on the reverse complementary strand within the
AREG gene. Such products could be RNAs like long non-coding RNAs (lncRNAs) or
micro RNAs (miRNA) which might interfere with the AREG gene regulation. To test
this hypothesis, a Northern blot experiment and a strand-specific PCR approach were
performed.
3.8.1 Northern blot experiments
For the Northern blot experiment, RNA-probes were designed binding to both strands.
The binding positions of the probes are shown in figure 34. The sequence of the RNA-
probe ”E2-sense” is reverse complementary to the AREG exon 2 sequence and therefore
would bind to the AREG mRNA. This probe was used as a positive control. To address
the potential promoter function of the reverse-oriented AREG exon 2, the ”I2-antisense”
probe was used for the experiment, because it would bind to a reverse-oriented RNA
sequence starting at AREG exon 2. ”E2-antisense” would also bind to a reverse-oriented
RNA sequence. However, this sequence is within AREG exon 2, because it is not clear,
where the sequence of the hypothesized ncRNA starts.
Figure 34:
Figure 34: Binding sites of RNA-probes within the AREG gene: Three probes were designed
to detect a hypothetical reverse complement non-coding RNA starting at exon 2. ”E2-sense”
binds within AREG exon 2 and should detect the AREG mRNA. ”E2-antisense” would bind
on the reverse complement sequence of AREG exon 2 and ”I1-antisense” would bind on a
reverse complement sequence in AREG intron 1 starting at exon 2.
In figure 35 the Northern blot results for poly-A RNA from 6 different cell lines
including LIM1215, as well as LIM1215 treated with DAC are shown using the three
probes described in figure 34. Three exposure times are shown to demonstrate that each
probe created signals depending on the exposure time. The signals of the AREG mRNA
detected by the ”E2-sense” probe correlated well with the AREG mRNA expression
detected by real-time PCR (see figure 3). Strong signals developed after short exposure
in the lanes loaded with CaCO2-, HT29- and HCT116 poly-A RNA. A further signal
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appeared after medium exposure in the lanes loaded with untreated and DAC-treated
LIM1215 poly-A RNA. Very low signals appeared after long exposure in the lanes loaded
with RKO- and SW480 poly-A RNA and also in the lane loaded with solvent treated
LIM1215 poly-A RNA. The main difference in the Northern blot experiments using
probe ”E2-antisense” and ”I1-antisense” was that it needed a long exposure of the ”E2-
antisense” blot to create a similar strong signal as appeared after short exposure of the
”I1-antisense” blot. Since both probes were equally long and were used in the same
amount, the difference might be due to different abundances of antisense binding sites.
However, the binding sites of both probes to a hypothetical antisense RNA are in close
proximity (see figure 34). The main similarity of both Northern blots was that the signals
were spread over the whole blots and no individual band could be identified, representing
the RNA. An argument could be that the signal spread was due to unspecific binding of
the ”E2-antisense” probe as well as the ”I1-antisense” probe. However, the ”E2-sense”
blot shows that the length of the probes was sufficient to create a specific signal.
To sum up, the hypothetic antisense-transcript which might regulate AREG gene
expression was not verified, because no specific signal appeared in the corresponding
blots. However, a signal spread was observed. The validity of the Northern blot expe-
riment is also reduced due to the discrepancy of the untreated LIM1215 RNA and the
solvent treated LIM1215 RNA (lane 2 and 3). Although the effect points for a wrong
amount of loaded RNA for this particular sample, a clear assumption could be made by
introducing a loading control for all blots. Furthermore, the marker lanes also showed
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Figure 35: Northern blot analysis of several cell lines: Poly-A RNA of 6 different cell lines
was loaded onto three gels. Northern blot was performed as described in section 2.10. The
blots were incubated with the RNA-probes described in figure 34. Signals on a radiographic
film are shown.
3.8.2 Strand-specific PCR
Because the Northern blot experiments only gave unclear results, a second approach
was applied to clarify if there is an antisense RNA starting at AREG exon 2. At this
PCR-based approach the cDNA obtained after reverse-transcription was converted using
sodium bisulfite. All cytosines within the cDNA, which would normally bind to guanine
in a double-stranded DNA, were converted into uracil, which would bind adenine. With
this technique, it is possible to distinguish both strands of a double-stranded DNA
product, or as used here to distinguish a cDNA derived from a sense-RNA as e.g. mRNA,
from a cDNA derived from an antisense RNA of the same region. With PCR-primers
specifically amplifying the antisense sequence, it is possible to detect the antisense RNA.
An overview of this technique is shown in figure 36.
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Figure 36:
Figure 36: Scheme of strand-specific PCR: An RNA and its antisense RNA give different
cDNAs, which could not be distinguished by standard PCR. Bisulfite conversion of the cDNAs
leads to a change of all cytosines (C) to uracil (U). The cDNAs can now be distinguished by
PCR using strand-specific primers.
An important requirement for using strand-specific PCR is that the RNA used
for reverse transcription is free of any genomic DNA, since bisulfite-converted genomic
DNA contains sequences of both strands and would lead to false-positive signals. A
test PCR was performed, using primers amplifying a well-characterized genomic region
within the KRAS gene. In figure 37 is shown that the genomic DNA (positive control)
gave a clear signal (lane 1), which was not present in the lanes of the RNAs isolated from
SW480, CaCO2 and LIM1215 (lanes 3-5) Only the absorbances of the RNAs itselves were
visible in these lanes. The RNA was then used as template for reverse-transcription and
the obtained cDNAs were bisulfite-converted using the Epitect-kit (Qiagen). To test,
if the presence of the RNAs might inhibit PCR reaction using these primers, a DNA-
contaminated RNA was used at a similar high concentration as template in another
PCR. Here the same signal appeared as seen in the positive control (data not shown).
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Figure 37:






Figure 37: Contamination test of isolated RNA: RNA isolated from SW480 cells (3), CaCO2
cells (4) and LIM1215 cells (5) were used as template for a PCR amplifying a well-characterized
locus within the KRAS gene. As a positive control HCT116-derived genomic DNA was used
(1), A non-template control (NTC) was used as negative control (2).
Primers were designed to detect the bisulfite-converted cDNA derived from the
AREG unspliced mRNA and the bisulfite-converted cDNAs derived from an antisense-
RNA located within AREG exon 2 and AREG intron 1 (see figure 38). As controls,
primers were designed to bind within two exons of the control gene UBE2D2. The
chosen exons are separated by an 86 bp intron, which means that the amplification
product confirmed the RNA, used for reverse-transcription, to be free of any residual
genomic DNA. As a negative control primers were designed to amplify the same locus
but on the reverse complementary strand. The results of the PCRs using bisulfite-
converted cDNA derived from RNA isolated from LIM1215, SW480 and CaCO2 cells
are shown in figure 39.
Figure 38:
Figure 38: Location of the strand-specific PCR-products within the genome: Primerpairs
were designed to detect the sense AREG intron 1 sequence as well as the antisense AREG
exon 2 and intron 1 sequences. As controls, primerpairs were designed to detect sequences
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Figure 39: Strand-specific PCR: Bisulfite-converted cDNA (bs-cDNA) derived from LIM1215
cells, SW480 cells or CaCO2 cells was used as template to amplify the loci described in figure 38
Bisulfite-converted DNA, derived from HCT116DKO cells (bsDNA) as well as a non-template
control (NTC) were used as controls. M: 100 bp-marker.
As shown in figure 39 the PCRs gave similar results for all three cell lines. It was
confirmed by the signals showing the ”UBE2D2 sense” amplification products that the
template was free from genomic DNA, since the bisulfite-converted cDNA signal (bs-
cDNA) appeared at approximately 150 bp, whereas the bisulfite-converted DNA signal
(bs-DNA) appeared about 80 bp above the bs-cDNA signal. This was as expected. The
amplification product detecting the unspliced AREG mRNA derived cDNA (AREG
int. 1 sense) was present in all bs-cDNA samples and also as expected in all bs-DNA
samples. The signal appeared as expected at approximately 150 bp. The PCRs, which
should confirm an antisense transcript to the AREG gene (AREG int. 1 as and AREG
ex. 2 as) showed signals in all three cell lines. These signals were similar to the signals
appearing in the PCRs using bs-DNA as template and had also the expected size of
approximately 100 bp and 150 bp, respectively. Therefore, the data strongly suggested
an antisense transcript to the AREG gene. There was also a signal in the NTC of
the PCR amplifying the AREG ex. 2 as. However, this signal laid below 100 bp and
did not represent the amplification product. The signal might appear due to primer-
dimerization, but did not influence the outcome. An unexpected signal was observed
in the negative control PCR (UBE2D2 as). It should function as a negative control,
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because its amplification product should only give signals in the presence of an antisense
RNA to the control gene UBE2D2. However, it raised a signal in all three cell lines. To
clarify, if this signal was unspecific, or if there is an antisense RNA within the UBE2D2
gene and to show that the conclusions drawn for the AREG antisense RNA were still
valid, the amplification products ”UBE2D2 as”, ”AREG ex. 2 as” and ”AREG int. 1
as” were sequenced using the TA cloning kit (Invitrogen). The amplification products
came from bs-cDNA derived from the LIM1215 cell line A comparison of the sequencing
results with the expected sequences is shown in figure 40.
When sequencing the amplification products, it was observed that the sequences
matched in all tested samples the expected sequences (see figure 40). The sequencing
results also showed that the PCR was strand-specific as expected. All former cytosines of
the sequence were converted to uracil by bisulfite-treatment which changed to thymine
during PCR (marked by asterisks above the sequences in figure 40). Because the li-
gation reaction at the TA-cloning kit occurred orientation-independently, the thymine
bases showed up at the sequence only, when the PCR product was ligated in forward
orientation. This occurred for ”AREG exon2 antisense” and ”AREG intron 1 antisense”.
Since the samples were all free of contaminating genomic DNA, the results pointed for an
AREG gene antisense transcript, which sequence contains a part of the reverse comple-
ment sequences of AREG intron 1 and AREG exon 2. The ”UBE2D2 antisense”-PCR
product was ligated by chance in reverse complement orientation into the TA-cloning
vector. Therefore, the sequencing result represents the reverse complement sequence of
the PCR-product. All thymine bases, derived from former cytosines are represented here
as reverse complement adenines (also marked by asterisks in figure 40). Importantly, al-
though the reverse complement sequence of the PCR product is shown here, the PCR




AREG exon 2 antisense.
AREG intron 1 antisense
UBE2D2 antisense
Figure 40: Sequencing results of strand-specific PCR products: bs-cDNA derived from
LIM1215 was used as template for strand-specific PCR amplifying three loci. The PCR prod-
ucts were sequenced using the TA-cloning kit (Invitrogen). Sequencing results (upper lanes)
were compared with expected sequences (lower lanes) using the webtool ”ClustalW”. Matched
bases are indicated with asterisks below the sequences. Asterisks above the sequences indicate
bisulfite-treatment dependent converted bases.
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3.9 Epigenetic compounds can change the sensitivity of colo-
rectal cancer cell lines towards EGFR inhibitors
In several studies, epigenetic compounds were tested for their therapeutic effects in cancer
treatment. It was shown for lung cancer cells,243 Hep-2 cancer cells (human larynx
squamous cancer cell)244 and SCCHN-cells,245 that HDACis can lead to an increased
sensitivity towards EGFR inhibitors like Erlotinib and Gefitinib. At the same time,
observations by Khambata-Ford et al.193 suggested a correlation between AREG and
EREG expression and response of patients towards EGFR-targeted therapies. Therefore,
it was tested next, if DAC or HDACis, while increasing AREG expression, may lead to
an increase of sensitivity towards EGFR-inhibition in our cell lines, and afterwards, if
the AREG expression is responsible for the increased sensitivity.
The sensitivity of different colorectal cancer cell lines upon Erlotinib and Gefitinib
treatment was tested first.
3.9.1 Sensitivity of untreated colorectal cancer cells towards EGFR-inhibition
Five cell lines, including two cell lines with low AREG expression (RKO, SW480), one cell
line with medium AREG expression (LIM1215) and two cell lines with high AREG ex-
pression (HCT116, CaCO2), were tested for their response towards the EGFR inhibitors
Erlotinib and Gefitinib. The phosphorylation of the EGFR and the phosphorylation of
the downstream proteins AKT, MEK and ERK were tested by the Bio-Plexr technique
(BioRad, see section 2.7) and the cell proliferation was tested by XTT proliferation as-
says. Besides the data shown here for Erlotinib and Gefitinib, the cells were also tested
for their growth response towards Cetuximab treatment, a monoclonal antibody against
EGFR and a common therapeutic compound in targeted therapies. However, all cells
were fully resistant to Cetuximab in vitro which was in contrast to observations made







Figure 41: Characterization of RKO cells after EGFR inhibitor treatment: RKO cells were
treated with 10 µM Erlotinib or 10 µM Gefitinib for 3 or 4 timepoints A: Growth was measured
using the XTT-assay: Treatment was performed daily starting 24 h after seeding and continuing
the next 96 h (see 2.3.5). Absorbance at 480 nm was measured 24 h after XTT solution dispense.
Mean values plus standard deviations of three replicates are shown. B: Phosphorylation of






Figure 42: Characterization of LIM1215 cells after EGFR inhibitor treatment: LIM1215 cells
were treated with 10 µM Erlotinib or 10 µM Gefitinib for 3 or 4 timepoints. A: Growth was
measured using the XTT-assay: Treatment was performed daily starting 24 h after seeding
and continuing the next 96 h (see 2.3.5). Absorbance at 480 nm was measured 24 h after
XTT solution dispense. Mean values plus standard deviations of three replicates are shown. B:







Figure 43: Characterization of HCT116 cells after EGFR inhibitor treatment: HCT116 cells
were treated with 10 µM Erlotinib or 10 µM Gefitinib for 3 or 4 timepoints. A: Growth was
measured using the XTT-assay: Treatment was performed daily starting 24 h after seeding
and continuing the next 96 h (see 2.3.5). Absorbance at 480 nm was measured 24 h after
XTT solution dispense. Mean values plus standard deviations of three replicates are shown. B:







Figure 44: Characterization of SW480 cells after EGFR inhibitor treatment: SW480 cells
were treated with 10 µM Erlotinib or 10 µM Gefitinib for 3 or 4 timepoints. A: Growth was
measured using the XTT-assay: Treatment was performed daily starting 24 h after seeding
and continuing the next 96 h (see 2.3.5). Absorbance at 480 nm was measured 24 h after
XTT solution dispense. Mean values plus standard deviations of three replicates are shown. B:







Figure 45: Characterization of CaCO2 cells after EGFR inhibitor treatment: CaCO2 cells
were treated with 10 µM Erlotinib or 10 µM Gefitinib for 3 or 4 timepoints. A: Growth was
measured using the XTT-assay: Treatment was performed daily starting 24 h after seeding
and continuing the next 96 h (see 2.3.5). Absorbance at 480 nm was measured 24 h after
XTT solution dispense. Mean values plus standard deviations of three replicates are shown. B:
Phosphorylation of EGFR and downstream proteins were tested by the Bio-Plexr technique
(see section 2.7).
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When treating the RKO cell line with 10 µM Erlotinib or Gefitinib, no reduction in
growth was observed (see figure 41 A). Therefore RKO is resistant to EGFR-inhibition.
Interestingly, EGFR-phosphorylation increased for Erlotinib treated cells compared to
the solvent treated cells after 48 h of treatment and for Gefitinib treated cells after 96
h of treatment (see figure 41 B). The EGFR-dephosphorylation, which should follow
EGFR-inhibition, was compensated by an unknown mechanism. The mechanism might
involve the MAPK-pathway, since ERK1/2-phosphorylation increased in the Erlotinib
and Gefitinib treated cells. The phosphorylation states of the other proteins fluctuated
at the different timepoints within the experiment.
When treating LIM1215 cells as well as HCT116 cells with Erlotinib or Gefitinib,
a small growth reduction was observed for both cell lines (see figures 42 A and 43 A).
In LIM1215 cells, growth reached for Erlotinib approximately 60 % and for Gefitinib
approximately 80 % of the value of the solvent treated cells at 72 h. Nevertheless,
growth continued to 96 h. In a similar way, HCT116 cells had a reduced growth at
72 h (reduction of approximately 20 % for Erlotinib, 10 % for Gefitinib). Different
to LIM1215 cells, Erlotinib and Gefitinib treated HCT116 cells stopped growing after
72 h. In both cell lines a reduced EGFR-phosphorylation was seen upon Erlotinib
and Gefitinib treatment, compared to the solvent control (see figures 42 B and 43 B).
Interestingly, although EGFR was dephosphorylated upon treatment, an increased phos-
phorylation in MEK1 and ERK1/2 was observed in LIM1215 cells at the late timepoints
for both Erlotinib and Gefitinib and in AKT for Gefitinib treated cells. In HCT116 cells,
Erlotinib treatment also led to an increased phosphorylation of MEK1 and ERK1/2.
A strong growth reduction upon Gefitinib treatment was observed in SW480 cells
(see figures 44 A). But the cells remained growing upon Erlotinib treatment. EGFR-
phosphorylation decreased slightly for both Erlotinib and Gefitinib treated cells com-
pared to the solvent treated cells (see figures 44 B). While phoshorylation of AKT
increased after 24 and 48 h of Erlotinib treatment, a decrease of phosphorylation was
observed in Gefitinib treated cells after 24 h and a similar phosphorylation was observed
after 48 h. In contrast ERK1/2 phosphorylation was stronger affected after Gefitinib
treatment at the early timepoints. However, at the late timepoints, phosphorylation of
MEK1 (96h) and ERK1/2 (72-96h) is higher than in the solvent treated cells. Phospho-
rylation of AKT after Erlotinib and Gefitinib treatment matched the phosphorylation
of AKT of the solvent treated cells at this timepoints.
By comparing solvent treated and Erlotinib/Gefitinib-treated CaCO2 cells, a strong
growth reduction was observed for both inhibitors (see figure 45 A). Also similar to
the other cells a reduction in EGFR-phosphorylation was observed (see figure 45 B).
In contrast to the other cells, phosphorylation of ERK1/2 decreased for all timepoints.
The phosphorylation of AKT remained almost constant in the whole experiment and
was not influenced by Erlotinib or Gefitinib treatment. To summarize, the five tested
cell lines behaved different upon Erlotinib and Gefitinib treatment. Although a dephos-
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phorylation of the EGFR was mainly seen in all cell lines, downstream proteins showed
various phosphorylation patterns. An increase of phosphorylation of the MAPK proteins
MEK1 and ERK1/2 was seen in 4 of the 5 tested cells. Only CaCO2, which was also
the only cell line having no mutations within the MAPK and PI3K-pathways, showed
a reduction in ERK1/2 phosphorylation. Interestingly, this cell line was also the most
sensitive cell line towards Erlotinib and Gefitinib treatment.
3.9.2 Sensitivity of cell lines after treatment with DAC and HDACi
To address the influence of epigenetically interfering compounds, experiments were de-
signed as follows: The cells were first treated with the epigenetically interfering com-
pound for 144 h (see section 2.3.4). Afterwards, the cells were collected and replated in
equal numbers into 96-well plates. Then they were either left untreated or treated with
Erlotinib, Gefitinib, or DMSO as a solvent control (see section 2.3.5). This treatment
will be referred to as ”post-treatment” on the following pages. Cell growth was evaluated
by XTT experiments.
Figure 46:
Figure 46: Influence of DAC treatment on cell growth: Four cell lines were treated with 2.5
µM DAC for 144 h as described in section 2.3.5. After transfer of equal cell numbers into a
96-well plate, cell growth was evaluated by XTT experiments. XTT absorbance was measured
24 h after XTT solution dispense.
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To test, whether DAC has an effect onto the cells’ sensitivity towards EGFR in-
hibitors, four cell lines were treated for 144 h with 2.5 µM DAC. After replating into
96-well plates, cell proliferation was monitored. As described in figure 46, none of the
DAC-treated cells started growing after replating. Therefore, the effect of DAC onto
sensitivity towards EGFR inhibitors could not be examined in that way. Lower con-
centrations of DAC were used for treatment, too (down to 0.5 µM). But also in these








Figure 47: XTT proliferation experiments in LIM1215 cells after HDACi treatment: LIM1215
cells were treated with 4 different HDACis and their solvents for 144 h (TSA: 25 ng/ml, SAHA:
1 µM, Cambinol: 20 µM, Valproat: 1 mM, solvent 1: DMSO, solvent 2: Methanol). The treated
cells were then replated into 96-well plates for XTT experiments. After 24 h, cells were treated
daily with Erlotinib, Gefitinib and the solvent for an additional 4 days. Each day, one plate
was used for XTT measurement. XTT absorbance was measured 24 h after XTT solution
dispense. Statistical test: A heteroscedastic t-test was performed as described in the text *:
the p-value is less than 0.05 at 96 h, **: the p-value is less than 0.01 upon condition that there
is no significant difference at 96 h between the untreated or solvent post-treated samples after








Figure 48: XTT proliferation experiments in SW480 cells after HDACi treatment: SW480
cells were treated with 4 different HDACis and their solvents for 144 h (TSA: 25 ng/ml, SAHA:
1 µM, Cambinol: 20 µM, Valproat: 1 mM, solvent 1: DMSO, solvent 2: Methanol). The treated
cells were then replated into 96-well plates for XTT experiments. After 24 h, cells were treated
daily with Erlotinib, Gefitinib and the solvent for an additional 4 days. Each day, one plate
was used for XTT measurement. XTT absorbance was measured 24 h after XTT solution
dispense. Statistical test: A heteroscedastic t-test was performed as described in the text *:
the p-value is less than 0.05 at 96 h, **: the p-value is less than 0.01 upon condition that there
is no significant difference at 96 h between the untreated or solvent post-treated samples after
treatment with the HDACi and the solvent 1 or 2.
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Similar to DAC-treated cells, HDACi-treated cells were tested for their growth
after replating and if the HDACis have an influence onto sensitivity towards Erlotinib
and Gefitinib. The response of LIM1215 and SW480 with or without HDACi treatment
is shown in figure 47 and figure 48. Statistical tests were made as follows to address
the effects of the HDACis onto the sensitivity. A heteroscedastic t-test was performed
to compare (1.) the absorbances of the Erlotinib or Gefitinib post-treated samples after
HDACi-treatment with the absorbances of the Erlotinib or Gefitinib post-treated sample
after solvent treatment. The t-test was performed for the timepoint 96 h, because here
the strongest effect should be seen. Additionally a heteroscedastic t-test was performed to
compare (2.) the absorbances of the post-treatment solvent controls (solvent/untreated)
after HDACi-treatment with the absorbances of the post-treatment solvent controls after
solvent treatment. A significant difference in the first t-test indicates that sensitivity
towards Erlotinib or Gefitinib depends on the HDACi treatment. However, a significant
difference in the second t-test indicates that the cell growth is also affected by the HDACi
itself. Only when the first test shows significant reduction and the second does not,
asterisks are drawn to emphasize the significant effect of the HDACi on the sensitivity
which is independent to growth related effects.
In contrast to DAC-treatment, both cell lines restarted proliferation after replating,
when treated with HDACis. One exception in LIM1215 cells was SAHA-treatment (see
figure 47 E) and another exception in SW480 cells was TSA-treatment (see figure 48
D). These exceptions were omitted from analysis. Interestingly solvent treated LIM1215
cells (DMSO and Methanol) were more resistant towards Erlotinib and Gefitinib than
untreated cells (see figure 47 B-C). However, compared to these solvent controls, treat-
ment with TSA and Valproat led to a higher sensitivity towards Erlotinib and Gefitinib
in LIM1215 cells, which was highly significant for Valproat-treatment. Reduced growth
curves occurred compared to the post-treatment solvent and untreated controls (see fig-
ure 47 D and G). Since the TSA-treated controls, solvent and untreated, showed also
reduced growth curves to the solvent 1 treated controls (compare figures 47 B and D),
it is obvious that TSA also had an effect on the growth of LIM1215 cells, and that
the effects, seen after Erlotinib and Gefitinib might additionally be influenced by this
TSA-effect. The HDACi Cambinol did not change sensitivity of LIM1215 cells towards
EGFR-inhibition (see figure 47 F).
In Valproat-treated SW480 cells, a significant decrease of growth was observed after
Gefitinib post-treatment (see figure 48 G). Therefore, similar to LIM1215 cells, Valproat
led to an increased sensitivity towards Gefitinib in SW480 cells. However, it is unclear,
why sensitivity towards Erlotinib is not influenced by Valproat. Besides this exception,
all treated and replated cells were as resistant to Erlotinib and as sensitive to Gefitinib
as the untreated control (compare figure 48 A with figures 48 B, C, E, F).
In both cell lines, Valproat increased response towards EGFR inhibitors (see figures






Figure 49: XTT proliferation experiments in SW480 cells after Valproat treatment: SW480
was treated with 1 mM or 2 mM Valproat (Valproat 1 or 2) or the solvent Methanol for
144 h. The treated cells were replated into 96-well plates for XTT experiments as described
earlier. XTT absorbance was measured 24 h after XTT solution dispense. Statistical test: A
heteroscedastic t-test was performed as described in the text *: the p-value is less than 0.05 at
96 h, **: the p-value is less than 0.01 upon condition that there is no significant difference at
96 h between the untreated or solvent post-treated samples after treatment with Valproat 1 or
2 and Methanol.
To test, if Valproat might have an effect on other cell lines and to test if a higher
concentration of Valproat might trigger an effect, SW480, RKO, LIM1215, HCT116 and
CaCO2 cells were treated for 144 h with 1 mM and 2 mM of Valproat. Afterwards, these
cells were tested for their sensitivity towards Erlotinib and Gefitinib by XTT proliferation
experiments as described earlier.
Similar to the experiment before, Valproat treatment significantly increased sen-
sitivity towards Gefitinib but not towards Erlotinib in SW480 cells (see figure 49 B).
Using a higher concentration of Valproat, an overall reduction of XTT absorbances was
seen (figure 49 C). Therefore, using this concentration a Valproat-derived reduction in






Figure 50: XTT experiments in RKO after Valproat treatment: RKO cells were treated with
1 mM or 2 mM Valproat (Valproat 1 or 2) for 144 h. The treated cells were replated into
96-well plates for XTT experiments as described earlier. XTT absorbance was measured 24 h
after XTT solution dispense. Statistical test: The statistical test was performed as described
in figure 49.
In figure 50 the effect of Valproat treatment onto EGFR-inhibition is shown for the
RKO cell line. A minimal reduction in growth was observed after post-treatment with
Gefitinib in Valproat treated cells irrespective of the Valproat concentration (see figure






Figure 51: XTT experiments in LIM1215 after Valproat treatment: LIM1215 cells were
treated with 1 mM or 2 mM Valproat (Valproat 1 or 2) for 144 h. The treated cells were
replated into 96-well plates for XTT experiments as described earlier. XTT absorbance was
measured 24 h after XTT solution dispense. Statistical test: The statistical test was performed
as described in figure 49.
It was already shown that LIM1215 cells had a significantly increased sensitivity
towards Erlotinib and Gefitinib upon Valproat treatment (see figure 47). After repea-
ting the experiment, the increase of sensitivity was observed again (compare figure 51
A and B). Using 2 mM Valproat, a similar overall reduction in growth was observed
in the LIM1215 cell line as seen in the SW480 cell line (see figure 51 C). Although the
cells grew only very slow upon Erlotinib post-treatment or almost stopped growing upon
Gefitinib post-treatment, the effect might be influenced by Valproat itself, since growth






Figure 52: XTT experiments in HCT116 after Valproat treatment: HCT116 cells were treated
with 1 mM or 2 mM Valproat (Valproat 1 or 2) for 144 h. The treated cells were replated into
96-well plates for XTT experiments as described earlier. XTT absorbance was measured 24 h
after XTT solution dispense. Statistical test: The statistical test was performed as described
in figure 49.
The results of HCT116 cells treated with Valproat are shown in figure 52. The
solvent treated control cells were sensitive towards the EGFR inhibitors (see figure 52
A). When treating with 1 mM Valproat, the XTT aborbances of the post-treatment
experiments were similar to the solvent treated cells (see figures 52 A and B). The
sensitivity towards Erlotinib and Gefitinib was not increased. But, when treating the
cells with 2 mM Valproat, the Erlotinib and Gefitinib post-treated cells grew slower (see
figure 52 C). However, the post-treatment controls (untreated and solvent treated) had
also a reduced growth rate compared to the solvent treated HCT116 cells (figure 52 A).







Figure 53: XTT experiments in CaCO2 after Valproat treatment: CaCO2 cells were treated
with 1 mM or 2 mM Valproat (Valproat 1 or 2) for 144 h. The treated cells were replated into
96-well plates for XTT experiments as described earlier. XTT absorbance was measured 24 h
after XTT solution dispense. Statistical test: The statistical test was performed as described
in figure 49.
The sensitivity of CaCO2 cells was not increased upon 1 mM or 2 mM Valproat
treatment. The aborbances were similar to the solvent treated control cells. After 2
mM Valproat treatment, CaCO2 grew much slower even in the absence of Erlotinib or
Gefitinib. As a consequence, similar to HCT116 cells, a Valproat-mediated effect could
not be distinguished from an EGFR inhibitor effect.
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3.9.3 Sensitivity of xenografted LIM1215 cells after treatment with 5-
Azacytidine
In LIM1215 cells, sensitivity towards Erlotinib and Gefitinib was increased by Valproat.
Valproat also led to an increase of AREG or EREG expression (see figure 6, figure 7 and
figure 10). As a next step, it was tested if the sensitivity increase could also be observed
in vivo. In cooperation with Maria Rivera (Experimental pharmacology, Max-Delbrück
Center Berlin-Buch), LIM1215 cells were processed as mouse xenografts to evaluate
the influence of Valproat on tumor growth with and without Erlotinib treatment (for
experimental details please refer to section 2.12.2). In addition, 5-Azacytidine, a DNA
methyltransferase whose effects in mice is well characterized and which has similar but
not identical functions as DAC, was tested for its influence on the tumor growth in
presence or absence of Erlotinib. The results of three independent experiments are




Figure 54: Experiments with xenografted LIM1215 cells: LIM1215 cells were processed as
xenografts and mice were subsequently treated as described in section 2.12.2. Three inde-
pendent experiments are shown. Each data curve represents the mean volume of 5 mice per
treatment with the error bars representing the standard deviations. The tumor volumes were
determined two times per week as described in section 2.12.2.
In the mouse experiment MV10107 it was examined, if Valproat could lead to a
higher sensitivity towards Erlotinib treatment when applied in combination with Er-
lotinib (see figure 54 A). Valproat as well as Erlotinib caused smaller tumor volumes
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compared to the xenografts in solvent treated mice. However, the volumes were not
significantly smaller. But, when treating Valproat in combination with Erlotinib the
xenografts grew at similar rates as the xenografts of solvent treated mice. Because the
differences were not significant the experiment was repeated. In experiment MV10532,
treatment was also adapted to the treatment modes used in cell culture, which means
Valproat treatment was done prior to Erlotinib treatment. Additionally, in control mice,
Valproat treatment was done after Erlotinib treatment to investigate if the treatment
mode influences the outcome of the experiment. As seen in figure 54 B, the xenografts
of the solvent treated mice grew similar like the xenografts of the Erlotinib treated mice.
Interestingly, both combination approaches, Valproat prior or after Erlotinib treatment,
caused increased tumor volumes compared to solvent treatment. The reason remains
unknown. Summing up, Valproat did not increase sensitivity towards Erlotinib in vivo.
In the experiment MV10533, it was tested, if the DNA methyltransferase inhibitor 5-
Azacytidine influences sensitivity towards Erlotinib in vivo. As described in figure 54 C,
the tumor volumes of Erlotinib treated mice did not change significantly compared to
solvent treated mice. Also 5-Azacytidine did not affect tumor volumes until day 29. How-
ever, a strong reduction of the tumor volumes was observed in the xenografts of the mice
treated with a combination of 5-Azacytidine and Erlotinib. Therefore, 5-Azacytidine
increased sensitivity towards Erlotinib in vivo.
After the experiment, AREG and EREG mRNA expression were tested. As seen
in figure 55, treatment with Valproat or with 5-Azacytidine did not lead to an increased
AREG or EREG mRNA expression in the xenografts compared to the xenografts of
the solvent treated mice. The ∆Ct-values in the AREG gene expression analysis were
similar in all experiments for all samples between -2 and -4, and the ∆CT-values in the
EREG gene expression analysis ranged in all samples in all experiments between -6 and
-8. The values were equal to the ∆Ct-values obtained for untreated LIM1215 cells in
cell culture experiments. In addition, mouse AREG and EREG mRNA expression were
tested. But, neither mouse AREG nor mouse EREG mRNA expression were increased
after Valproat or 5-Azacytidine treatment. After all, no xenograft sample showed any
expression of mouse AREG or EREG mRNA (data not shown).
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Figure 55:
Figure 55: AREG and EREG mRNA expression in xenografts: human AREG and EREG
mRNA expression of the xenografts obtained in the mouse experiments were measured by real-
time PCR as described in section 2.6. The ∆Ct-values were calculated by subtraction of the
AREG or EREG Ct-value from the control Ct-value For each experiment the mean ∆Ct values
of five samples per treatment are shown together with the standard deviations.
Additionally, the tumors were fixed with formalin and embedded in paraffin by
a standard protocol performed in the in-house facility of the Institute for Pathology.
The resulting paraffin-blocks were cut in 3 µm slices and transferred to glass slides.
Immunohistochemistry experiments (IHC) were performed to detect the AREG protein
(see section 2.11). The experiment was analyzed together with Dr. Florian Rossner
(Institute for Pathology, Charité, Berlin) The results are shown in table 21
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Table 21: IHC evaluation of AREG protein expression in the mouse xenograft experiments:
fail: sample could not be analyzed, -: no AREG protein, +/-: some cells show positive, some
show negative AREG protein expression, +: cells show positive AREG protein expression, ++:
cells show strong AREG protein expression.
experiment treatment fail - -/+ + ++
MV10107 Solvent 2 2 1
Valproat 1 2 1 1
Erlotinib 2 1 1 1
Erlotinib + Valproat 2 2 1
MV10532 Solvent 2 2 1
Solvent + Erlotinib 4 1
Erlotinib + Valproat 1 1 1 1 1
Valproat + Erlotinib 2 1 2
MV10533 Solvent 4 1
5-Azacytidine 2 2 1
Erlotinib 1 1 1 2
5-Azacytidine + Erlotinib 5
In all three experiments the expression of AREG protein varied strongly among
the different treatment modes. No correlation is visible between the AREG protein
expression and the treatment. High failure rates of AREG IHC were also observed in
some examples (see table 21). In most of the cases this was due to too small sample
sizes to perform IHC. The sample size depended on the tumor volume after treatment.
Nevertheless, an example, on how the samples looked like is shown in figure 56. Here
microscopy pictures are shown representing the results of MV10107. For each treatment a
sample is given showing no AREG protein, a sample showing intermediate AREG protein
and a sample showing high AREG protein expression. To summarize, the expression of











Figure 56: AREG protein expression in xenografted LIM1215 cells of experiment MV10107:
The AREG protein expression was evaluated by IHC. For each treatment option three figures
are shown representing three samples with different AREG protein expression. Magnification
factor: 200x, brown: AREG protein staining, blue: nuclei staining. (-): no AREG protein,
(+/-): some cells show positive, some show negative AREG protein expression, (+): cells show






Figure 57: Methylation of CpGs within the AREG or EREG genes in xenografts: The methy-
lation of AREG CpG p150 and p220 as well as EREG CpG p143 and p297 was measured in all
xenografts obtained in the mouse experiments as described in section 2.12.1. The methylation
index shows the content of methylation indicating products within the primer extension prod-
ucts in msSNuPE-experiments and is an indicator for DNA methylation at the given CpG. A
methylation index of 1 means fully methylated whereas a methylation index of 0 means fully
unmethylated.
Methylation of the same AREG and EREG intragenic CpGs, which were tested
in cell culture, were also tested in each xenograft (see figure 57). In comparison to
the LIM1215 cell line in cell culture, the xenografted LIM1215 cells showed a treatment
independent reduction of methylation of AREG CpG p150 and CpG p220. In cell culture
the CpG methylation of the AREG intragenic CpGs ranged from 0.4 to 0.6, whereas in
the xenografts the methylation index ranged from 0.2 to 0.4 (compare figures 14 and 57).
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In comparison the methylation of EREG CpGs p142 and p297 did not differ strongly
between cell culture and xenografted LIM1215 cells. In both cases, the methylation
index of the tested EREG intragenic CpGs ranged from 0.2 to 0.4. Similar to the cell
culture results, Valproat treatment did not influence methlylation of the tested CpGs
(see figures 18 and 19). Methylation of AREG CpG p150, AREG CpG p220 and EREG
CpG p297 was affected by 5-Azacytidine when the mice were treated with 5-Azacytidine
alone or in combination with Erlotinib. That means similar to the cell culture results,
a methylatransferase inhibitor led to a demethylation of the tested GpGs in vivo (see
figures 15 and 16).
3.10 Over-expression of AREG in LIM1215 has no significant
effect on sensitivity towards EGFR inhibitors
Figure 58:
Figure 58: AREG protein expression after transient transfection: LIM1215 cells were
transfected transiently with the Plasmid EX-A0114-M02 containing the AREG sequence
(GeneCopoeia) and a control plasmid containing the EGFP sequence (Invitrogen). AREG
protein expression was determined by ELISA and was normalized per 1 µg total protein.
As described in section 3.2.2 the mRNA expression and protein levels of AREG
increased by up to 4-fold upon treatment of LIM1215 cells with Valproat. At the same
time the sensitivity of these cells towards the EGFR inhibitors Erlotinib and Gefitinib
was increased following Valproat treatment (see section 3.9.2 and figure 47). These
observations raised the question to what extent AREG is functionally involved in the
increased response at LIM1215 cells towards EGFR inhibitors.
LIM1215 cells were transfected transiently with an AREG expression plasmid (EX-
A0114-M02) and AREG protein expression was monitored by ELISA 24 h to 96 h post
transfection. 24 h after transfection, AREG protein levels were up to 6-fold higher
compared to the untransfected LIM1215 cells (see figure 58). However, protein levels
decreased down to approximately 3-fold 96 h after transfection. AREG levels also in-
creased after 24 h in LIM1215 cells transfected with an EGFP control plasmid, but only
up to 1.5-fold.
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To test whether AREG levels correlate with the sensitivity towards EGFR in-
hibitors, LIM1215 cells were transfected either with the AREG expression plasmid EX-
A0114-M02 or the EGFP control plasmid. Cells were seeded into 96-well plates and






Figure 59: XTT proliferation after transient Transfection: LIM1215 cells were transfected
transiently with the AREG sequence containing Plasmid EX-A0114-M02 or the EGFP control
plasmid. 24 h after transfection cells were plated into 96-well plates and XTT experiments
were performed as described earlier to evaluate the sensitivity towards Erlotinib and Gefitinib.
As shown in figure 59 non-transfected LIM1215 cells behaved similar as determined
before. After transfection, both EGFP and AREG transfected cells grew much slower.
In contrast to the non-transfected cells, transfected LIM1215 cells even stopped growing
after treatment with Erlotinib and Gefitinib (compare figure 59 A with B and C). The
XTT absorbance of the EGFR inhibitor treated non-transfected cells was approximately
25 % lower at 72 h and 96 h than the XTT absorbance of the untreated and solvent
treated control cells (see figure 59 A). Interestingly, the XTT absorbance of the EGFR
inhibitor treated transfected cells (transfection plasmid independent) is at 96 h approx-
imately 50 % lower than the untreated and solvent treated control cells (see figure 59
B and C). However, the transfection method itself influences growth rates negatively,
too. As mentioned before, it was observed that transfecting the EGFP control plasmid
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causes also an increase of AREG protein levels (see figure 58). To verify this result,
AREG mRNA expression was measured after the XTT proliferation experiment. In
figure 60 is shown that AREG mRNA was also increased after transfecting the EGFP
plasmid. That means, AREG might be responsible for the increase of sensitivity to-
wards EGFR inhibitors, but since transient transfected cells grew much slower than
non-transfected cells a second approach was necessary to clarify the influence of AREG
onto EGFR inhibitor sensitivity.
Figure 60:
LIM1215:
Figure 60: AREG mRNA expression after the XTT proliferation experiment: LIM1215 cells
were transfected transiently with the plasmid EX-A0114-M02 containing the AREG sequence
and the EGFP control plasmid. 24 h after transfection cells were plated into a 10 cm petri
dish and incubated until the XTT experiment was finished (see figure 59). After this, RNA
was isolated and AREG mRNA expression was detected by real-time PCR.
Lentiviruses were produced as described in section 2.9.2. LIM1215 cells were in-
fected with lenitviruses containing either a plasmid with the complete AREG coding
sequence (AREG), an AREG sequence lacking all C-terminal aminoacids encoded by
AREG exon 5 (AREG-short or A-short) or an empty control vector (empty). Infected
cells were tested for AREG mRNA expression and protein levels (figure 61). Real-time
PCR analysis (TaqManr) showed that the AREG mRNA expression was increased up
to 3-fold in the ”AREG” vector infected cells. No increase was observed for the ”A-
short” vector infected and the ”empty” vector infected cells. The AREG-Taqman assay
used detects the AREG cDNA sequence with primers spanning exon 4 and 5. The se-
quence of ”A-short” ends at exon 4. Therefore, ”A-short” could not be detected by this
assay. To circumvent the problem, mRNA expression was determined by SybrGreenr
using primers binding in exon 1 and 2. By this approach, it could be demonstrated that
”A-short” as well as ”AREG” infected cells had an increased AREG mRNA expression.
SybrGreenr was performed twice. AREG mRNA expression was increased by 3 to 4-
fold (AREG) or 5 to 7 -fold (A-short). Also an increased AREG protein level in the
supernatant could be demonstrated for the ”AREG” and ”A-short” infected cells (figure
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61, right). In contrast to the AREG mRNA expression in the transfected cells, protein
levels increased only 3 to 3.5-fold. However, since Valproat treatment also led to an
increase of AREG protein by 2 to 4 fold (see figure 7) and AREG mRNA expression
by 2 to 4 fold (see figure 6), LIM1215 cell growth and sensitivity towards Erlotinib and
Gefitinib was tested with the infected cells as described before.
Figure 61:
LIM1215:
Figure 61: AREG expression after lentiviral transfection: LIM1215 cells were infected by
lentiviruses containing AREG gene expression plasmids (AREG), AREG gene w/o C-terminus
expression plasmids (A-short) or the empty plasmids. Left: AREG mRNA expression was
detected by TaqManr or SybrGreenr real-time PCR. Relative Quantification was calculated
according to the non-transfected control. Right: The AREG protein amount in the supernatant
was detected by ELISA and normalized to the corresponding RNA concentration. Here, the
relative AREG level compared to the untransfected control is shown.
XTT absorbances dropped in non-transfected LIM1215 cells by approximately 20
to 25 % after 48, 72 and 96 h of Erlotinib and Gefitinib treatment compared to the
untreated or solvent treated cells (see figure 62 A). Therefore, the sensitivity towards
Erlotinib and Gefitinib was similar as seen before (see 42 A). No change in sensitivity was
observed, when infecting LIM1215 cells with the plasmids ”AREG” or ”AREG-short”
(see figure 62 C-D). To conclude, AREG over-expression, which was achieved by lentiviral







Figure 62: XTT experiment after lentiviral infection: LIM1215 cells were either used directly
(A) or they were infected by lentiviruses to introduce an empty plasmid (B), an AREG plasmid
w/o C-terminus (AREG-short, C) or an an AREG-expressing plasmid (D). After determination
of the AREG expression (see figure 61), cells were seeded into 96-well plates. Sensitivity towards
EGFR inhibitors was determined by XTT experiments as described earlier. XTT-absorbance
was measured 24 h after XTT solution dispense. Simultaneously, the cells were seeded into 10
cm dishes for RNA isolation after the experiment. AREG mRNA expression was tested again
by real-time PCR (E).
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4 Discussion
4.1 The EGFR-ligands are regulated by versatile mechanisms
AREG and other EGFR ligand genes such as TGF-α, HB-EGF, BTC and EREG can be
activated by different mechanisms. One example is the activation via EGFR-signaling
by an autocrine loop. In a study using prostate stromal cells, Soerensen et al. found
out that AREG, but also HB-EGF expression increased after stimulation of EGFR with
EGF or HB-EGF,247 indicating that HB-EGF can activate its own gene. Examina-
tions in zebrafish verified the results for HB-EGF, but in contrast, BTC was observed
to be down-regulated upon BTC-treatment.248 The underlying mechanism of the au-
tocrine regulation includes downstream signaling pathways like the MAPK- and the
PI3K-pathway. A connection between AREG gene expression and MAPK-pathway is
strengthened by the fact that during puberty and pregnancy AREG gene expression
is stimulated by estrogen and progesterone.31,32 It was shown that both receptors can
activate MAPK-signaling.249 In addition, Sizemore and Cox showed that farnesyltrans-
ferase inhibitors caused a decreased AREG and TGF-α expression, hinting for RAS as a
protein involved in AREG regulation.250 In cancer cells, the MAPK and PI3K-pathways
might not only be activated via receptors, but also via activating mutations. As de-
scribed in section 1.2.3 KRAS, BRAF and PI3K belong to the most frequently mutated
genes within these pathways in colorectal cancer. Therefore, it was analyzed in this
work if mutations in these genes correlate with AREG or EREG expression. Although
AREG and EREG were differentially expressed in the cell lines tested (see figure 3),
the expression did not correlate with mutations within the MAPK- or PI3K-pathway.
SW480 as well as HCT116 cells harbor KRAS mutations (see table 12). However, SW480
was a low AREG and EREG expressing cell line whereas HCT116 was a high AREG
and EREG expressing cell line (see figure 3). Also BRAF mutated cells were found
among the low AREG and EREG expressing cells (RKO) and among the high AREG
and EREG expressing cells (HT29), too. RKO and HT29 cells are also examples for
PIK3CA mutated cells harboring a deregulated PI3K-pathway. If the mutation states of
MAPK- or PI3K-signaling components influence the AREG and EREG expression, as
expected from literature, they may not be responsible alone for the AREG and EREG
regulation within the cell lines used in this work.
Another possible mechanism for AREG regulation is the regulation via activated
wnt-signaling. TCF/LEF binding sites were identified within the AREG promoter.251
Therefore, the cells were analysed for APC mutations, which deregulate the wnt-
signalling. Similar to KRAS and BRAF, mutations within the APC gene were found
in high AREG expressing cell lines (CaCO2,252 HT29 (COSMIC Cell Lines Project))
as well as in low AREG expressing cell lines (SW480,252 Colo678 (COSMIC Cell Lines
Project)) Also, cells with wildtype-APC are within the low AREG expressing cells (RKO
(COSMIC Cell Lines Project)) and within the high AREG expressing cells (HCT116252).
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Nevertheless, the impact of wnt-signaling onto AREG expression cannot be deduced
from the analysis of APC mutations within the cell lines alone because publications also
suggest that wnt-signaling might also be activated by β-catenin mutations.253
A further regulatory mechanism of different EGFR-ligand genes is cAMP-mediated
regulation. In a study using murine granulosa cells AREG, EREG and BTC -mRNA ex-
pression was increased in the presence of cAMP.254 Also a CRE-element was identified
within the AREG promoter255,256 supporting theses findings. The CRE-element serves as
a binding site for the CRE-binding protein (CREB), which recruits the CREB-binding
protein (CBP)/p300 coactivator complex. This complex is then able to interact with
transcription factors TFIIB and TFIID as well as with the RNA polymerase II to initi-
ate transcription.257,258 CBP and p300 are histone acetyltransferases (HATs).259 Thus,
if cAMP-mediated regulation takes place, CBP/p300 could contribute to the AREG ex-
pression via an open chromatin structure at the AREG promoter. Because HDACis also
shift the chromatin structure to open chromatin, this mechanism could serve as a hint,
why AREG and EREG expression increases after HDACi treatment and suggest that
the AREG promoter is involved in AREG regulation.
In addition to a HAT-mediated open chromatin structure at the AREG pro-
moter, DNA methylation is another possible epigenetic regulatory mechanism influencing
AREG. As already described in section 1.4.2, chromatin structure and DNA methyla-
tion are tightly linked to each other. For EREG, a methylation-dependent regulation
was already suggested, since EREG promoter methylation was observed in gastric can-
cer cells.260 Also, experiments comparing the global mRNA expression between HCT116
and the DNMT1/3b lacking cell line HCT116DKO hint for a DNA methylation-dependent
regulation of AREG, EREG and BTC.261,240 (Sers et al. 2009, Gius et al. 2004 and data
not shown) Following these data, a deeper insight into the epigenetic regulation of AREG
and to a lower extent EREG was made in this work. The results are discussed in section
4.2.
In addition to the multiple mechanisms acting at the genes’ levels, AREG and
EREG proteins can also be regulated by indirect mechanisms. The ADAM-17 protein for
instance is responsible for the segregation of several EGFR-ligands into the extracellular
space. A decreased expression of TIMP3, an ADAM-17 inhibitor, was shown e.g. to
correlate with an increased release of AREG, HB-EGF and TGF-α.262
To summarize, no clear connection could be made between distinct signaling path-
ways and AREG and EREG expression in colon cancer cell lines. The mutations of genes
within these pathways described in literature to influence AREG and EREG regulation
did not correlate with the AREG and EREG expression in this study.
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4.2 AREG and EREG are regulated via epigenetic mechan-
isms
Due to the availability of new genome-wide detection methods as for example Second
Generation Bisulfite Sequencing, it was found that a major part of DNA methylation is
not located within CpG-islands of promoter regions. They were rather detected in regions
with low CpG-density.80 These CpGs might influence gene expression. It was e.g. shown
in a genome wide study that exon methylation is linked to transcriptional silencing.79
Also in a different study using the human B-cell methylome, it was shown that although
only a subset of all CpG-islands are methylated (about 26 %), the ratio of CpG-islands
being methylated within genes is higher (approximately 36 %).263 By comparing their
data with gene expression data, the authors also showed that increased intragenic CpG-
island methylation is correlated with reduced expression of the corresponding genes.
These studies emphasize that intragenic methylation patterns might become important
issues in future research, since they might be responsible for regulatory mechanisms,
which are not yet completely understood. Nevertheless, the data presented in this work
might contribute strongly to an uncovering of these regulatory mechanisms.
As described in section 3.1, AREG was differentially expressed within the cell lines
tested. However, the expression did not correlate with promoter methylation but it
correlated with the methylation of CpGs within the gene (CpG p150, CpG p220, see
section 3.5). The results were supported by experiments with the DNMT- inhibitor
DAC, because demethylation of the intragenic CpGs was observed in combination with
an increase in AREG mRNA and protein expression (see figures 4, 5 and 15). Fur-
thermore, the increase in AREG expression was higher in cells with lower initial AREG
expression and higher AREG intragene methylation. It was lower in cells with higher
initial AREG expression and lower AREG intragene methylation. These facts suggested
a direct methylation-dependent mechanism of AREG gene expression, which is different
to promoter methylation-dependent gene regulation mechanisms.
With the exception of RKO cells, EREG promoter methylation did not correlate
with gene expression (see figure 12). RKO cells showed high methylation within the
EREG promoter sequence and they also showed very low EREG gene expression (see
figure 3). Therefore, in RKO cells a promoter methylation-dependent regulatory mechan-
ism of the EREG gene might be active, like it was already described in gastric cancer
cells.260 EREG promoter methylation might also be due to the CpG-island-methylator
phenotype. RKO is the only cell line within this work, which was described to be CIMP-
positive.264 However, the fact that SW480 cells showed no EREG promoter methylation
but a similar low EREG gene expression suggests that there are also other regulatory
mechanisms responsible for EREG expression. One possible mechanism might be an
intra-gene methylation-dependent regulatory mechanism, as it was seen for AREG. But
in contrast to AREG, the methylation of the CpGs investigated within the EREG gene
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did not correlate with the observed EREG gene expression (see figures 3 and 14). Nev-
ertheless, similar to AREG, DAC treatment led to a high EREG increase in low EREG
expressing cells and to a low EREG increase in high EREG expressing cells (see figure 4).
But changes in CpG-methylation did not correlate with changes in expression. First, no
demethylation of the intragenic CpGs was observed in the cell lines SW480 and LIM1215,
although EREG mRNA expression increased upon treatment; and second, although the
highest demethylation of the EREG intragenic CpGs was observed in the CaCO2 cell
line, DAC did not result in an increase of EREG expression (compare figure 16 and figure
4). The DAC-treated SW480 and LIM1215 cells showed a demethylation of AREG CpG
p150 and CpG p220 (see figure 16), indicating that the missing effect on EREG CpG
p143 and CpG p297, was not caused by a failure in treatment. Probably the regulation
of EREG is similar to AREG, but the tested CpGs within the EREG gene are not re-
sponsible for this regulation. Even though the results lead to a methylation-dependent
regulation, it should be noted that DAC, as well as all other DNMT inhibitors, have
a global effect on DNA methylation. Therefore, it cannot be excluded that changes in
EREG expression by DAC might also be mediated by demethylation-dependent expres-
sion changes in other genes. AREG might be a candidate, since autocrine activation of
the MAPK- and PI3K-pathways was shown to influence also EREG expression.254 In
the same way, AREG might also influence its own expression.
Histone deacetylase inhibitor treatment (HDACis) also led to an up-regulation of
AREG and EREG gene expression. While Valproat mainly had effects on LIM1215,
SW480 and RKO cells (see figures 6 and 7), TSA affected all cell lines (see figures 8 and
9). During his master thesis, Stephan Bartels (Charité Berlin, Institute for Pathology)
aimed at defining the mechanism how HDACi treatment affects the MAPK- and PI3K-
pathways. He observed in three cell lines that Valproat treatment led to an increase in
phosphorylation of MEK, ERK and AKT, indicating an activation of these pathways.241
Since the direct mechanistic processes were not addressed, yet, it remains unclear, to
what extent MAPK and PI3K-pathway signals and epigenetic regulatory mechanisms
influence AREG and EREG expression upon HDACi treatment. According to current
knowledge, three regulatory mechanisms might be possible:
1. HDACi treatment might influence AREG and/or EREG expression by shifting the
chromatin structure at the genes’ promoters to open chromatin. AREG and EREG then
activate the MAPK- and PI3K-pathways via an autocrine loop. 2. HDACi treatment
might influence the MAPK- and PI3K-pathway independent of AREG or EREG. AREG
and EREG are then activated as target genes of the pathways. 3. AREG and EREG
expression are influenced by both, pathway-signal dependent mechanisms and epigenetic
mechanisms.
Besides the arguments showing a possible MAPK- and PI3K- pathway dependent
regulatory mechanism (see section 4.1), the following argument strengthens an epige-
netic mechanism influencing AREG or EREG expression upon HDACi treatment: As
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already described in section 1.4.2, DNA methylation is tightly linked to chromatin struc-
ture. Recruitment of HDACs to methylated DNA via MBD-containing proteins101 leads
to transcriptional silencing which can be relieved via HDACis like TSA.102,101,103 By
this mechanism, AREG gene activation by HDACi-induced AREG promoter acetylation
might be possible, which might be similar to the effect after HAT-recruitment in the
cAMP-mediated regulatory mechanism mentioned above.
In addition to the possible effects on signaling mechanisms or epigenetic mechanism
other mechanisms, not directly impinging on the AREG promoter, might also be respon-
sible for the increased AREG and EREG expression upon HDACi treatment. 1. Global
deacetylation influences the intra-cellular pH by changing the amount of free acetate
anions which non-specifically influence the effect of the HDACis on gene expression.265
2. Side effects of Valproat itself might influence expression. It was e.g. described that
Valproat has effects on processes like inhibition of GABA-transaminase266 or reduction
of Inositol-3-phosphate levels.267 Inositol-3-phosphate is a second messenger, which e.g.
changes ion concentrations within the cell. This might also affect other genes.
To summarize, there is great evidence that AREG and EREG expression are reg-
ulated by epigenetic mechanisms. Most likely, this is not the only mechanism regulating
AREG and EREG gene expression. Probably, there is a complex interplay between
signaling-mediated and epigenetically determined processes controlling the expression of
both genes.
4.3 AREG expression is influenced by zinc finger associated
transcription factors
As described in section 3.7, CTCF was highly expressed in all cell lines, whereas
ZBTB33 and ZBTB4 were differentially expressed. The expression of the latter tran-
scription factor genes was inversely correlated with the AREG gene expression (see
figure 32). An argument showing that AREG and ZBTB33 expression are also cor-
related functionally was given by the PhD-student Natalia Kuhn (Charité Berlin,
Institute for Pathology), who used siRNAs targeting ZBTB33. In these experiments
it was shown that an siRNA-mediated decreased expression of ZBTB33 was accompa-
nied with an increased AREG expression (see figure 33). Furthermore, bioinformatic
approaches searching for potential binding sites showed that ZBTB33 but also CTCF
might be able to bind within the AREG gene. CTCF-binding sites were identified by
Sascha Tierling (University of Saarbrücken) using the webtool ”CTCF-binding sites”
(http://bsproteomics.essex.ac.uk:8080). ZBTB33-binding sites were identified by Ju-
liane Perner (Max-Planck-Institute for Molecular Genetics, Berlin) based on a recent
publication of Blattler et al.109 (see figure 63). Interestingly, one CTCF- and one
ZBTB33-binding site are located within AREG exon 2. The ZBTB33-binding site
is located only two bases downstream the AREG CpG p150 in reverse complement
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orientation and it is the only site, which is located directly on the AREG gene (see
figures 63 B and C). The next ZBTB33-binding sites are either located approximately
9.5 kb upstream the AREG promoter or approximately 15 kb downstream the last
AREG exon. EREG contained several ZBTB33-binding sites, too, which might hint
for a similar regulatory mechanism (see figure 63 A). In the publication of Blattler et
al., ENCODE data were used to identify interaction partners of ZBTB33.109,110 They
showed that ZBTB33 is associated with RNA-polymerase II and other transcription
factors. Therefore, the ZBTB33-binding site, identified within AREG exon 2, might
hint for AREG exon 2 to have promoter function.
To prove that, several Firefly-luciferase-gene containig reporter plasmids were ge-
nerated and promoter function analysis experiments were performed (see section 3.6).
The AREG CpG p150 and CpG p220 containing exon 2 was used for analysis alone
or coupled to the AREG promoter sequence or the Tata-binding motif, mimicking a
generic promoter. The complete AREG exon 2 sequence, as well as the exon 2 parts
containing only CpG p150 or CpG p220, did not show promoter function in any of the
cell lines tested when analyzed alone (see figures 25 A and 26 A). However, in HCT116
cells, the reverse-oriented exon 2 sequence showed promoter function (see figures 30 A).
Also, when coupling the AREG exon 2 sequence in reverse orientation to a Tata-binding
motif, promoter function of the Tata motif increased highly significant in HCT116 cells
(up to 10-fold), but also in the cell lines LIM1215 and CaCO2 (see figures 25 D, 26
D, 28 C-D and 29 C). In HCT116 cells promoter function increased even more, when
the reporter plasmid was methylated in vitro (see figure 28 C). These data suggest
a) a promoter function of the AREG exon 2 sequence which is b) methylation- and
orientation-dependent. A second interesting result was observed, when coupling the
AREG exon 2 sequence in both orientations to the AREG promoter. The promoter
function compared to the AREG promoter alone was significantly increased in HCT116
cells (see figures 26 B and 28 A and B). It also increased slightly in LIM1215 cells (see
figure 25 B). However, a reduction of promoter function was observed in CaCO2 cells (see
figure 29 B), which was significant for the reverse-oriented exon 2 sequence. Therefore,
a cell type specific regulatory mechanism might occur, which is sequence orientation-
independent. However, it is unclear why promoter function dropped in CaCO2 cells to
a lower value than the promoter function of the AREG promoter alone.
As already described, ZBTB33 might be responsible for the cell type specific pro-
moter function of AREG exon 2, because it is higher expressed in LIM1215 and HCT116
cells than in CaCO2 cells (see figure 32). Nevertheless, ZBTB33 might not be alone
responsible, because an orientation-dependent promoter function of AREG exon 2 in
combination with the Tata-binding motif was seen in CaCO2 cells, too. To clarify the
influence of ZBTB33 on the promoter function of AREG exon 2, experiments are cur-
rently in progress to mutate the identified ZBTB33-binding site within the AREG exon
2 sequence and afterwards test the constructs in promoter analysis experiments.
127
Experiments addressing the influence of CTCF, the second candidate which might
be involved in AREG expression, were already performed in HCT116 cells. Interestingly,
mutation of the CTCF-binding site in the AREG exon 2 coupled in forward orientation
to the AREG promoter led to a reduction of promoter function compared to the AREG
promoter alone (see figure 30 B). Remarkably, a complete loss of promoter function
was observed, when the mutated AREG exon 2 was coupled in reverse-orientation to the
AREG promoter. These data suggest that CTCF influences the promoter function of the
AREG exon 2 when coupled to the AREG promoter. But, in contrast to ZBTB33, CTCF
mRNA expression was comparably high in all cells tested (see figure 32). Data obtained
by Defossez et al. support a hypothesis including both CTCF and ZBTB33 in AREG
regulation, because they showed that CTCF can be an interaction partner of ZBTB33,
when there is a ZBTB33-binding site in close proximity to a CTCF-binding site.268 The
authors also showed that ZBTB33 inhibits the insulator function of CTCF by using
an insulation assay in vitro, where CTCF blocks the promoter function of a neomycin
resistance gene in the absence of ZBTB33. However, this is inconsistent to the results
in this work, since mutation of the CTCF-binding site, which resulted in eliminating
the possibility of CTCF to bind the AREG exon 2 sequence, led to a loss of promoter
function. As a consequence, CTCF function in the promoter assays is not explained by its
insulator function but rather by its function as a transcriptional activator as described by
Vostrov et al.114 To determine the role of CTCF on AREG expression, experiments could
be done using siRNAs targeting CTCF. Chromatin-immunoprecipitation experiments
should also be done to prove the CTCF- and ZBTB33-binding on the AREG exon 2.
These experiments are currently in progress.
ZBTB33 as well as ZBTB4 were mainly identified as repressors of gene expres-
sion.107,108 This also holds true for the AREG gene expression, since a reverse correla-
tion was observed between the expression of both transcription factors and AREG. In
literature, the function of ZBTB33 and ZBTB4 is mostly explained by their interaction
with chromatin remodeling complexes.108 Therefore, it is not clear if the effects seen
in the promoter experiments are influenced by ZBTB33 or ZBTB4 at all, because the
reporter plasmids are chromatin-free.
A hypothesis explaining the chromatin-free results might be as follows: An in-
creased promoter function in the reverse-oriented AREG exon 2 sequence coupled to the
Tata-binding motif or uncoupled, suggested a promoter function in reversed-orientation
within the AREG gene. This might lead to an antisense transcript. If the antisense
transcript interferes with the AREG gene expression, an inhibition of AREG gene ex-
pression would occur, independent of the chromatin structure. Therefore, it was further
tested, if an antisense transcript exists, or not (see next section).
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Figure 63:
Figure 63: ZBTB33-binding sites identified at the AREG and EREG gene-locus: A: 44
unique ZBTB33-binding sites were identified at the AREG and EREG gene-locus, B: One
ZBTB33-binding site is located at the AREG gene, C: This site is located closely to AREG
CpG p150.
4.4 The ENCODE-dataset suggests an antisense transcript
within the AREG gene
As shown previously, the AREG exon 2 sequence increased promoter function of the
Tata-binding motif when coupled in reverse orientation to it, but not in forward ori-
entation. This indicates that the AREG exon 2 could exert a regulatory function for
transcription of an antisense transcript within the AREG gene. This hypothetical an-
tisense RNA might be an enhancer-templated noncoding RNA as described in a review
by Natoli and Andrau. The authors grouped these RNAs into 2 groups, 2d-eRNAs and
1d-eRNAs. Interestingly, the 1d-eRNAs, are defined to be transcribed unidirectional.269
A second hypothesis could be that the AREG exon 2 is a promoter for a long
noncoding RNA (lncRNA), which interferes transcription of the AREG gene by being
transcribed in reverse orientation. During transcription, the RNA-polymerase II tra-
verses the AREG promoter which in consequence blocks the promoter.270 One example
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seen in mouse is described for the lncRNA Airn. By being transcribed in reverse orien-
tation through another promoter, Airn can block the transcription of the protein-coding
gene Igf2r.271
To address this hypothetical RNA, Northern blot experiments were performed (see
section 3.8). The probe ”E2-sense” was used as positive control to detect the AREG
mRNA. Distinct signals being also as strong as expected, validated the experimental
procedure and the probes used, because the antisense-specific probes were designed in the
same way as the ”E2-sense” probe. However, no distinct antisense product was identified
using the probe ”I1-antisense” and ”E2-antisense. There was rather a strong signal
spreading over the whole blot. Unspecific binding of the probes might be responsible for
this result, because the lanes loaded with the marker showed similar strong signals as
the lanes loaded with the samples. Also degraded RNA might lead to a signal spreading.
Thus, Northern blot analyses could not identify the antisense RNA. Therefore, a second
approach was performed to unravel a potential antisense transcript within the AREG
gene.
CDNA was generated from cells with low or high AREG expression. Bisulfite-
treatment of these cDNA enabled the detection of an antisense transcript within the
AREG gene via a strand-specific PCR. Amplification products were detected, demon-
strating the antisense sequence of AREG intron 1 and AREG exon 2 (see section 3.8.2).
After sequencing, an unspecific PCR product could be ruled out. Several controls showed
that the RNA used for cDNA synthesis was free of genomic DNA. Thus, the amplifica-
tion product had to be derived from cDNA. Unfortunately, the assigned negative control
(UBE2D2 ) was also positive for an antisense construct, although this was not expected
and not indicated in the UCSC genome browser. Interestingly, an unspecific amplifica-
tion product could be ruled out by sequencing, too. It remained controversial how the
results should be interpreted. It might even possible, that an unknown aspect of the
method itself might lead to false positive signals.
However, data acquired by the ENCODE-project110 indicate also an antisense tran-
script starting at AREG exon 2 (see figure 64). The ENCODE project identified genome-
wide histone modification patterns for different cell lines. The H3K27-acetylation e.g.
is a mark for active regulatory elements, distinguishing active enhancers and promoters
from inactive counterparts. In the AREG gene this mark is of course increased down-
stream the AREG promoter, but more interestingly, also upstream of exon 2 (see figure
64 A). This observation is further supported by the DNaseI hypersensitivity clusters,
which show not only a strong peak at the promoter but also a weak peak at the exon 2
(see figure 64 A). Next, several transcription factor binding sites within the AREG exon
2 were identified by Chip-sequencing in the ENCODE project including chromodomain
helicase DNA binding protein 2 (CHD2), the DNA endonuclease Rad2, the Tata-binding
protein (TBP) and Z274 (see figure 64 C).110 Interestingly, the RNA polymerase II (Pol2)
was also found binding up- and downstream AREG exon 2 within two different cell lines
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in independent data sets. Finally, H3K4-methylation, characteristic for open chromatin,
showed an increased signal at the AREG exon 2 region for example in the K562 cell line
(see figure 64 D). Therefore, most of the ENCODE-dataset suggest a promoter function
at AREG exon 2.
Figure 64:
Figure 64: Selected ENCODE-data within the AREG gene: ENCODE-data were aligned to
the AREG gene including exon 2. The UCSC genome browser was used for visualization. A:
H3K27Ac-mark merged from 7 different cell lines; B: DNaseI hypersensitivity clusters merged
from 125 cell lines; C: Selected transcription factor binding sites, identified by ChIP-seq; D:
Histone methylation marks in K562 identified by three independent institutions within the
ENCODE consortium. The black bordered area represents the AREG exon 2 region.
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4.5 AREG and EREG expression and methylation of AREG
CpG p150 and CpG p220 might be predictive markers
for the outcome of EGFR-targeted therapies in KRAS -
wildtype cells
In standard clinical settings, the KRAS mutation status of colorectal cancers is a selec-
tive negative marker for treatment with the EGFR inhibitor Cetuximab. It has been
shown in several studies that only KRAS -wildtype patients can benefit from a therapy,
since inhibition of EGFR might not inhibit downstream pathways when KRAS is mu-
tated. In this work, Cetuximab was substituted by Erlotinib and Gefitinib in the in vitro
experiments, because none of the cell lines showed any sensitivity towards Cetuximab.
The reason was never resolved, but might include the microenvironment of the tumor.
An increased immune-response upon Cetuximab treatment was for example detected in
vivo,272,273 which can never occur in vitro, because an immune system is not present in
cell culture. Beside possible effects on the immune-system, Cetuximab also influences
tumor growth by inhibiting the EGFR. It blocks the EGFR at the extra-cellular domain
preventing EGFR-ligand induced dimerization and autophoshorylation of the receptor.
This leads to a reduced activation of the downstream signaling-pathways. Erlotinib and
Gefitinib inhibit the EGFR-function, too, but here an inhibition of the intra-cellular
tyrosine kinase domains takes place preventing also autophosphorylation of the receptor.
This also leads to a reduced activation of the downstream signaling-pathways. The
results obtained by using these compounds should therefore be similar to the results
obtained by Cetuximab treatment in vivo. Nevertheless, when interpreting the data,
one should keep in mind that in in vivo settings, several other effects might also occur
upon EGFR-targeted therapies.
Table 22: Comparison between AREG expression, intra-gene methylation and sensitivity
towards Erlotinib and Gefitinib in five colorectal cell lines: The ∆Ct-values of the AREG
mRNA expression (see figure 3), and the methylation indices of CpG p150 and CpG p220 (MI,
see figure 14) were averaged from four different timepoints. The sensitivity towards Erlotinib
and Gefitinib was estimated from XTT-experiments (see section 3.9.1). -: cell line is resistant,
+: cell line shows little response, ++: cell line shows intermediate response, +++: cell line
shows strong response.
Cell line AREG expression AREG CpG p150 / p220 Sensitivity towards
(mean ∆Ct) (mean MI) Erlotinib / Gefitinib
SW480 -3,87 0,23 / 0,32 ++ / +++
RKO -3,78 0,78 / 0,85 - / -
LIM1215 -1,42 0,57 / 0,64 + / +
HCT116 0,20 0 / 0,11 + / +
CaCO2 1,40 0 / 0,03 +++ / +++
Among the cell lines tested, RKO cells were completely resistant, LIM1215 and
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HCT116 cells showed little response and SW480 as well as CaCO2 cells were highly sen-
sitive towards Erlotinib or Gefitinib treatment (see section 3.9.1). Interestingly, HCT116
as well as SW480 cells have a KRAS mutation and therefore should not react upon
treatment (see table 12). Since EGFR also influences other pathways directly, like the
PI3K-pathway, inhibition of EGFR might also affect this pathway and might lead to a re-
duction of proliferation. Another example: RKO cells should be sensitive upon treatment
since this cell line is KRAS -wildtype. However, this cell line has got a BRAF mutation.
The BRAF protein acts downstream KRAS and also activates the MAPK-pathway in-
dependent of the EGFR-signal. Therefore, BRAF might be another candidate gene to
predict the outcome of EGFR-targeted therapies and to select patients more stringent
for treatment. A restrospective study using 113 patients showed that wildtype BRAF
is necessary for successful Cetuximab or Panitumumab therapies.274 However, due to
its low abundance among all colorectal cancer patients leading to insignificant results in
clinical studies, the predictive power of mutated BRAF could not be proven until now.
AREG and EREG expression was already described to correlate with the outcome
of EGFR-targeted therapies in KRAS -wildtype patients,194,195 or independent to the
KRAS -status.193 Nevertheless, in our cell lines, no correlation was observed between
the endogenous AREG or EREG expression and the sensitivity towards Erlotinib and
Gefitinib. HCT116 cells, LIM1215 and RKO cells were resistant or showed only little
response, but in these cells AREG and EREG expression differed strongly (compare
figures 3 and 41 A, 42 A and 43 A, see also table 22). Also, the sensitive cell lines, CaCO2
and SW480, showed very different AREG and EREG expression. However, in this study,
only CaCO2 was KRAS -wildtype (see table 12) and had no other known mutations
within the MAPK-pathway. This cell line was indeed sensitive to Erlotinib and Gefitinib
and expressed the highest levels of AREG and EREG among the cells tested. Therefore,
CaCO2, showed a correlation between AREG expression and sensitivity towards EGFR
inhibitors. To increase the validity of this result, a future experiment would be to test
several other KRAS -wildtype cell lines and compare the results and to modulate AREG
expression in CaCO2 cells followed by sensitivity testing.
On the one hand, AREG expression correlated with the methylation of AREG
CpG p150 and CpG p220 (see section 3.4). Cells with an MI of 0 for AREG CpG p150
and an MI of less than 0.2 for AREG CpG p220 belong to the high AREG expressing
cells. Cells showing an MI greater than 0.1 for AREG CpG p150 and an MI greater than
0.2 for AREG CpG p220 belong to the AREG low and medium expressing cells. On
the other hand, AREG expression did mainly not correlate with the sensitivity towards
Erlotinib and Gefitinib. Therefore, it is unlikely that the methylation of AREG CpG
p150 and CpG p220 correlated with the sensitivity towards the inhibitors. Interestingly,
by taking a closer look to the methylation indices (MI), it was noticed that the resistant
cell lines RKO and the low sensitive cell line LIM1215 showed the strongest methylation
at the AREG CpGs (see table 22, MI >0.5). On the contrary, the most sensitive cell
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line CaCO2 showed the lowest methylation index at the AREG CpG p150 and CpG
p220. SW480 cells, showing an intermediate response towards Erlotinib treatment, were
stronger methylated than CaCO2 cells but less methylated than RKO and LIM1215 cells
at the AREG CpGs p150 and p220. Thus, methylation of the the AREG CpGs p150
and p220 correlated with the sensitivity towards Erlotinib with the exception of HCT116
cells and towards Gefitinib with the exception of HCT116 and SW480 cells. (see table
22). To summarize, while the AREG expression in cell lines is a poor predictive marker
for the sensitivity towards EGFR inhibitors in vitro, methylation of AREG CpG p150
and CpG p220 showed a better correlation.
In the ColoNET consortium, patient-derived xenografts were tested, to compare
the results obtained in vitro with in vivo data. A summary of the data, collected by
Maria Rivera-Markelova and Alexandra Schwan, is given in the supplemental mate-
rial 8.11. Here, in nine xenografts deriving from KRAS -wildtype colorectal cancers or
metastases five were sensitive to Cetuximab. These five xenografts expressed the high-
est AREG mRNA and protein levels among all samples. Only one additional xenograft,
which also expressed high levels of AREG was resistant. Eight KRAS -mutant xenografts
were tested, too. Only two showed some response towards Cetuximab, but these two
xenografts did not represent high AREG mRNA and protein expressing samples. There-
fore, the results indicated that the KRAS -wildtype status, together with AREG expres-
sion, might indeed be predictive for EGFR-targeted therapies in vivo. Interestingly, none
of the xenografts showed any methylation in the AREG CpGs p150 and p220 (data not
shown). The reason for that could not be uncovered by subsequent experiments (data
not shown). Therefore, methylation of AREG CpG p150 and CpG p220 could not be
used to predict the outcome of EGFR-targeted therapies in this xenograft experiments.
4.6 Epigenetic treatment influences the outcome of EGFR-
targeted therapies
HDACis were reported to influence the response towards EGFR-inhibition in several
cancer models.225,226,227,228,229 To test, if these findings might be adapted to our settings
the cell lines SW480, RKO, LIM1215 and CaCO2 were treated with HDACis and af-
terwards treated with Erlotinib or Gefitinib. LIM1215 cells showed the strongest effect
on sensitivity towards Erlotinib and Gefitinib after Valproat treatment (see figures 47
and 51). Since AREG and EREG expression increased upon HDACi-treatment, a con-
sequence was to test, if AREG or EREG are responsible for the increased sensitivity.
LIM1215 cells were transfected transiently or by lentiviral infection with an AREG-
sequence containing plasmid. As shown in section 3.10, in none of the experiments,
an increased sensitivity towards EGFR-inhibition was achieved although AREG protein
amounts and mRNA-expression increased in a similar way than after HDACi-treatment
(compare figures 6, 7 and 10 with 61). Direct application of recombinant AREG into the
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supernatant did also not lead to an increased sensitivity towards Erlotinib or Gefitinib
(data not shown). Although LIM1215 cells were described to be a KRAS -wildtype cell
line,275 in our laboratory a mutation within the KRAS gene was detected in exon 4 (see
table 12). It might be possible that AREG over-expression alone will not affect sensitiv-
ity due to this KRAS mutation. It could also be possible that the effect of the HDACis
onto sensitivity is independent of AREG. To clarify this problem, a low AREG ex-
pressing cell line would be necessary without any mutations within the MAPK-pathway
components. However, such a cell line was not available during this work. Therefore,
the direct contribution of AREG to the sensitivity towards EGFR inhibitors could not
be proven by the experiments presented here. Nevertheless, in a publication by Ferraros
et al., the authors verified a causal relationship between AREG and EREG expression
and response to Cetuximab in KRAS -wildtype cells.276 In contrast to the experiments
presented here, they studied the effects of AREG and EREG expression on sensitivity
towards Cetuximab by decreasing the levels of these proteins. They showed that tar-
geting either AREG or EREG gene expression with shRNAs led to decreased response
rates towards Cetuximab.
A further interesting issue is that in LIM1215 cells HDACi-treatment increases
sensitivity towards EGFR-targeted therapeutics KRAS mutation independently. A con-
sequence of this experiment could be that HDACis might have the potential to overcome
KRAS mutation dependent resistance towards EGFR-targeting therapeutics. But, if this
is true, it is unclear why the HDACi-treatment did not affect the other KRAS -mutated,
or even the KRAS -wildtype cell lines, in a similar way. One reason might be that the
cell lines tested have different response rates towards the HDACis used. Also, the target
HDACs might account for the dissimilar effectiveness of the HDACis. In LIM1215 cells,
Cambinol, for example, did not increase sensitivity towards EGFR-inhibition, although
Trichostatin A and Valproat did (see figure 47). Nevertheless, while TSA and Valproat
are mainly targeting HDACs class I and II, Cambinol targets the HDAC Sirtuin I, a
HDAC class III.277 SAHA, in contrast, was not tolerated by LIM1215 at all. Addition-
ally, it was tested if these findings can be applied in vivo. LIM1215 cells were injected
in mice to create xenografts. But, in contrast to the in vitro results, HDACi treatment
did not lead to an increase of senstitivity towards EGFR inhibitors (see figure 54).
As a second approach the mice, injected with LIM1215 cells, were treated with the
DNA methyltransferase inhibitor 5-Azacytidine. By using the DNA methyltransferase
inhibitor DAC in in vitro experiments, AREG and EREG expression increased (see figure
4). But, as already described, post-treatment procedures were not possible, since the
cells died after replating. Nevertheless, in mice 5’Azacytidine treatment, which is also
a DNA methyltransferase inhibitor, led to an increased response to Erlotinib (see figure
54). Therefore, in in vivo systems global epigenetic changes might also play a role for
EGFR-treatment response. But, when testing the AREG and EREG expression in the
xenografted cells, it was observed that treatment did not influence mRNA-expression of
135
AREG or EREG (see figure 55). Additionally, IHC-experiments showed that the AREG
protein expression varied strongly among the xenografted cells treatment independently
(see table 21 and figure 56). As a consequence AREG or EREG mRNA-expression as
well as AREG protein amounts might not correlate with the increase of sensitivity in
this experimental model or cannot be measured precisely. It was, for example, hardly
possible to analyze the 5-Azacytidine treated samples, because the tumor growth was
reduced dramatically upon treatment. Nevertheless, a decreased methylation index was
observed in the AREG intragenic CpGs p150 and p220 as well as in the EREG intragenic
CpG p297 upon 5-Azacytidine treatment alone or in combination with Erlotinib (see
figure 57). Therefore, the epigenetic regions might function as predictive markers in
combination therapies, when the expression of AREG cannot be evaluated. The lack
between methylation and expression in the xenograft model has to be further addressed.
Overall, the results indicate for clinical settings that patients, which do not respond
to EGFR-targeted therapies might become sensitive after treatment with epigenetically
interfering compounds by different, yet largely unknown mechanisms.
4.7 AREG CpG p150 and CpG p220 are differentially methyl-
ated in human tumor samples
Subsequent experiments were performed in the ColoNET-consortium to evaluate if the
results of this work could also be applied to human tissues. As already described, KRAS -
wildtype and mutant tumors were grown on mice and the xenografts were measured for
their AREG mRNA and protein expression and for their response towards Cetuximab
(see supplementary material 8.11). Similar to the cell lines, AREG was differentially
expressed in human carcinoma-derived xenografts. Additionally the xenografts also re-
sponded differently to Cetuximab according to their mutation status and AREG expres-
sion (see supplemetary tables 27 and 28).
As a next approach, methylation of the identified intragenic CpGs in the AREG
gene was measured in 5 different human tissue samples. Each tissue was separated by
Florian Rossner (Charité Berlin, Institute for Pathology) into 4 parts using microdi-
section: normal epithelium, normal stroma, tumor epithelium and tumor stroma. The
results are shown in supplementary material 8.12. Three of the 4 normal epithelium
samples (1 sample failed) and 3 of 5 normal stroma samples showed high methylation
within the tested CpGs (MI >0.5). Four of 5 tumor stroma samples showed also high
methylation. Interestingly only 1 of 5 tumor epithelium samples showed high methy-
lation for one CpG (CpG p220), which means that the tumor epithelium samples were
mainly unmethylated at the tested CpGs, whereas in the other compartments the CpGs
were mainly methylated. To verify the results, the approach was repeated with 20 addi-
tional human tissues. Additionally to the AREG CpGs p150 and p220 also the EREG
CpGs p143 and p297 were tested. The boxplots of all methylation indices observed in
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this experiment are shown in supplementary material 8.13. Similar to the results before,
the methylation at the AREG CpGs were in general lower in the tumor epithelium com-
partments compared to the tumor stroma, the normal stroma or the normal epithelium.
This was also seen for the methylation of the EREG CpGs. However, looking in detail
to the samples, there are also 5 samples, which show a high methylation index greater
than 0.6 at the AREG CpG p150 and CpG p220 in the tumor epithelium. In contrast,
for EREG the highest methylation index is only 0.6. Nevertheless, it needs to be clari-
fied to what extent the differential methylation of the AREG and EREG CpGs within
the tumor epithelium samples and between the different tissue types are influenced by
remaining tumor stroma cells within the tumor epithelium samples. It would also be
interesting to clarify with corresponding patient data, if the methylation of AREG CpG
p150 and CpG p220 within the tumor epithelium might also predict the outcome of
EGFR-targeted therapies, as it was seen for the AREG expression in in vivo experi-
ments using xenografts (see section 4.5). However, to test that, the number of tested
samples has to be increased dramatically to ensure significant results.
4.8 Remarks on experimental designs
4.8.1 AREG and EREG were analyzed in this work
In this work AREG and EREG were chosen from all known EGFR-ligand genes, be-
cause they are commonly over-expressed in colorectal cancer cells.56,61 They were also
found to be potential predictive markers for EGFR-targeted therapies.193,194,195 Together
with BTC, AREG and EREG were discovered to be regulated via DNA methylation in
an experiment which showed different mRNA-expression patterns in HCT116 cells and
HCT116 derivatives, lacking DNMT1 and 3b.240 All other EGFR-ligands were not iden-
tified to be regulated epigenetically.240 Also, intragenic CpG-positions were identified for
all three genes, which have different methylation patterns in different cell lines. However,
in first tests using two cell lines, only the CpG-positions identified for the AREG and
EREG genes were found to correlate with the expression of the genes. The identified
CpG-positions within the BTC gene showed similar methylation although BTC expres-
sion differed in these cells (see supplemtary material 8.10). Therefore, BTC was omitted
from analysis within this study. Nevertheless, when finding an intragenic CpG, whose
methylation correlates with BTC expression, it would be interesting to consider BTC in
future experiments.
4.8.2 Solvents influence experimental outcome
When comparing the solvent treated samples (DMSO, Ethanol) with untreated samples
an interesting effect was seen in the proliferation experiments. In some experiments,
cells grew faster or were more resistant to subsequent Erlotinib or Gefitinib treatment
(compare e.g. figure 47 A and B). This effect was not consistent between different
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experiments. The reason is unknown. However, one of the solvents, DMSO, used as
control for Erlotinib and Gefitinib treatment, was reported to influence differentiation in
erythroleukemia cells278 by influencing the cell cycle,279 enzyme activity280 and DNA.281
DMSO was also the starting point for the development of HDACis like SAHA.213 Solvent
controls were necessary to evaluate the effects of the inhibitors to the cells. Therefore, in
each growth experiment, the effects of the inhibitors on proliferation were compared to
the solvent treated cells since the same amount of solvent was present in each inhibitor
approach. The solvent effect was then taken into consideration when interpreting the
results.
4.8.3 Differences between in vitro and in vivo results
AREG and EREG mRNA-expression were increased upon HDACi- and DAC-treatment
in vitro. In mice, no increase of AREG or EREG mRNA-expression was observable
after treatment (see figure 55). In addition, all ∆Ct-values, obtained by real-time PCR
expression analysis of the LIM1215 cell-derived xenografts, were similar to the ∆Ct-
values of untreated LIM1215 cells in vitro (compare figures 3 and 55). Mouse derived
RNA within the sample, which might lead to this result, could be ruled out by expression
analysis of mouse-specific AREG and EREG. Neither of them was detected (data not
shown), illustrating that the AREG mRNA measured within the xenografts derived
completely from the human cells. The reason, why no increase was observed upon
treatment could depend on the ratio between the human and mouse cells within the
sample. However, the human-specific control gene expression should adjust the results
to the input cell or RNA amount. Immunohistochemistry of the xenografts with an
antibody targeting AREG revealed that also the protein levels of AREG differed between
different samples of the same treatment group (see figure 56 and table 21). Together
these results indicate that a strong heterogeneity of AREG expression in LIM1215 cells
grown in vivo render a quantitative evaluation of the effects of the epigenetic compounds
onto sensitivity towards EGFR inhibitors impossible. Furthermore, contributing effects
of mouse stromal cells onto AREG expression could not be ruled out.
CpG-methylation analysis was performed by Dr. Sascha Tierling (University of
Saarbrücken), using the methylation-dependent single-nucleotide primer extension ap-
proach (msSNuPE). The methylation of AREG CpG p150 and CpG p220 was different
between the LIM1215 cells in vitro and the LIM1215 derived xenografts (compare figures
14 and 57). In vitro, the MI ranged between 0.4 in CpG p150 and 0.6 in CpG p220,
whereas in the xenografts the MI ranged from 0.2 in CpG p150 to 0.4 in CpG p220.
Interestingly the MIs of the EREG CpGs p143 and p297 did not differ strongly between
LIM1215 cells in vitro and in vivo (compare figures 14 and 57).
To address this problem, the AREG gene sequence of the human genome was
compared to the sequence of the mouse genome. In figure 65 is shown that the sequences
of AREG exon 2 are very similar in human and mouse. However, the AREG CpG
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p150 is changed in the mouse genome to a TC-dinucleotide. After bisulfite conversion,
unmethylated human cells and all mouse cells have binding sites within their DNA for
the msSNuPE-primer detecting the unmethylated state of the AREG CpG p150. The
reason is that bisulfite-treatment necessary for the msSNuPE approach will convert the
Cytosine in the unmethylated human AREG CpG p150 to an Uracil, which is a derivative
of Thymine. As a consequence every remnant mouse cell within the xenografted sample
will decrease the MI-value of AREG CpG p150. Additionally, there is an Adenine in
the mouse gene at the position of the cytosine of AREG CpG p220, which might also
influence the MI.
In contrast to AREG, when comparing the EREG gene sequences between human
and mouse, it was observed that there is a strong difference within the region of EREG
CpG p143 and p297 (see figure 65). In the region of EREG CpG p143, there is no con-
sensus sequence within the mouse gene, in the region of EREG CpG p297, the sequence
is very different between human and mouse. As a consequence, the msSNuPE-primers,
which are used for the detection of these CpGs, only bind to human DNA. Therefore, the
results between in vitro and in vivo should be similar as it was seen in the experiments.
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Figure 65:
AREG CpGs p150 and p220:
EREG CpG p143:
EREG CpG p297:
Figure 65: Sequence similarities at the AREG and EREG genes between human and mouse:
The human genome hg19 (human) and the mouse genome mm9 (mouse) were compared at the
genloci within the AREG and EREG genes where the intragenic CpGs of interest are located.
(.): sequence is equal, (-): deletions within the mouse sequence, (N): base substitutions between
mouse and human sequence, ( ): no sequence similarities.
4.9 Outlook
AREG gene expression is regulated by an epigenetic mechanism involving the intragenic
CpGs within AREG exon 2. By comparing the results of promoter function analysis in
different cell lines, bioinformatic approaches, and strand-specific PCR a hypothesis was
made, how AREG exon 2 influences AREG expression (see figure 66). In this hypothesis,
the methylation-dependent transcription factors CTCF, ZBTB33 and ZBTB4 play an
important role. They interact methylation-dependently with the AREG exon 2 and sup-
press AREG expression. The gene suppression might be achieved either by interacting
with histone modifying enzymes or by supporting the transcription of an antisense-RNA
which interferes with the AREG transcription. Deregulating these transcription factors
in the cell lines tested by over-expression, shRNA mediated down-regulation or by chemi-
cals, followed by AREG expression analysis or promoter function analysis of AREG exon
2 would in consequence lead to a gain of information verifying or falsifying the importance
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of ZBTB33 and CTCF on the AREG expression. Also chromatin-immunoprecipitation
experiments need to be made to investigate if the transcription factors directly influ-
ence AREG expression by binding to the methylated or unmethylated AREG exon
2. Stronger efforts are also necessary to address the possible antisense-RNA by differ-
ent methods as ribonuclease-protection-assays or other strand-discriminating methods.
These experiments are currently in progress.
Xenograft experiments revealed that AREG high expressing KRAS -wildtype co-
lorectal tumors show a higher senitivity to Cetuximab than AREG low expressing tumors
(see supplementary material 8.11). As a consequence, high AREG expression or low
methylation of AREG CpG p150 and p220 might be predictive markers in combination
with wildtype KRAS to predict a positive outcome of EGFR-targeted therapies.
A next step would be to verify the correlation between AREG mRNA and protein
expression and the methylation of AREG CpG p150 and CpGp220 in vivo. When using
material with known KRAS mutation states and response rates towards EGFR-targeted
therapies, it could further be tested, if there is a correlation between these characteristics
and the methylation of the intragenic AREG CpGs. So, the predictive power of AREG
expression or its intragene methylation could be evaluated.
Further experiments within this study showed that HDACi treatment in vitro and
5-Azacytidine treatment in vivo led to an increased sensitivity towards EGFR inhibitors,
respectively. Interestingly, this effect occurred in the KRAS mutated cell line LIM1215.
Additionally, these results were accompanied by increases in AREG expression or de-
creases in AREG exon 2 methylation. It would be interesting if this result might also
be achieved in human tumor samples. It would be a milestone in cancer therapy, if
non-responding patients might become sensitive to EGFR-targeting therapeutics KRAS
mutation independently by pre-treating the patients with epigenetic compounds like
HDACis. AREG expression or its intragenic methylation might then be a means of
monitoring the process of becoming sensitive. First experiments to test the situation
in vivo might be realized by xenografting tumor cells with different KRAS mutation
states into mice and monitor their growth upon treatment with epigenetic compounds




Figure 66: Hypothetic influence of AREG exon 2 on AREG expression: A: Normal tran-
scription of the AREG gene, when the CpGs within AREG exon 2 are unmethylated. B:
When the CpGs within AREG exon 2 are methylated, ZBTB33, CTCF or a complex con-
taining both proteins is able to bind. As a consequence it closes the chromatin structure e.g.
by interaction with chromatin remodeling complexes. ZBTB33 and CTCF also influence the
RNAPII-dependent transcription of an antisense transcript. By traversing the AREG pro-
moter, the antisense RNA anticipates binding of RNAPII to the AREG promoter. Empty red
circles: unmethylated CpGs within AREG exon 2; full red circles: methylated CpGs. Black
lines: DNA sequence; black bars: exons of the AREG gene, Green filled circle: RNAPII; blue
form: CTCF and ZBTB33 interacting with AREG exon 2. Grey full circles: nucleosomes.
Arrows indicate the orientation of transcription.
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5 Summary
Amphiregulin and Epiregulin are ligands of the Epidermal Growth Factor Receptor
(EGFR) whose expression correlates with a positive EGFR-targeted therapy response
in colorectal cancer.193,194,195 Aim of this work was to define the influence of epigenetic
mechanisms on AREG and EREG gene expression. It could be shown that AREG and
EREG are differentially expressed in a set of colorectal cancer cell lines and that the
expression of both genes increases after treatment with epigenetically interfering com-
pounds such as DNA methyltransferase inhibitors and histone deacetylase inhibitors.
Therefore, the epigenetic mechanism regulating AREG and EREG gene expression was
verified. Methylation analysis in five cell lines showed that the promoters of both genes
were unmethylated, except in one cell line for the EREG promoter. Furthermore, short
intragenic regions within both genes were identified to be differentially methylated. For
AREG, this region is located within exon 2, indicating an uncommon epigenetic regula-
tory mechanism. Promoter function analyses showed that the region containing AREG
exon 2 harbor methylation- and orientation dependent promoter function and they sug-
gested CTCF, an MDB-protein, to be involved in the promoter function. A reduction of
promoter function of reporter plasmids was observed upon mutation of a CTCF-binding
site within the AREG exon 2 sequence. Expression analysis experiments suggested also
ZBTB33, another MDB-protein, to be involved in AREG regulation. ZBTB33 was dif-
ferentially expressed in the cells and the expression correlated inversely with the AREG
expression. Further experiments modulating the ZBTB33 expression as well as a bioin-
formatic analyses identifying a ZBTB33 binding site within AREG exon 2 strengthen
the hypothesis that also ZBTB33 is involved in AREG regulation.
It was also shown in this work that LIM1215 cells treated with HDACis were more sen-
sitive towards EGFR inhibitors in vitro. This effect was accompanied by an increased
AREG and EREG expression. In vivo, an increased sensitivity towards EGFR inhibitors
was achieved in LIM1215 cells by treatment with a DNA methyltransferase inhibitor.
Here the effect was accompanied by a reduced methylation within the AREG and EREG
intragenic CpGs. Together, the results suggested a new possibility to potentially make
EGFR-targeted therapy resistant patients suitable for EGFR-targeted therapies by epi-
genetic compound treatment. In that case AREG as well as EREG might be predictive
markers to evaluate the effect of the epigenetic compounds during therapy.
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6 Zusammenfassung
Amphiregulin und Epiregulin sind Liganden des epidermalen Wachstumsfaktor Rezep-
tors (EGFR), deren Expression mit einem positiven EGFR-zielgerichtetem Thera-
pieansprechen in Darmkrebs korreliert.193,194,195 Ziel dieser Arbeit war es, einen epi-
genetischen Einfluss auf die AREG und EREG Expression zu klären. Es wurde gezeigt,
dass AREG und EREG in verschiedenen kolorektalen Krebszelllinien differenziell ex-
primiert sind, und dass die Expression beider Gene durch Substanzen, die mit epi-
genetischen Prozessen interferieren, zum Beispiel DNA-Methyltransferaseinhibitoren
oder Histondeazetylaseinhibitoren, erhöht werden kann. Dadurch konnte der epigene-
tische Einfluss auf die AREG und EREG Expression bestätigt werden. Eine Analyse
der DNA-Methylierung in fünf Zelllinien zeigte, dass die Promotoren beider Gene, bis
auf eine Ausnahme in EREG, unmethyliert vorlagen. Hingegen wurden kurze Regionen
innerhalb der kodierenden Bereiche der Gene als differentiell methyliert identifiziert. Im
AREG Gen liegt diese Region im Exon 2, was auf einen ungewöhnlichen epigenetisch ges-
teuerten Regulationsmechanismus hindeutet. Promotorfunktionsanalysen zeigten, dass
die AREG Exon 2 Region eine methylierungsabhängige und orientierungsabhängige
Promoterfunktion hat, in die das MDB-Protein CTCF involviert sein könnte. Die
Mutation einer CTCF-Bindungsstelle in der AREG Exon 2 Sequenz einiger Reporter-
plasmide führte zur Veringerung der Promotorfunktion dieser Plasmide. Expression-
sanalysen wiesen jedoch darauf hin, dass auch ZBTB33, ein anderes MDB-Protein,
in die AREG Regulation involviert sein könnte. Die ZBTB33 Expression war in den
getesteten Zelllinien differentiell und sie war negativ mit der AREG Expression korre-
liert. Weiterführende Experimente zur Modulation der ZBTB33 Expression und eine
bioinformatorische Untersuchung, die eine neue ZBTB33-Bindungsstelle im AREG Exon
2 identifizierte, stärkten die Hypothese, dass ZBTB33 eine wichtige Rolle in der AREG
Regulation spielt.
Des Weiteren wurde gezeigt, dass die Behandlung der Zelllinie LIM1215 mit His-
tondeazetylaseinhibitoren im in vitro Experiment zu einer Erhöhung der Sensitivität
gegenüber EGFR-zielgerichteten Medikamenten führt. Begleitet wurde der Effekt mit
einer Erhöhung der AREG- und EREG-Expression. Im in vivo Versuch konnte die
Sensitivität von LIM1215 Zellen gegenüber EGFR-zielgerichteten Medikamenten durch
die Behandlung mit DNA-Methyltransferaseinhibitoren erhöht werden. Begleitet wurde
der Effekt hier mit einer Verringerung der Methylierung der untersuchten AREG- und
EREG-intragenischen CpGs. Diese Ergebnisse zeigen eine neue Möglichkeit auf, wie
Patienten, die resistent gegenüber EGFR-zielgerichteten Therapien sind, möglicherweise
sensitiv gemacht werden können. In diesem Fall könnten sowohl AREG als auch
EREG als prädiktive Marker eingesetzt werden, um den Effekt der die Epigenetik
beeinflussenden Substanzen zu evaluieren.
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Barber, T., Ptak, J. et al. (2007). The genomic landscapes of human breast and colorectal cancers.
Science 318(5853):1108–1113.
[14] Baker, S.J., Preisinger, A.C., Jessup, J.M., Paraskeva, C., Markowitz, S., Willson, J.K., Hamilton,
S. and Vogelstein, B. (1990). p53 gene mutations occur in combination with 17p allelic deletions
as late events in colorectal tumorigenesis. Cancer Res 50(23):7717–7722.
[15] Teodoro, J.G., Evans, S.K. and Green, M.R. (2007). Inhibition of tumor angiogenesis by p53: a
new role for the guardian of the genome. J Mol Med (Berl) 85(11):1175–1186.
[16] Mendelsohn, J. and Baselga, J. (2000). The EGF receptor family as targets for cancer therapy.
Oncogene 19(56):6550–6565.
[17] Boulougouris, P. and Elder, J. (2001). Epidermal growth factor receptor structure, regulation,
mitogenic signalling and effects of activation. Anticancer Res 21(4A):2769–2775.
145
[18] Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Luca, A.D., Caponigro, F.
and Salomon, D.S. (2005). The ErbB receptors and their ligands in cancer: an overview. Curr
Drug Targets 6(3):243–257.
[19] Graus-Porta, D., Beerli, R.R., Daly, J.M. and Hynes, N.E. (1997). ErbB-2, the preferred het-
erodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J
16(7):1647–1655.
[20] Baldus, S.E., Schaefer, K.L., Engers, R., Hartleb, D., Stoecklein, N.H. and Gabbert, H.E. (2010).
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal
adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790–799.
[21] Palomba, G., Colombino, M., Contu, A., Massidda, B., Baldino, G., Pazzola, A., Ionta, M.,
Capelli, F., Trova, V., Sedda, T. et al. (2012). Prevalence of KRAS, BRAF, and PIK3CA somatic
mutations in patients with colorectal carcinoma may vary in the same population: clues from
Sardinia. J Transl Med 10:178.
[22] O’dwyer, P.J. and Benson, A.B. (2002). Epidermal growth factor receptor-targeted therapy in
colorectal cancer. Semin Oncol 29(5 Suppl 14):10–17.
[23] Busser, B., Sancey, L., Brambilla, E., Coll, J.L. and Hurbin, A. (2011). The multiple roles of
amphiregulin in human cancer. Biochim Biophys Acta 1816(2):119–131.
[24] Shoyab, M., McDonald, V.L., Bradley, J.G. and Todaro, G.J. (1988). Amphiregulin: a bifunctional
growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human
breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci U S A 85(17):6528–6532.
[25] Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T. and Hanada,
K. (1995). Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary
hepatocytes. J Biol Chem 270(13):7495–7500.
[26] Brown, C.L., Meise, K.S., Plowman, G.D., Coffey, R.J. and Dempsey, P.J. (1998). Cell surface
ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor.
Release of a predominant N-glycosylated 43-kDa soluble form. J Biol Chem 273(27):17258–17268.
[27] Sunnarborg, S.W., Hinkle, C.L., Stevenson, M., Russell, W.E., Raska, C.S., Peschon, J.J., Cast-
ner, B.J., Gerhart, M.J., Paxton, R.J., Black, R.A. et al. (2002). Tumor necrosis factor-alpha
converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol
Chem 277(15):12838–12845.
[28] Isokane, M., Hieda, M., Hirakawa, S., Shudou, M., Nakashiro, K., Hashimoto, K., Hamakawa, H.
and Higashiyama, S. (2008). Plasma-membrane-anchored growth factor pro-amphiregulin binds
A-type lamin and regulates global transcription. J Cell Sci 121(Pt 21):3608–3618.
[29] Sahin, U., Weskamp, G., Kelly, K., Zhou, H.M., Higashiyama, S., Peschon, J., Hartmann, D.,
Saftig, P. and Blobel, C.P. (2004). Distinct roles for ADAM10 and ADAM17 in ectodomain
shedding of six EGFR ligands. J Cell Biol 164(5):769–779.
[30] Singh, A.B. and Harris, R.C. (2005). Autocrine, paracrine and juxtacrine signaling by EGFR
ligands. Cell Signal 17(10):1183–1193.
[31] Tsark, E.C., Adamson, E.D., Withers, G.E. and Wiley, L.M. (1997). Expression and function of
amphiregulin during murine preimplantation development. Mol Reprod Dev 47(3):271–283.
[32] Kariagina, A., Xie, J., Leipprandt, J.R. and Haslam, S.Z. (2010). Amphiregulin mediates estrogen,
progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent
rat mammary cancers. Horm Cancer 1(5):229–244.
146
[33] Ejskjaer, K., Srensen, B.S., Poulsen, S.S., Mogensen, O., Forman, A. and Nex, E. (2005). Expres-
sion of the epidermal growth factor system in human endometrium during the menstrual cycle.
Mol Hum Reprod 11(8):543–551.
[34] Das, S.K., Chakraborty, I., Paria, B.C., Wang, X.N., Plowman, G. and Dey, S.K. (1995). Am-
phiregulin is an implantation-specific and progesterone-regulated gene in the mouse uterus. Mol
Endocrinol 9(6):691–705.
[35] Park, J.Y., Su, Y.Q., Ariga, M., Law, E., Jin, S.L.C. and Conti, M. (2004). EGF-like growth
factors as mediators of LH action in the ovulatory follicle. Science 303(5658):682–684.
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[252] Lüchtenborg, M., Weijenberg, M.P., Roemen, G.M.J.M., de Brune, A.P., van den Brandt, P.A.,
Lentjes, M.H.F.M., Brink, M., van Engeland, M., Goldbohm, R.A. and de Goeij, A.F.P.M. (2004).
APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcino-
genesis 25(7):1219–1226.
[253] Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B. and Kinzler, K.W.
(1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or
APC. Science 275(5307):1787–1790.
[254] Mack, E.M., Smith, J.E., Kurz, S.G. and Wood, J.R. (2012). cAMP-dependent regulation of
ovulatory response genes is amplified by IGF1 due to synergistic effects on Akt phosphorylation
and NF-B transcription factors. Reproduction 144(5):595–602.
[255] Plowman, G.D., Green, J.M., McDonald, V.L., Neubauer, M.G., Disteche, C.M., Todaro, G.J.
and Shoyab, M. (1990). The amphiregulin gene encodes a novel epidermal growth factor-related
protein with tumor-inhibitory activity. Mol Cell Biol 10(5):1969–1981.
[256] Johansson, C.C., Yndestad, A., Enserink, J.M., Ree, A.H., Aukrust, P. and Taskén, K. (2004).
The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine
3’,5’-monophosphate pathway in various cell types. Endocrinology 145(11):5177–5184.
[257] Nakajima, T., Uchida, C., Anderson, S.F., Lee, C.G., Hurwitz, J., Parvin, J.D. and Montminy, M.
(1997). RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90(6):1107–
1112.
[258] Felzien, L.K., Farrell, S., Betts, J.C., Mosavin, R. and Nabel, G.J. (1999). Specificity of cyclin
E-Cdk2, TFIIB, and E1A interactions with a common domain of the p300 coactivator. Mol Cell
Biol 19(6):4241–4246.
[259] Ogryzko, V.V., Schiltz, R.L., Russanova, V., Howard, B.H. and Nakatani, Y. (1996). The tran-
scriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87(5):953–959.
[260] Yun, J., Song, S.H., Park, J., Kim, H.P., Yoon, Y.K., Lee, K.H., Han, S.W., Oh, D.Y., Im, S.A.,
Bang, Y.J. et al. (2012). Gene silencing of EREG mediated by DNA methylation and histone
modification in human gastric cancers. Lab Invest 92(7):1033–1044.
[261] Gius, D., Cui, H., Bradbury, C.M., Cook, J., Smart, D.K., Zhao, S., Young, L., Brandenburg,
S.A., Hu, Y., Bisht, K.S. et al. (2004). Distinct effects on gene expression of chemical and ge-
netic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell
6(4):361–371.
[262] Murthy, A., Defamie, V., Smookler, D.S., Grappa, M.A.D., Horiuchi, K., Federici, M., Sibilia, M.,
Blobel, C.P. and Khokha, R. (2010). Ectodomain shedding of EGFR ligands and TNFR1 dictates
hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest 120(8):2731–2744.
[263] Rauch, T.A., Wu, X., Zhong, X., Riggs, A.D. and Pfeifer, G.P. (2009). A human B cell methylome
at 100-base pair resolution. Proc Natl Acad Sci U S A 106(3):671–678.
162
[264] Easwaran, H.P., Neste, L.V., Cope, L., Sen, S., Mohammad, H.P., Pageau, G.J., Lawrence,
J.B., Herman, J.G., Schuebel, K.E. and Baylin, S.B. (2010). Aberrant silencing of cancer-related
genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus.
Cancer Res 70(20):8015–8024.
[265] McBrian, M.A., Behbahan, I.S., Ferrari, R., Su, T., Huang, T.W., Li, K., Hong, C.S., Christofk,
H.R., Vogelauer, M., Seligson, D.B. et al. (2013). Histone acetylation regulates intracellular pH.
Mol Cell 49(2):310–321.
[266] Maitre, M., Ciesielski, L. and Mandel, P. (1974). Effect of 2-methyl 2-ethyl caproic acid and
2-2-dimethyl valeric acid on audiogenic seizures and brain gamma aminobutyric acid. Biochem
Pharmacol 23(17):2363–2368.
[267] Eickholt, B.J., Towers, G.J., Ryves, W.J., Eikel, D., Adley, K., Ylinen, L.M.J., Chadborn, N.H.,
Harwood, A.J., Nau, H. and Williams, R.S.B. (2005). Effects of valproic acid derivatives on
inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and
viral replication: a screening approach for new bipolar disorder drugs derived from the valproic
acid core structure. Mol Pharmacol 67(5):1426–1433.
[268] Defossez, P.A., Kelly, K.F., Filion, G.J.P., Pérez-Torrado, R., Magdinier, F., Menoni, H.,
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8.2 Plasmids for promoter analysis
Table 24: pCpGl-basic and -derived plasmids: CpG free plasmids were produced to analyze




pCpGl-AREG-e2150 pCpGl-basic AREG exon2 CpG p150
pCpGl-AREG-e2220 pCpGl-basic AREG exon2 CpG p220
pCpGl-AREG-exon2 pCpGl-basic AREG exon2
pCpGl-AREG-exon2-R pCpGl-basic AREG exon2 reverse
pCpGl-AREG-promoter pCpGl-basic AREG promoter
pCpGl-AREG-e2150- pCpGl-AREG-promoter AREG exon2 CpG p150
AREG-promoter
pCpGl-AREG-e2220- pCpGl-AREG-promoter AREG exon2 CpG p220
AREG-promoter
pCpGl-AREG-exon2- pCpGl-AREG-promoter AREG Exon2
AREG-promoter
pCpGl-AREG-e2150-R- pCpGl-AREG-promoter AREG exon2 CpG p150 reverse
AREG-promoter
pCpGl-AREG-e2220-R- pCpGl-AREG-promoter AREG exon2 CpG p220 reverse
AREG-promoter
pCpGl-AREG-exon2-R- pCpGl-AREG-promoter AREG exon2 reverse
AREG-promoter
pCpGl-EF1 pCpGl-basic EF1 promoter
pCpGl-e2150-EF1 pCpGl-EF1 AREG exon2 CpG p150
pCpGl-e2220-EF2 pCpGl-EF1 AREG exon2 CpG p220
pCpGl-exon2-EF1 pCpGl-EF1 AREG exon2
pCpGl-e2150-R-EF1 pCpGl-EF1 AREG exon2 CpG p150 reverse
pCpGl-e2220-R-EF1 pCpGl-EF1 AREG exon2 CpG p220 reverse
pCpGl-exon2-R-EF1 pCpGl-EF1 AREG exon2 reverse
pCpGl-Tata pCpGl-basic Tata-binding motif
pCpGl-e2150-Tata pCpGl-Tata AREG exon2 CpG p150
pCpGl-e2220-Tata pCpGl-Tata AREG exon2 CpG p220
pCpGl-exon2-Tata pCpGl-Tata AREG exon2
pCpGl-e2150-R-Tata pCpGl-Tata AREG exon2 CpG p150 reverse
pCpGl-e2220-R-Tata pCpGl-Tata AREG exon2 CpG p220 reverse
pCpGl-exon2-R-Tata pCpGl-Tata AREG exon2 reverse
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************************************* * ********************** **** *************************************************
AATACTTTGAGATGTCTGTGAGGCTGGCAGAAGCCATGAAAAGATATGGACTGAACACCAACCACAGGATTGTGGTGTGCTCTGAGAACTCTCTCCAGTTCTTCATGCCTGTGTTAGGAG
AATACTTTGAGATGTCTGTGAGGCTGGNAGAAGCCATGAAAAGATATGGACTGAACACCAACCACAGGATTGNNGNGTGCTCTGANA-CTCTCTC-AGTNNN--ATGCCTGTGNTAGNAN








































































































































































































************************************************************************************ ***************** ************* ***
CAAGACTGACTACCAGGGCTTCCAGAGCATGTATACCTTTGTGACCAGCCACTTACCCCCTGGCTTCAATGAGTATGACTTTGTGCCTGAGAGCTTTGACAGGGACAAGAC---------
CAAGACTGACTACCAGGGCTTCCAGAGCATGTATACCTTTGTGACCAGCCACTTACCCCCTNNNT-CAATGAGTATGACTTTGTGCCTGANANCTTTGACAGGGNNAGANCATTGCTCTG


















































































************************************************************** * * ************** ****** ***** ******** * ***********
TGAT------------------------------TATGAACAGCTCTGGCT---------
TGATATNANAGCTCTGNNCNCTGACTGCCNANGGTNNGNNNNNCCCNNNNNACNGCTNNN

























































******************* ** ***************** ************* ********************************* **************************
GCTTCAATGAGTATGACTTTGTGCCTGAG------AGCTTTGACAGGGACA------AGA
NNNN--ANGANTATGANTTTGNNCNGNNNCTTNGANNNNNNNACATGNNNNGATATGANN























































































































































































































































8.4 Example of lower results in promoter function analysis
Figure 67:
Figure 67: Verification of the t-test of the promoter function analysis: Figure 26 D was
enlarged to show that some results, although they are not recognized in the original figure to
be significant, have low non-overlapping error bars, which is an indication for significance in
figures. Of course, the p-values calculated for these data proves significance.
xvi
8.5 In vitro methylation for promoter function analysis
Figure 68:
Figure 68: Analysis of in vitro methylation by restriction digest: Four plasmids were methy-
lated as described in section 2.2.8 and afterwards either digested with NcoI/AvaI (left) or with
HindIII/AvaI (right). Methylated CpGs and the mutation of the CTCF-binding site lead to
different restriction bands which are shown in the schemes below the gel figure. AvaI is the
methylation dependent restriction enzyme. In the agarose gel the unmethylated plasmid (U)
is shown next to the methylated plasmid (M) to compare the restriction digest bands.
xvii






























Figure 69: Restriction maps of expression plasmids: PCDH-IRES-GFP-Puro, pCDH-AREG
and pCDH-AREG-short were digested in silico with HindIII and NheI using the webtool NEB-
cutter.233
Table 25: Linear fragments after restriction digest of expression plasmids with HindIII and
NheI
No Ends pCDH-IRES-GFP-Puro pCDH-AREG pCDH-AREG-short
1 HindIII-HindIII 3424 3424 3424
2 NheI-HindIII 1960 1067 977
3 HindIII-HindIII 1496 1496 1496
4 HindIII-HindIII 1479 1479 1479
5 HindIII-HindIII 728 728 728
6 HindIII-HindIII 583 583 583
7 HindIII-HindIII 553 553 553
8 HindIII-NheI 305 305 305
Figure 70:
1 2 3 1kb 100b 1 2 3
Figure 70: In silico VS in vitro digest of pCDH-plasmids: 1: PCDH-IRES-GFP-Puro, 2:
pCDH-AREG and 3: pCDH-AREG-short were digested in silico using the webtool NEBcut-
ter233 and in vitro with HindIII and NheI.
xviii
8.7 Control digest for Northern blot probe generation
Figure 71:
Figure 71: Plasmid map of pBluescript II KS +: Inserts were cloned into the plasmid pBlue-
script II KS + after digest with EcoRV for Northern blot probe generation. Plasmids were
sequenced with the sequencing primer T7. Plasmids were linearized either with HindIII or
EcoRI which depended on the orientation of the inserts.
Figure 72:
E2
/ E H E/H
I2
/ E H E/H
I1
/ E H E/H
Figure 72: Control digest of pBluescript II KS + -derived plasmids: Plasmids were digested
either with HindIII or EcoRI or with both to analyze if only one insert is located within the
plasmid after cloning
xix
8.8 Sequencing results of plasmids for Northern blot probe gen-
eration
pBluescript II KS + - E2









********* ********************************************* ****************************** ** ****************************
pBluescript II KS + - I1









***************************************** ****************************** ** *******************************
All inserts were sequenced correctly. The three to five bases ins/dels were identified
to be the former EcoRV-site. Therefore, they flank the inserts. After the insert orien-
tation was identified, EcoRI or HindIII digests were performed to linearize the plasmid
for probe generation.
Table 26: Linearization of pBluescript II KS + -derived plasmids
PCR-prod. Insert-orientation. Restriction digest RNA-Pol. Probe
AREG exon 2 forward HindIII T7 E2-antisense
AREG intron 1 forward HindIII T7 I1-antisense
AREG exon 2 forward EcoRI T3 E2-sense
xx
8.9 The effect of Zebularine on AREG expression
Figure 73:
120 h: 144 h:
Figure 73: AREG mRNA expression after Zebularine treatment: Five cell lines were testet
for their AREG mRNA expression after treatment with 100 µM Zebularine for 120 and 144 h.
In each plot the relative quantification of the expression is shown compared to the untreated
control.
Figure 74:
120 h: 144 h:
Figure 74: AREG protein expression after Zebularine treatment: Five cell lines were testet
for their AREG protein amount in the supernatant after treatment with 100 µM Zebularine
for 120 and 144 h. In both plots the relative AREG level is shown compared to the untreated
control.
xxi
8.10 Betacellulin: gene expression VS methylation
Figure 75:
Figure 75: Protein expression of BTC in HCT116 and LIM1215: HCT116 and LIM1215 were
tested for their BTC-protein expression in cell lysate by ELISA. Cells were seeded into 6-well
plates as described in section 2.3.4 and cell lysates were isolated as described in section 2.5.1,




Figure 76: Methylation of the BTC promoters after 454 GS-FLX deep bisulfite amplicon
sequencing: Four different cell lines and colon mucosa DNA as a negative control were tested
for their BTC promoter methylation. Per sequenced sample, 40 to 50 reads, represented by
the lines, are shown. CpG positions are represented by the columns. Genomic positions are
defined by the first proximal and last distal CpG of the analysed amplicon. Averaged DNA
methylation and total number of reads are given at the right of the respective map. Blue:




Figure 77: Methylation of four CpGs within the BTC gene: HCT116 and LIM1215 were tested
for their methylation of intragenic CpGs within the BTC-gene. CpG p168 and CpG p333 are
located within intron 2, CpG p85 and CpG p225 are located within intron 4. Methylation was
determined by MsSNuPE experiments (see section 2.12.1. A methylation index of 1 means























































































































































































































































































































































































































































































































































































































































































































































































































































8.12 AREG intragenic methylation in 4 microdisected human
cancer tissues
Table 29: AREG intragenic methylation in microdisected tumor samples
No. ID tissue region AREG CpG p150 AREG CpG p220
1 4548/11 Normal Epithel 0.178 0.255
2 Stroma 0 0
3 Tumor Epithel 0 0.237
4 Stroma 0.328 0.373
5 7135/11 Normal Epithel 0.851 1
6 Stroma 0.779 1
7 Tumor Epithel 0 0
8 Stroma 1 1
9 42460/11 Normal Epithel NA NA
10 Stroma 0.805 0.561
11 Tumor Epithel 0 1
12 Stroma 1 1
13 43604/11 Normal Epithel 0.803 1
14 Stroma 0.723 0.793
15 Tumor Epithel 0 0
16 Stroma 1 1
17 43467/11 Normal Epithel 1 1
18 Stroma 0.115 0.364
19 Tumor Epithel 0.242 0
20 Stroma 0.593 0.547
xxvi
8.13 AREG and EREG intragenic methylation in 24 microdi-
sected human cancer tissues
Figure 78:
Figure 78: AREG and EREG intragenic CpG methylation in microdisected human cancer
tissues: 24 human colorectal cancer tissues were microdisected into four parts (normal stroma,
normal epithel, tumor stroma and tumor epithel) AREG and EREG intragenic methylation
was measured by msSNuPE (see section 2.12.1) The Methylation Indices of each sample were
either presented as boxplot (left) or directly (right).
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Figure 79: AREG mRNA expression after EGFR inhibitor treatment in different colorectal
cancer cells: Seven colorectal cancer cell lines were tested for their AREG mRNA expression
after treatment with 10 µM Erlotinib or 10 µM Gefitinib. The relative quantification of the
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